View conference programme - The British Society for Rheumatology

BSR 2004 

Annual Meeting 

A joint meeting with 

British Health Professionals in Rheumatology 

20 - 23 April 2004 

Edinburgh International Conference 

Centre, Edinburgh, Scotland 

with the 

British Health Professionals in Rheumatology 

Spring Meeting, 21 - 23 April 2004 

Printed with the assistance of

BSR Annual Meeting & BHPR 

Spring Meeting 2004 

FINAL PROGRAMME 

CONTENTS 

Meeting at a Glance 2 – 3 

Scientific Programme; Tuesday 20 April 4 – 9 

Scientific Programme; Wednesday 21 April 9 – 16 

Scientific Programme; Thursday 22 April 16 – 22 

Scientific Programme; Friday 23 April 22 – 23 

Additional Meetings 24 

Abstracts for oral presentations 

BSR Concurrent Oral Sessions; Tuesday 20 April, 16:30 – 18:00 25 – 27 

BSR Plenary Oral Session; Wednesday 21 April, 14:00 – 16:00 28 

BHPR Plenary Oral Session; Wednesday 21 April, 14:00 – 16:00 29 

BSR Concurrent Oral Sessions; Thursday 22 April, 14:30 – 16:30 30 – 33 

BHPR Oral Presentations; Friday 23 April, 10:00 – 11:00 34 

Abstracts for poster presentations 

Poster Viewing Session 1; Wednesday 21 April, 08:30 – 10:00 34 – 50 

Poster Viewing Session 2; Thursday 22 April, 08:30 – 10:00 51 – 65 

Poster Viewing Session 3 (inc. BHPR); Friday 23 April, 08:30 – 10:00 66 – 80 

Abstract Reviewers 81 

Exhibition Floor Plan 82 

Exhibitor’s Details 83 - 88 

Acknowledgements 89 

1

BSR Annual Meeting & BHPR Spring 

Meeting, 20 -23 April 2004 

Edinburgh International Conference Centre 

BSR & BHPR SCIENTIFIC PROGRAMME 

Tuesday 20 April 2004 

08:00 Registration opens Strathblane Hall 

09:00 – 10:30 Satellite Symposium 

Genzyme Biosurgery Tinto 

10:30 – 11:00 Coffee Cromdale Hall 

11:00 – 13:00 BSR: Update on management of systemic sclerosis – organ based 

complications Pentland/Sidlaw 

Chair: Chris Denton 

• Recent advances in treatment of pulmonary arterial hypertension in 

systemic sclerosis Gerry Coghlan 

Advances in CTD associated PAH. The availability of bosentan has simplified the 

management of CTD-PAH at least for patients with grade 3 disease, however, 

remarkably little long term follow up data has been available to date. By combining 

our registry data with the extension trials, we have data on the survival impact on 

100 patients treated for up to three years. The data shows that survival at two 

years is 67%, thus much improved when compared to historical controls but still 

much higher than that observed in idiopathic PAH. 

• Assessment and treatment of pulmonary fibrosis in systemic sclerosis 

Ron du Bois 

Our concept of pulmonary fibrosis in systemic sclerosis has changed significantly 

over recent years. This has had important implications with regard to the 

assessment and treatment of lung complications in patients with this disease. 

This talk will focus on these novel aspects of management. 

• Pitfalls in management of scleroderma renal disease Ed Kingdon 

Renal involvement in scleroderma is not uncommon and scleroderma renal crisis 

(SRC) is well described. However, SRC is not the only renal manifestation of this 

disease and SRC presentation may be atypical. The pattern of renal involvement in 

SSc patients has therapeutic and prognostic significance and correctly identifying 

different types of renal disease is likely to be important when designing therapeutic 

trials or studies of the natural history of SSc. 

• Management of the peripheral vascular complications – 

critical digital ischaemia Ariane Herrick 

This session will cover assessment of severity, causation, and treatment (including 

prevention) of digital ulceration and ischaemia in patients with systemic sclerosis’ 

4

11:00 – 13:00 BSR Special Interest Groups 

• arc/BSR Education SIG Carrick 2 

Convenors: Lesley Kay and Andrew Hassell 

The aim of the education SIG is to start a network of Rheumatology health 

professionals who are interested in the delivery of Rheumatology education 

to students and practitioners, and in educational research. This is a joint 

initiative between the BSR and arc. In the first session we plan to outline 

current work of the arc education sub-committee and the BSR Education 

and Training Committee, and give some examples of current educational 

research. 

• Osteoarthritis Carrick 1 

Convenor: Fraser Birrell 

11:00 Introduction & welcome Dr Fraser Birrell 

Deciding the role of the Osteoarthritis Special Interest Group 

11:00 Coordinate collaborative studies Prof Paul Dieppe 

11:25 Determine future research directions Prof Cyrus Cooper 

11:40 Develop related clinical guidelines Prof Michael Doherty 

11:55 Promote dissemination or implement changes of best clinical 

practice Dr Nigel Arden 

12:10 Promote public information about osteoarthritis 

Dr Philip Conaghan 

12:25 General discussion 

12:50 Consensus & action plan Dr Fraser Birrell 

13:00 Close 

• Polymyalgia rheumatica and giant cell arteritis Harris 2 

Convenor: Bhaskar Dasgupta 

• Update on PMR Cohort Study Bhaskar Dasgupta, Southend Hospital 

• Consensus on PMR Andrew Hutchings, London School of Hygiene & 

Tropical Medicine 

• Infliximab in GCA Bhaskar Dasgupta, Southend Hospital 

• Antiphospholipid antibodies in GCA Kuntal Chakravarty, 

Haroldwood Hospital 

• Takayasu’s Arteritis Justin Mason, Hammersmith Hospital 

• RA Outcomes Moorfoot 

Chair: Dr Adam Young 

• Clinical guidelines for management of RA and RA outcomes 

Perspectives from the Arthritis & Musculo-skeletal Alliance (ARMA) 

Dr. Mike Webley FRCP, Stoke Mandeville 

BSR guidelines and relevance to outcomes 

Dr. Tom Kennedy FRCP, Wirral 

• Recent developments in use of hand bone density in 

assessment of outcome 

Prof David Reid FRCP, Aberdeen 

• Evaluating progression in x-ray changes. A mathematical view. 

Prof. Peter Jones PhD, Keele University 

• RA and podiatry outcomes. Brief update following BSR RA SIG 2003. 

Simon Otter, Lecturer in Podiatry, Brighton. 

• ERAN. Brief update following BSR SIG 2003. Wendy Garwood, 

ERAN Coordinator. 

5

• Spondyloarthritis Harris 1 

Convenor: Paul Bowness 

What’s new in Psoriatic Arthritis 

11:00 Introduction Paul Bowness 

11:10 What’s so special about PsA? PsA versus RA - what’s the 

difference and does it matter? Neil McHugh 

11:40 Looking into the PsA joint Douglas Veale 

12:10 Psoriatic arthritis, a T Cell-mediated disease. Oliver FitzGerald 

12:40 Comments from the floor and round table discussion 

• Ultrasound Carrick 3 

Chairpersons: David Kane and Richard Wakefield 

How to establish Musculoskeletal Ultrasound in a rheumatology department? 

13:00 – 14:00 Lunch Cromdale Hall 

1. How to Train in Musculoskeletal Ultrasound 

11:00 Musculoskeletal Ultrasound Training in Rheumatology – what is the 

consensus of rheumatologists already performing musculoskeletal 

ultrasound? Andrew Brown, Leeds General Infirmary 

11:15 How to establish Musculoskeletal Ultrasound in a busy Rheumatology 

Department – The Belfast experience. Gary Wright, Royal Victoria 

Hospital, Belfast 

11:30 Discussion: David Kane 

2. How to get Equipment and Funding. 

11:45 Choosing the right equipment. David Kane, University of Newcastle 

12:00 How to get funding for ultrasound equipment in your rheumatology 

department? Roger Sturrock, Glasgow Royal Infirmary 

12:15 Discussion: Richard Wakefield 

BSR Standards, Audit and Guidelines Working Group Open Meeting – 

presentation of current clinical guidelines in development Harris 1 

RATs Meeting Kilsyth 

14:00 – 16:00 BSR: Rheumatoid arthritis from the patient’s perspective Pentland/Sidlaw 

Chairs: Rod Hughes and Enid Quest 

• The patient as educator Jane Dacre 

A discussion of trained patients as educators of doctors and other 

healthcare professionals. 

• The patient as expert Kate Lorig 

When one is diagnosed with a chronic disease life changes. Corbin and Strauss 

have identified three major management tasks for people with chronic disease; 

medical management, role management, and emotional management. At the 

same time patients have told us that they need two types of knowledge, medical 

knowledge and knowledge gained from the experience of living with an illness. 

Health care professionals, are experts at helping people with medical management 

but are less adept at helping with role and emotional management. Patients who 

have lived with and managed a disease over time have much to offer each other. 

This is especially true if this is done in a structured setting which allows sharing in a 

non judgmental atmosphere. 

This talk will discuss the sharing of expert patient knowledge and will include some 

of the data we have collected over the years on the similarities and difference in 

professional and patient led groups. 

6

• The patient as recipient of treatment Jenny Donovan 

Jenny will talk about research which shows how patients make rational and 

sensible decisions about the medications they take for their joint symptoms, 

based on the information they have available to them. She will also present 

evidence about how doctors and patients can have very different 

perceptions of issues discussed in consultations which can lead to confusion 

and dis-satisfaction, and also some work we have done very recently 

synthesising qualitative research studies which summarises the contribution 

that qualitative research can make to rheumatology. 

• How do patients prioritise outcomes in RA Alison Carr 

Clinical management is aimed at achieving a good outcome and most 

clinicians have an intuitive feeling for what constitutes a good outcome in 

their patients but this might vary between individual patients and even 

within individual patients over time. Definitions of good outcome from 

clinical trials are based on disease based measures of outcome (acute phase 

response, pain) and increasingly on patient-based measures (function, quality 

of life) but do not take account of the ways in which patients prioritise 

outcomes in relation to: the stage and severity of their condition, their 

expectations or adaptation. This talk will present evidence of patient 

priorities for outcome and discuss the implications for the ways in which 

outcomes are measured, analysed and interpreted. 

14:00 – 16:00 BSR: Angiogenesis; basic science and therapeutic possibilities 

Tinto/Moorfoot 

Chair: Ewa Paleolog 

• Approaches to angiogenesis in oncology Andreas Bikfalvi 

Vascular development is governed by a number of regulatory molecules 

called “angiogenesis “ factors. In recent years a number of molecules have 

been identified and pathways of normal and pathological vascular 

development have been elucidated. Angiogenesis research also significantly 

impact on the development of new therapeutic strategies for the treatment 

of cancer, ocular neovascular disease, chronic inflammatory disorders or 

cardiovascular disease. 

• Angiogenesis in synovitis Michel De Bandt 

Angiogenesis is potentially important in RA. Angiogenesis is the sprouting 

of new vessels, that contributes to the proliferation of tissues and 

participates in the inflammatory process in the rheumatoid joint. 

The angiogenic pathways within the joint will be reviewed. The clinical 

importance of angiogenesis in RA will be discussed. Various aspects of 

angiogenesis inhibition in animal models will be presented. 

• Angiogenesis in osteoarthritis and spondylosis David Walsh 

Angiogenesis is an integral part of bone formation, cartilage and disc 

changes in OA and spondylosis, and accompanying nerves may 

mediate pain. 

• Imaging angiogenesis in joints Peter C Taylor 

Power Doppler ultrasonography is a sensitive method for demonstrating the 

presence of blood flow in small vessels in rheumatoid synovitis and there is a 

very close relationship between extent of vascular flow signal and the rate of 

early synovial enhancement on dynamic gadolinium-enhanced MRI. 

Emerging evidence indicates that vascular imaging in RA is a sensitive tool 

for the assessment of disease activity and response to therapy and also 

prognostic for the rate of structural damage to joints. 

7

16:00 – 16:30 Tea Cromdale Hall 

16:30 – 18:00 BSR: Concurrent oral presentations of abstracts 

Osteoarthritis and crystal diseases Sidlaw 

Chair: Mike Doherty 

• Gain of function ANKH variants cause of familial and sporadic calcium 

pyrophosphate dehydrate chondrocalcinosis Yun Zhang 

• Monocyte-macrophage differentiation in vivo and the control of monosodium 

urate (MSU) crystal-stimulated inflammation. Dorian Haskard 

• Sequencial measurements of serum cartilage oligometric matrix protein (COMP) 

indicate a non-linear progression of knee osteoarthritis Mohammed Sharif 

• Neurovascular invasion at the osteochondral junction in osteoarthritis Sunita Suri 

• Cancellous bone changes in the proximal tibia of patients with knee osteoarthritis 

Elizabeth Messent 

• Long term outcome following total hip arthroplasty: a case controlled study 

Janet Cushnaghan 

Epidemiology Fintry 

Chair: Marwan Bukhari 

• Birth order as a determinant of osteoporosis risk: the Hertfordshire cohort study 

Elaine Dennison 

• Joint hypermobility is common and strongly genetically determined: results of a 

female twin study Alan Hakim 

• Association between dietary carotenoids and risk of developing inflammatory 

polyarthritis Dorothy Pattison 

• Young Investigator Award Winner: Predicting persistence of neck pain following a 

motor vehicle accident: a prospective study of persons attending emergency 

department Kate Atherton 

• Hypothalamic-pituitary-adrenal stress axis function – the relationship with chronic 

widespread pain and its antecedents: a population based study John McBeth 

• Is musculoskeletal pain more common now than 40 years ago? Results from two 

population-based cross-sectional studies John Mcbeth 

Vascular injury Tinto/Moorfoot 

Chair: George Kitas 

• Systemic rheumatoid vasculitis – facing extinction? Richard Watts 

• Young Investigator Award Winner: The haemoglobin scavenger receptor CD163 

mediates macrophage interleukin-10 and haem oxygenase-1 synthesis: an inducible 

cytoprotective pathway against haemoglobin-mediated oxidative vascular injury 

Pandelis Philippidis 

• Young Investigator Award Winner: Upregulation of membrane-bound 

complement regulatory proteins by atorvastatin protects vascular endothelium 

against complement-mediated injury during hypoxia-reoxygenation 

Anne Kinderlerer 

• Renal artery stenosis in hypertensive patients with antiphospholipid syndrome 

(APS): the effects of anticoagulation Shirish Sangle 

• Cardiovascular and cerebrovascular disease incidence and risk factors in 

ANCA-associated primary systemic vasculitis (AASV) John McLaren 

• Molecular profile of symptomatic and asymptomatic carotid plaques 

Eugene Halligan 

8

Therapeutics Pentland 

Chair: John Isaacs 

• The armada trial: efficacy and safety of adalimumab (humira ® ) over 30 

months in patients with active rheumatoid arthritis Oscar Segurado 

• Adalimumab (humira ® ) inhibits radiographic progression in rheumatoid 

arthritis (RA) patients with long-standing disease: data at two years 

Oscar Segurado 

• Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic 

resonance imaging study Ai Lyn Tan 

• Predictive value of synovial cytokine expression for response to 

anti-tumour-necrosis factor-α treatment in rheumatoid arthritis in 

clinical practice Maya Buch 

• A randomised, double-blind, placebo controlled multi-centre trial of 

combination therapy with methotrexate plus cyclosporine v methotrexate 

plus placebo in patients with active psoriatic arthritis A Fraser 

• A randomised controlled trial of intra-articular triamcinolone and/or 

physiotherapy in shoulder capsulitis Ian Ryans 

18:00 – 19:00 Welcome Buffet Reception Cromdale Hall 

19:00 – 20:00 Clinico-pathological Conference Pentland Suite 

Chair: David GI Scott, UK 

Discussant: Robert Thompson, Liverpool, UK 

Presenter: Kuntal Chakravarty, Romford, UK 

Wednesday 21 April 2004 

08:30 – 10:00 BSR Poster viewing session 1 Strathblane Hall 

10:00 – 11:00 BSR Poster discussions 

Cytokines and basic science Sidlaw 

Chairs: Andrew Cope and Iain McInnes 

Posters to be discussed: 7, 10, 3, 11, 28, 12, 2, 5 

Genomics Fintry 

Chairs: Anne Barton and Matthew Brown 


Osteoporosis and bone disease Tinto/Moorfoot 

Chairs: John Halsey and Jon Tobias 


Treatment of rheumatoid arthritis Pentland 

Chairs: Julie McHale and Bryan Williams 



9

11:30 – 13:00 BSR: Interface of rheumatology with the community 

Pentland/Sidlaw 

Chair: David GI Scott 

11:30 Community interface with secondary care Elaine Hay 

Increasingly, it is recognised that there is a significant gap in the provision of 

clinical care for patients with non-inflammatory and non-surgical 

musculoskeletal problems, who often access services in an ad-hoc manner. 

There are a number of key principals to consider when developing a clinical 

service for such patients at the primary / secondary care interface. 

1. Delivering an effective and efficient musculoskeletal service that meets 

the needs of the community has less to do with geographical location of 

clinics than with developing a cohesive patient centred model of care. 

2. Local strategies need to be developed to breakdown barriers and 

facilitate coherent care between professions, between settings and 

organisations and between different models of care (medical model versus 

“patient centred” model). 

3. To be effective, the service must incorporate clinical services 

(“New Ways of Working” and cohesive clinical teams), training and 

education, and audit and research. 

Some form of triage by practitioners with special interests (usually general 

practitioners or physiotherapists) is increasingly popular as a way to try to 

improve the efficiency and appropriateness of the referral process for patients 

with musculoskeletal problems. This approach has tangible benefits including 

reduced wait times, convenient access, high levels of patient satisfaction and 

increased conversion rate for surgery. However, it is important that practitioners 

with special interests work as part of a multidisciplinary team, providing an 

integrated service spanning primary and secondary care. The importance of 

robust, transparent procedures to ensure appropriate training and experience; 

evidence of continuing professional development; adequate clinical facilities, 

support and accountability as well as a commitment to clinical governance, 

audit and evaluation have recently been highlighted (A Musculoskeletal 

Clinical Framework for GPs with special interests 

www.doh.gov.uk/pricare/gp-specialinterests ). 

11:55 The GP’s perspective on the role of rheumatology Michael Dixon 

• How do we commission effectively? Primary and secondary care clinician 

leadership and frontline involvement in designing services. Ensuring cost 

effective use of services commissioned. Clinical leadership at the 

interface between secondary care and general practice. 

• Service redesign - how much rheumatology can be done in primary care? 

• Improving the patient experience - the role of PCTs and the impact of 

patient forums and practice patient participation groups. 

• Patient choice - the effect on rheumatology services of moving the locus 

of control from Whitehall to the patient and his chosen practitioner. 

12:15 GPs with special interests in rheumatology Steven Longworth 

12:35 Rheumatology serving the community Carol Black 

The demographics of the population are changing, we are living longer and 

chronic diseases are on the increase. These changes plus those embodied in 

shifting the balance of power require the rheumatological community to 

examine how, where and with whom care will be delivered in the future. 

10

11:30 – 13:00 BSR: Genetics for the terrified Tinto/Moorfoot 

Chairs: Robert Moots and Jane Worthington 

• The biology of genes Andrew Read 

This talk is for people who see a yawning chasm between the modern 

post-genome world view and their vague memories of the genetic code, and 

who are terrified because a crucial area of science seems to have run out of 

their reach. I will summarise the function of our DNA (only 2% codes for 

protein), the structure of our genes and the significance of the many 

variations that exist between the DNA of different people. It will become 

apparent that, although we now have a ‘finished’ human genome sequence, 

we still understand rather little about how it works. 

• How can studies link genes to disease? Sally John 

Most common diseases of major public health impact have a complex 

aetiology in which many genetic and environmental factors may contribute 

to disease onset. Whilst mapping disease genes for Mendelian traits has 

been successful, mapping the genes for complex disease has been more 

challenging. The main reason for this, is that many genes, each conferring a 

small risk, often interacting with other genes and or environmental 

exposures are responsible for more complex traits. 

A case-control association study is the most efficient method of 

demonstrating a link between a gene and a disease. Well-designed 

association studies require careful consideration of the phenotype or 

outcome and appropriate selection of genetic markers. Common problems 

encountered in genetic association studies and methods to overcome them 

will be described. 

There are now >5 million polymorphisms documented in the human 

genome, Understanding linkage disequilibrium and haplotypes on a genome 

wide basis will ensure we design more efficient and powerful association 

studies in the future. 

• Taking genetics back to the clinic for therapy of rheumatic diseases 

Yuti Chernajovsky 

Current advances in gene transfer and protein engineering methods enable 

the use of cytokine-inhibitors and inhibitory cytokine genes to treat 

polygenic diseases such as rheumatoid arthritis. Genetic engineering of cells 

ex vivo or direct in vivo therapeutic interventions have proven extremely 

useful to study local effects of immunomodulatory agents as well as being a 

safe and cost effective alternative therapy when compared with current 

protein therapies. 

11:30 – 13:00 BSR: Inherited defects of connective tissue Fintry 

Chair: Rodney Grahame 

11:30 Overview of key developments Michael Pope 

Connective tissue matrix is a very complex mixture of structural proteins, 

such as collagens, elastic components, proteoglycans etc, of particular 

relevance to specialties such as Rheumatology. This symposium illustrates 

the medical disorders caused by errors in some of those constituents. 

11

11:45 Collagen III and V mutations Anne de Paepe 

The Ehlers-Danlos syndrome groups a number of inherited connective tissue 

disorders in which skin and joint hyperlaxity, easy bruising, dystrophic scarring 

and generalized connective tissue fragility are prominent features. Mutations 

affecting the biosynthesis and structure of fibrillar collagens are causal in 

several EDS subtypes. One of the most severe subtypes, vascular EDS, is 

characterized by arterial fragility and reduced life expectancy due to vascular 

rupture and results from mutations in the gene encoding type III collagen. 

Approximately half of the patients with the classical form of EDS, in which skin 

hyperextensibility and fragility are prominent, carry a mutation in one of the 

genes encoding type V collagen. The clinical and molecular aspects of these 

conditions as well as diagnostic and management issues will be discussed. 

12:05 Collagen II, XI and other mutations in Stickler syndrome Martin Snead 

Stickler syndrome forms part of the spectrum of type II/XI collagen 

chondrodysplasias and is the commonest inherited cause of retinal detachment. 

12:25 Extracellular matrix mutations in the epiphyseal and other 

chondrodysplaysias Mike Briggs 

Multiple epiphyseal dysplasias are inherited bone diseases that are 

characterised by joint pain and stiffness and early onset osteoarthritis. 

Autosomal dominant forms of these diseases are genetically heterogeneous 

and result from mutations in important cartilage structural proteins. Recent 

studies have contributed significantly to our understanding of the pathobiology 

of these relatively common diseases. 

12:45 One gene, many clinical consequences: the lessons from G proteins 

Paul Wordsworth 

G proteins fulfill a vital role in cell signaling pathways. Activating and 

inactivating mutations have been described in the alpha subunit. Depending on 

whether these are of maternal or paternal origin widely differing phenotypes 

may result (Albright’s hereditary osteodystrophy, progressive osseous 

heteroplasia, pseudohypoparathroidism). Somatic mosaicism for activating 

mutations results in polyostotic fibrous dysplasia (McCune Albright syndrome). 

Authorship acknowledgement: Lisa Miles 


BSR Biologics Register Open Meeting – progress update for BSR and 

BHPR members Tinto/Moorfoot 

14:00 – 16:00 BSR: Plenary oral presentations of abstracts Pentland/Sidlaw 


• Targeting B cells with rituximab: an effective and well tolerated treatment for active 

rheumatoid arthritis (RA) John Isaacs 

• Heberden’s nodes: what Heberden didn’t see – a high resolution MRI study of the 

micro-architectural abnormalities in early and established hand osteoarthritis 

Ai Lyn Tan 

• Psoriatic arthritis synovitis: a critical role for IL-15 and IL-18? David Kane 

• Young Investigator Award Winner: Very early rheumatoid arthritis is characterised 

by a unique and transient T cell and stromal cytokine profile Karim Raza 

• Moderate alcohol is good for women’s bones Frances Williams 

• Michael Mason Prize winner: Autoantibodies, lupus and the science of sabotage 

Anisur Rahman 

12

14:00 – 16:00 BHPR: Oral presentations of abstracts and presentation of arc medal 

Tinto/Moorfoot 

Chairs: Candy McCabe and Sarah Ryan 

• Conservative hand therapy treatments in rheumatoid arthritis (RA) – 

a randomised controlled trial Anne Chadwick 

• Pain is not always the priority – rheumatoid arthritis value other 

outcomes Sarah Hewlett 

• How does rheumatoid arthritis affect female patients’ ability to continue 

household activities. Results of the development and validation of a 

questionnaire Cathy Boys 

• Patients’ and rheumatologists’ different views on analgesia in RA 

Stella Howden 

• The patient’s experience of attending either a lupus or a scleroderma 

education programme: a qualitative evaluation Sue Brown 

• The future of shared care monitoring of DMARDS with the advent of the 

new general medical services GP contract – a survey in the Merthyr and 

Cynon valleys Elizabeth Thomas 


16:30 – 17:30 Heberden Oration - What causes rheumatic diseases: 

nature vs nurture revisited Pentland Suite 

Orator: Prof Alan Silman, Manchester, UK 

Chair: Prof David GI Scott, Norwich, UK 

As a mark of distinction every year the BSR 

President appoints a Heberden Orator to give an 

hour keynote lecture at the BSR Annual Meeting. 

This tradition dates back to 1938 and the 

distinguished Orator is awarded a medal. 

This year the oration will be given by Alan Silman, 

Professor of Rheumatic Diseases Epidemiology at 

University of Manchester. He is also Director of 

the United Kingdom’s Arthritis Research 

Campaign Epidemiology Unit at the University 

of Manchester Medical School. Prof Silman’s interests are wide and cover 

genetics of rheumatoid arthritis, pregnancy and hormonal aspects of arthritis, 

the natural history of early arthritis, epidemiological studies of chronic pain 

syndromes, epidemiology of osteoporosis, Behçet’s disease and scleroderma. 

17:45 – 19:45 BSR Special Interest Groups 

• Clinical Trials Harris 2 

Convenor: Ernest Choy 

• Complex Intervention Trial Professor Paul Dieppe 

• Patient research partners: benefits, practicalities and challenges 

Dr Sarah Hewitt and Mrs Pam Richards who is a special guest as a 

patient research partner. 

• Update on EU Clinical Trials Directives Dr Sara Meredith 

13

• EMG / NCS Carrick 3 

Convenor: Ian Morris 

Chairman: Jumbo Jenner 

• Talk: Clinical Governance - experience with Peer Review so far Ian Morris 

• Discussion on Peer Review, with call for volunteers to undertake and receive 

• Review 

• Debate: What are the boundaries for Rheumatologists undertaking EMGs 

Jumbo Jenner and Rupa Bessant 

• Progress on CTS project and call for participants in the study: Rupa Bessant 

• Management of Ulnar nerve lesions – Ian Morris 

• Heritable Disorders of Connective Tissue Ochil 3 

Co-chairmen: Rodney Grahame, Howard Bird 

“New insights into the hypermobility syndromes” – 

short papers and discussion 

• Dysautonomia in JHS; specific to the disease or a common feature of 

deconditioning? Alan Hakim 

• Proprioceptive impairment in JHS and its restoration William Ferrell 

• Experience of hypermobility in a DGH paediatric rheumatology clinic 

Nathan Hasson 

• Is the JHS/EDSHM phenotype ubiquitous? Rodney Grahame 

• Sjögrens Syndrome Carrick 1 & 2 

Convenor: Simon Bowman 

Chairperson: Elizabeth Price 

• Managing the neurological complications of Sjögrens Syndrome 

Professor Patrick Venables 

• Managing lymphoma risk in Sjögrens Syndrome Dr Nurhan Sutcliffe 

• Managing pulmonary & renal complications of Sjögrens Syndrome 

Dr Ian Griffiths 

• Systemic lupus erythematosus Kilsyth 

Convenors: Bridget Griffiths and Ian Bruce 

• Maintenance therapy in patients with severe SLE - the BILAG RCT comparing 

azathioprine versus cyclosporin A: preliminary results Bridget Griffiths 

• Brief update on current multicentre studies in SLE patients Lead investigators 

• Are immunosuppressive drugs as safe as we think in pregnancy? 

Caroline Gordon 

• The use of rituximab in patients with SLE Michael Ehrenstein 

• Vasculitis Harris 1 

Convenor: David Carruthers 

1) Management update - Biological therapies in SNV 

Clinical case SpR presentation 

Literature review - anti-TNF and Rituximab Dr R Luqmani 

Discussion 

2) Current research update 

Clinical trials – HiCy Dr D Carruthers 

Assessment methodology - BVAS2003 Dr R Luqmani 

Genetic studies Dr R Watts 

Atheroma in SNV (Edin/Birm data) Dr J McLaren 

3) Any other business 

14

17:45 – 19:45 ARMA/BSR/SSR Event – All Welcome Pentland Auditorium 

A panel of service users, policy makers and health professionals will discuss the 

ARMA Standards of Care project and the need for strategies for musculoskeletal 

conditions. We are pleased to announce that the Rt. Hon. John Reid MP, 

Secretary of State for Health, is planning to join us for the event. 

20:00 – 21:30 Satellite symposia 

Abbott Immunology: What are your views on current anti-TNF 

therapy issues? Tinto/Moorfoot 

• Introduction from the chairman. Paul Emery 

• Implementing guidelines. Brian Hazleman 

• Funding considerations. Gabriel Panayi 

• Treatment goals and considerations. Duncan Porter 

• Screening and monitoring. David Isenberg 

• Cessation of therapy. Iain McInnes 

• Summary of key points. Paul Emery 

• Question and answer session. 

Novartis Pharmaceuticals UK Ltd: Delivering on the COX-2 promise: 

towards proven GI safety Sidlaw 

20:00 Chair’s welcome G. Nuki, Edinburgh, UK and C. Hawkey, 

Nottingham, UK 

20:05 Current issues with NSAIDs and COX-2s G. Nuki, Edinburgh, UK 

20:20 The emerging clinical profile of lumiracoxib 

A. Tyndall, Basel, Switzerland 

20:40 COX-2 selective inhibitors: learnings from large outcomes studies 

D. Walker, Newcastle, UK 

20:55 TARGET: the definitive outcomes study? C. Hawkey, Nottingham, UK 

21:15 Panel Q&A session 

20:25 Chair’s closing remarks G. Nuki, Edinburgh, UK and C. Hawkey, 

Nottingham, UK 

MSD Ltd: Controversies and Challenges in Rheumatology 2004 

To be held off-site at the Edinburgh Suite, Sheraton Grand Hotel, Edinburgh 

We would like to invite you on behalf of Merck Sharp & Dohme Limited to join 

Professor David Blake and Professor Bryan Williams along with a panel of UK 

rheumatologists for a clinical update followed by a battle of great (and not so 

great) minds in the quiz, ‘Controversies and Challenges in Rheumatology’. 

19:30 Buffet 

20:10 Welcome and introduction Chairmen 

20:15 Etoricoxib review – key clinical data Chairmen 

20:20 Questions from the audience Chairmen and Panel 

20:30 Rheumatology Quiz 

21:20 Satellite close 

Panel: Professor Paul Bacon, University Hospital Birmingham 

Professor Michael Doherty, City Hospital, Birmingham 

Dr Peter Hollingworth, Southmead Hospital, Bristol 

Professor Robert Moots, University Hospital Aintree, Liverpool 

Professor Gabriel Panayi, Guys Hospital, London 

Dr Usha Srinivasan, Princess of Wales Hospital, Bridgend 

Dr Doug Veale, St Vincent’s Hospital, Dublin 

15

Pfizer Pain Management: Hot Topics 3 – the third in a continuing series 

of symposia exploring the latest developments in rheumatology 

To be held off-site at the Main Hall, The Hub, Castlehill, Edinburgh 

• Chairman’s introduction Dr Frank McKenna, Manchester, UK 

• The impact, on individuals and populations, of the introduction of COX-2 inhibitors 

– the Ontario experience. Dr Muhammad Mamdani, Toronto, Canada 

• The role and relevance of both haematopoietic and mesenchymal stem cells in 

Rheumatology Prof Dennis McGonagle, Leeds, UK 

• Endothelial function in patients with coronary artery disease – can it be improved? 

Dr Frank Ruschitzka, Zurich, Switzerland 

Thursday 22 April 2004 

07:30 – 08:30 Meet the Expert Workshops 

These workshops will be given by experienced clinicians in the chosen topic area 

and are intended to be informal, interactive sessions based on problem solving. 

The workshops are relevant to all clinicians, but especially to newly appointed 

consultants and SpRs. 

• Connective tissue disease – FULLY BOOKED Carrick 1 

Expert: David D’Cruz 

This interactive session will discuss selected patients with complex clinical problems 

that proved to be challenging in terms of either diagnosis or management. The 

topics covered will include systemic lupus erythematosus, antiphospholipid 

syndrome and systemic vasculitis. At the end of the session participants will be able 

to develop their problem solving skills to improve their management of patients 

with multisystem autoimmune diseases. 

• Management of difficult rheumatoid arthritis – FULLY BOOKED Carrick 2 

Expert: Ernest Choy 

Whilst we have more options for treating patients with rheumatoid arthritis, the 

goal in management has also moved significantly. Delivering the best care for 

patients with rheumatoid arthritis remains challenging. This “Meet the Expert” 

session will look that various therapeutic options available for managing difficult 

cases. Attendees are encouraged to bring their own examples for discussion at 

the session. 

• Paediatrics Carrick 3 

Expert: Clive Ryder 

Dr Clive Ryder has been a full time NHS paediatric rheumatologist for over 8 years. 

He is happy to discuss any aspects of the care of children with rheumatological 

conditions and to discuss recent advances in treatment and research. If no cases 

are received by the audience then sample cases will be presented which will 

address the difficulties of differential diagnosis, the impact of chronic disease in 

childhood and treatment options. 

16

• Respiratory - musculoskeletal comorbidity: a joint session with a 

rheumatologist and a chest physician Ochil 3 

Experts: George Kitas and Michael Cushley 

Pulmonary pathology is common in the connective tissue diseases and 

primary chest disease can also involve the joints. Diagnostic and treatment 

approaches may differ between the 2 disciplines and the evidence base is 

limited, so a combined approach may help. We will be presenting some 

examples for discussion and hope also to discuss cases submitted by 

the audience. 

Please note that there is an additional fee of £20 to attend a Meet the 

Expert workshop, and continental breakfast is included in this fee. 

Places are limited and are allocated on a first come, first served basis. 

To enquire about the availability of the workshops, please ask at the 

registration desk. 

08:30 – 10:00 BSR Poster viewing session 2 Strathblane Hall 

08:30 – 09:30 BHPR SIGs 

• Connective tissue disease Sidlaw 

08:30 Management of Sjögren’s Elizabeth Price 

08:50 Quality of life in Sjögren’s Simon Bowman 

09:10 Panel discussion on Sjogren’s 

• Osteoporosis Harris 1 & 2 

08:30 Chairperson opening Rachel Lewis 

08:35 Fracture Liason Service with information on outline of the service, 

outcomes and case studies as requested by last years attendees 

Marine Fraser Bone and Metabolism unit, 

Western infirmary, Glasgow 

09:15 Questions 

09:25 Next years meeting 

• Rheumatoid arthritis Fintry 

Patient education - the New Forest experience. Heather Unsworth, Senior OT 

Anti-TNF agents - to switch or not to switch? - The Basingstoke story. 

Kate Wise, Nurse Specialist 

09:30 – 10:00 BHPR AGM Fintry 


10:30 – 12:30 BSR: Spondyloarthritis – recent advances in pathogenesis, 

imaging and treatment Tinto/Moorfoot/Kilsyth 

Chair: Andrew Keat 

• Why does HLA-B27 predispose to spondyloarthritis? Paul Bowness 

This talk will describe the biology of HLA-B27 and the cellular mechanisms 

by which it may cause inflammatory disease 

• CD4 T cells and spondyloarthritis – breaking the rules Hill Gaston 

The association between HLA-B27 and spondyloarthropathies is usually 

thought to imply a central role for CD8+ T lymphocytes in the pathogenesis 

of these diseases. This presentation will present evidence that CD4+ T cells 

can also be involved in recognition of HLA-B27, and the implications of 

these findings 

17

• Recent advances in spondyloarthritis imaging – is enthesitis the key? 

Dennis McGonagle 

Enthesitis on closely associated osteitis present at all sites of disease in the 

spondyloarthropathies are present in both axial and peripheral sites of disease in 

the spondyloarthropathy. This talk will be to review the imaging findings of 

enthesitis and the advantages and disadvantages of sonography in the assessment 

of enthesial related pathologies and will show how imaging has transformed the 

understanding of these diseases. 

• Anti-TNF therapy for ankylosing spondylitis Jürgen Braun 

10:30 – 12:30 BSR: Muscle: the neglected organ in arthritis Fintry 

Chair: Andrew Lemmey 

• The concept of rheumatoid cachexia Laura Rall 

Patients with rheumatoid arthritis (RA) experience a loss of metabolically active 

tissue that we have termed ‘rheumatoid cachexia’. This loss of lean body mass is 

an important contributor to morbidity and mortality in RA. Many factors appear to 

contribute to rheumatoid cachexia, including catabolic cytokines, inadequate 

dietary intake, steroid effects, and decreased physical activity. 

• The consequences of sarcopenia – lessons from ageing Marco Narici 

Sarcopenia is regarded as a major cause of muscle weakness in ageing. Several 

factors are known to contribute to the development of sarcopenia and the 

associated impact on function. Loss of skeletal muscle fibres secondary to 

decreased numbers of motoneurons appears to be a major contributing influence, 

but other factors, including decreased physical activity, altered hormonal status, 

decreased total caloric and protein intake, inflammatory mediators, and changes in 

protein synthesis, are also involved. However, in ageing, the loss of muscle strength 

typically exceeds that of muscle size and this leads to a decrease in force-per unit 

area (muscle-quality). Although, this phenomenon is partly explained by a decrease 

in the force per unit area of muscle fibres (specific tension) and by a reduction in 

voluntary neural drive to the muscle, recent evidence suggests that changes in 

muscle architecture and in tendon mechanical properties may significantly 

contribute to this phenomenon. The present paper will present new findings in 

this field and will illustrate the role of myotendinous alterations, associated with 

sarcopenia, in the loss of muscle function in old age. 

• The role of exercise and other anabolic interventions Samuele Marcora 

Studies on the effects of resistance exercise, anabolic steroids, dietary amino acids 

supplementation and anti-TNF therapy on muscle wasting and physical function in 

rheumatoid arthritis patients will be presented and discussed. 

• Exercise in management of RA - safe, effective and efficient. Impossible? 

Oh ye of little faith Mike Hurley 

In order to convince the doubters, the safety and efficacy of exercise in improving 

pain and disability in RA is briefly reviewed. In order to confront the doubters, the 

difficulties of implementing clinical practicable exercise regimens, and how these 

might be addressed, are discussed. In order to blame the doubters, the vital role 

healthcare professionals play in helping patients help themselves is emphasised. 

18

10:30 – 12:30 BSR/BHPR session: The impact of illness Pentland/Sidlaw 

Chairs: Alan Silman and Krysia Dziedzic 

• The impact of arthritis Deborah Symmons 

This talk will describe the number of people with arthritis in the UK at the 

population, primary care and secondary care levels. It will examine the 

prevalence and risk factors for disability associated with arthritis and will 

explore the potential for primary and secondary prevention of arthritis 

associated symptoms. 

• The impact of illness from an individual perspective Ailsa Bosworth 

The impact of chronic disease on both the individual and their family is huge 

and at times overwhelming. My presentation will reflect on personal 

experience and also relate to the experience of NRAS members who have 

recently taken part in our second survey on the emotional and psychological 

impact of rheumatoid arthritis, entitled ‘Beyond the Pain’. 

• Illness beliefs of patients and spouses Maggie Carr 

This presentation explores beliefs about RA and examines the 

impact of any discordance in beliefs of patients and spouses on outcomes. 

• Common musculoskeletal pain in primary care: the example of 

knee pain and knee osteoarthritis in older adults George Peat 

Primary healthcare is the point of first presentation and on-going care for 

the majority of people with musculoskeletal pain. Taking the example of 

knee pain and knee OA in older adults this presentation will consider issues 

related to the impact of illness in primary care and at their relation to the 

general population. 


BSR AGM (12:45 – 14:00) Fintry 

Lunch will be available for BSR AGM attendees after the meeting. 

14:30 – 16:30 BSR: Concurrent oral presentations of abstracts 

Health service and education research Tinto/Moofoot 

Chair: Lesley Kay 

• Improved access and targeting of musculoskeletal services: the teams 

programme Peter Maddison 

• Using the health assessment questionnaire and welfare benefits advice to 

help people disabled through arthritis to access financial support 

John Kirwan 

• RCT of patient-initiated review versus regular physician-initiated follow-up in 

• Development of e-learning tutorials in rheumatology: experience from the 

University of Bristol Robert Marshall 

• Competence based assessment of specialist registrars in rheumatology: 

assessment of out-patient consultation skills Caitlyn Dowson 

• Hospital services for low back pain: are they efficient? Michael Plant 

• Evaluation of an interactive intelligent telephone based monitoring system 

for patients with rheumatoid Rosie Hampson 

• Early physiotherapy management of back pain in primary care: a randomised 

clinical trial of physical treatments versus a brief pain management 

programme Elaine Hay 

19

Rheumatoid arthritis pathogenesis Fintry 

Chair: Chris Buckley 

• The balance of signalling molecules downstream of the notch receptor in 

CD4+CD25 high regulatory T-cells in RA resembles the balance observed in 

anergic cells Frederique Ponchel 

• Oxdative inactivation of CD45 phosphate contributes to the disregulation of 

T cells in RA Stephen Young 

• Angiopoietin 2 in inflammation, a primary role for angiogenesis in the invasive 

process? Ursula Fearon 

• Synovial HIF-2α expression is inversely related to tissue oxygen levels in 

inflammatory arthritis Peter Taylor 

• Bystander activated lymphocytes: a phenotypic comparison with rheumatoid 

synovial lymphocytes Jonathan Beech 

• Young Investigator Award Winner: The angiotensin-converting enzyme inhibitor 

quinapril suppresses inflammatory arthritis Nicola Dalbeth 

• Defects in the generation and function of regulatory T cells in rheumatoid arthritis: 

reversal by anti-TNFα therapy Claudia Mauri 

• Protease-activated receptor-2 is highly expressed in rheumatoid synovium 

Elizabeth Kelso 

Genomics Kilsyth 

Chair: Yuti Chernajovsky 

• Sequestosome 1 gene mutations in Paget’s Disease of bone lead to disregulated 

NFKB signalling Anna Daroszewska 

• OX40L, but not OX40, is associated with systemic lupus erythematosus 

Deborah Cunninghame 

• Heterogeneity amongst patients with chronic infantile neurological cutaneous 

and articular (CINCA) syndrome Ebun Aganna 

• High resolution linkage disequilibrium mapping identifies association to single 

nucleotide polymorphism markers mapping to a region of linkage on chromosome 

17q22 with rheumatoid arthritis Anne Barton 

• The BXSB interval on chromosome 13 (Bxs6) is necessary and sufficient for high 

titre gp70 autoantigen synthesis and concomitant autoantibody production 

Joanna Rankin 

• Microarray analysis of chromosome 1 congenic BXSB mice reveals novel 

lupus-susceptibility gene candidates Michelle Haywood 

• Young Investigator Award Winner: The IL-1 gene cluster is a major locus 

determining susceptibility to ankylosing spondylitis Andrew Timms 

Connective tissue diseases Sidlaw 

Chair: Neil McHugh 

• Upregulation of the monocyte chemoattractant protein-1 ligand-receptor axis in 

early stage diffuse cutaneous scleroderma Maria Teresa Carulli 

• A longitudinal analysis of skin sclerosis and organ-based endpoints in a cohort of 

early diffuse cutaneous systemic sclerosis Lynne Shand 

• Altered lipid raft expression and associated signalling in T lymphocytes from 

patients with systemic lupus erythematosus (SLE) Elizabeth Jury 

• Serological investigation of autoantibodies in 577 families with systemic lupus ery 

thematosus Timothy Vyse 

• Genetic dissection of BXSB lupus phenotype using mice congenic for chromosome 

1 demonstrates that separate intervals direct different aspects of disease 

Michelle Haywood 

20

• Reconstitution of C1q-deficiency with bone marrow deprived cells amelio 

rates the autoimmunity associated with C1q deficiency 

Josefina Cortes-Hernandez 

• Serological changes following B lymphocyte depletion therapy in systemic 

lupus erythematosus Maria Leandro 

• Quality of life and disability at presentation in polymyalgia rheumatica 

(PMR): results from a multi-centre prospective cohort study 

Andrew Hutchings 

14:30 – 16:30 BHPR: Rheumatology pain Pentland 

Chairs: Paul Creamer and Julia Taylor 

• Pain mechanisms Bruce Kidd 

Up to 85% of patients with chronic back pain and related disorders cannot 

be given a precise anatomical diagnosis. It is apparent that internal and 

external factors act in concert to produce sensitization of nociceptive/pain 

pathways at peripheral, spinal and cortical levels. This lecture will discuss the 

clinical implications of these changes and show how the evaluation and 

treatment of musculoskeletal pain may be facilitated using a 

mechanism-based approach. 

• Multidisciplinary team assessment and management of chronic pain 

Mike Shipley 

Chronic pain is difficult to manage. The way an experienced and 

multidisciplinary team including physicians, psychologists, physiotherapists 

and nurses assesses the patients and then encourages better coping 

strategies in groups of patients will be discussed. 

• Clinical assessment of fibromyalgia Sarah Ryan 

This presentation will focus on the clinical features of Fibromyalgia and the 

need for a biopsychosocial approach to assessment 

• Pain from a therapists perspective Kay Stevenson 

Kay will use a new referral pathway for patients with musculoskeletal disease 

to demonstrate how a multidisciplinary approach to patient care can 

improve patient outcomes and opportunities for healthcare professionals. 

She will also include a discussion on her role as a Consultant Physiotherapist 

and how this contributes to patient care 


17:00 – 18:00 Heberden Round – Stepping stones in rheumatology Pentland Suite 

Prof Roger Sturrock, Glasgow, Scotland 


The Heberden Round was initiated in 1948 to 

the work of an individuals’ outstanding contribution to 

clinical rheumatology. The award traditionally took the 

form of a ward round in the appointee’s own hospital. 

In 1999 it was decided that the Round would be 

incorporated into the BSR’s Annual Meeting to ensure 

greater exposure to the membership. 

21

This has proved to be a huge success and the one hour annual Heberden Round 

presentation remains a highlight within the rheumatology calendar. 

This year the round will be given by Roger Sturrock, McLeod/arc Professor of 

Rheumatology, Centre for Rheumatic Diseases, Glasgow, Scotland. Prof Sturrock has 

been President of the BSR and is currently Chairman of the Board of Trustees at the 

Arthritis Research Campaign. 

18:00 onwards Drinks reception, followed by dinner and ceilidh 

Museum of Scotland 

Friday 23 April 2004 

07:30 – 08:30 Wyeth sponsored fun run The Meadows Park, Edinburgh 

07:30 – 08:30 Christian Medical Fellowship breakfast meeting Harris 1 

08:30 – 10:00 BSR & BHPR Poster viewing session 3 Strathblane Hall 

10:00 – 11:00 BSR Poster Discussions 

Clinical aspects of rheumatoid arthritis Pentland 

Chairs: Hilary Cappell and Peter Dawes 


Connective tissue disease Sidlaw 

Chairs: Ian Bruce and Ariane Herrick 


Health service research and education Kilsyth 

Chairs: Andy Hassell and Deborah Symmons 


Spondyloarthropathies Tinto/Moorfoot 

Chairs: Gabrielle Kingsley and Roger Sturrock 


10:00 – 11:00 BHPR Poster prize and oral presentation of 3 abstracts Fintry 

Chairs: Lindsey Hawley and Margaret Somerville 

• “Clinic at home” an audit of a multidisciplinary service Yvonne Hough 

• Patient perception of reason for folic acid supplementation while on methotrexate 

for rheumatoid arthritis Moira McDonald 

• Winner of the NRAS Patients in Focus Award 

Setting up a home based patient self-administration subcutaneous methotrexate 

service for adults and children. Gill Jackson and Jo White 


22

11:30 – 12:30 BSR State of the Art Lecture - 

New therapies for autoimmune disease: 

anti-TNF and beyond Pentland/Sidlaw 

Prof Lawrence Steinman, Beckman Centre, 

California, USA 

Chair: David Isenberg 

The State of the Art lecture is generally of broader 

interest, but relevant to rheumatologists, and is 

traditionally given by an invited lecturer who is 

eminent within their field. This year Lawrence 

Steinman, Professor of Neurology and 

Neurological Sciences at the Beckman Centre, 

Stanford University, California will give delegates a 

vision of the future with new biologics. 

Prof Steinman will describe how large scale profiles of gene transcripts from 

material taken from lesions has lead to the identification of new targets in 

autoimmunity. Some surprising new targets in Th1 autoimmunity including 

leptins, histamine receptors and enzymes in the cholesterol pathway will be 

discussed. The use of large scale profiling of the immune response to develop 

a “reverse genomic” approach to the antigen specific therapy of autoimmune 

disease, using suppressive DNA vaccines will be described. 

11:30 – 12:00 BHPR: Evidence based guidelines Fintry 

Speaker: Tom Kennedy 

Chairs: Alison Hammond and Bett Barrett 

This session will cover the principles, levels and evaluation tools used for 

evidence based guidelines development. There will be discussion of the BSR 

approach to standards, guidelines and audit. 

12:00 – 12:30 BHPR: Update on arc education initiative Fintry 

Speaker: Karen Mounce 

Chairs: Alison Hammond and Bett Barrett 

This flexible, modular, rheumatology education programme is nearing 

accreditation as a post-graduate certificate with a chosen university. 

The course will be open to all Allied Health Professionals, with a masters 

programme planned for subsequent development. 


13:00 – 14:30 Satellite symposium 

Schering Plough: “Beneath the Skin” Treatment goals for underlying 

disease in IMIDs Tinto 

• Welcome Dr Peter Taylor, Chair 

• Immunological Basis for IMID Professor Iain McInnes 

• Could healing of underlying damage now be a goal of treatment in 

Rheumatoid Arthritis? Dr Peter Taylor and Professor Paul Emery 

• Ankylosing Spondylitis and Inflammatory Bowel Disease – common 

treatment aims? Professor Subrata Ghosh 

• Questions 

• Thanks and close 

23

Additional Meetings 

Please note that all meetings with the exception of the RATs Meeting, BSR Standards, Audit and Guidelines 

Working Group Open Meeting, BSR Biologics Register Open Meeting, and the Christian Medial Fellowship 

Breakfast, are by invitation only. 

Date & Time Meeting Name Room 

Tuesday 20 April 

11:00 – 13:00 BSR External Relations Committee Ochil 3 

13:00 – 14:00 RATs Meeting (lunch provided) Kilsyth 

13:00 – 14:00 Academic Rheumatology Forum Carrick 1 

13:00 – 14:00 Rheumatology Editorial Board Meeting Carrick 2 

13:00 – 14:00 BSR Standards, Audit and Harris 1 

Guidelines Working Group Open Mtg 

16:00 – 18:00 BSRBR Management Committee Harris 1 

Wednesday 21 April 

10:00 – 11:00 BSR Clinical Affairs Committee Harris 1 

12:00 – 14:30 arc/BSR MIPA Clinical Trial Carrick 3 

13:00 – 13:45 BSR Biologics Register Open Mtg Tinto/Moorfoot 

14:00 – 16:00 ARMA Governance Meeting Harris 1 

Thursday 22 April 

12:45 – 14:00 BSR AGM Fintry 

Friday 23 April 

07:00 – 08:30 Fun Run – sponsored by Wyeth The Meadows Park 

07:30 – 08:30 Christian Medical Fellowship Breakfast Harris 1 

14:30 onwards The Raynaud’s & Scleroderma Association Moorfoot 

24

Concurrent Oral Sessions 

Tuesday 20 April 2004, 16:30 – 18:00 

Osteoarthritis and crystal diseases (OP1 – OP6) Sidlaw 

OP1 GAIN OF FUNCTION ANKH VARIANTS CAUSE BOTH FAMILIAL AND SPORADIC CALCIUM 

PYROPHOSPHATE DIHYDRATE CHONDROCALCINOSIS. 

Y Zhang 1,2 , K Johnson 3 , GG Russell 2 , BP Wordsworth 2 , AJ Carr 2 , RA Terkeltaub 3 , MA Brown 1,2 . 

1 

Wellcome Trust Centre for Human Genetics, Spondyloarthritis and Bone Disease Research Group, 

University of Oxford, Oxford, United Kingdom; 2 Institute of Musculoskeletal Sciences, the Botnar 

Centre, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom; 3 VA Medical 

Center, Division of Rheumatology, University of California, San Diego, United States 

OP2 MONOCYTE-MACROPHAGE DIFFERENTIATION IN VIVO AND THE CONTROL OF 

MONOSODIUM URATE (MSU) CRYSTAL-STIMULATED INFLAMMATION. 

DR Yagnik, BJ Evans, C Landis, DO Haskard. Eric Bywaters Centre for Vascular Inflammation, 

Imperial College, London, United Kingdom 

OP3 SEQUENCIAL MEASUREMENTS OF SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN 

(COMP) INDICATE A NON-LINEAR PROGRESSION OF KNEE OSTEOARTHRITIS. 

M Sharif 1 , JR Kirwan 2 , R Granell 2 , S Clarke 2 . 1 

Department of Anatomy, University of Bristol, Bristol, 

United Kingdom; 2 Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom 

OP4 NEUROVASCULAR INVASION AT THE OSTEOCHONDRAL JUNCTION IN OSTEOARTHRITIS. 

SE Gill 1 , CS Bonnet 1 , S Suri 1 , D Wilson 2 , DA Walsh 1,2 . 1 

Academic Rheumatology, University of 

Nottingham, Nottingham, Nottinghamshire, United Kingdom; 2 Back Pain Unit, King’s Mill Hospital, 

Mansfield, Nottinghamshire, United Kingdom 

OP5 CANCELLOUS BONE CHANGES IN THE PROXIMAL TIBIA OF PATIENTS WITH KNEE 

OSTEOARTHRITIS. 

EA Messent, C Buckland-Wright. Applied Clinical Anatomy, King’s College London, London, 

United Kingdom 

OP6 LONG TERM OUTCOME FOLLOWING TOTAL HIP ARTHROPLASTY: A CASE CONTROL 

STUDY. 

J Cushnaghan 1 , I Reading 1 , P Byng 1 , D Coggon 1 , K Cox 1 , P Croft 2 , P Dieppe 3 , C Cooper 1 . 1 

MRC EEU, 

Southampton University, Southampton, United Kingdom; 2 Primary Care Sciences Research Centre, 

Keele University, Keele, United Kingdom; 3 MRC Health Services Research Collaboration, Bristol 

University, Bristol, United Kingdom 

Epidemiology (OP7 – OP12) Fintry 

OP7 BIRTH ORDER AS A DETERMINANT OF OSTEOPOROSIS RISK: THE HERTFORDSHIRE 

COHORT STUDY. 

E Dennison, H Syddall, A Aihie Sayer, H Gilbody, C Cooper. Medical Research Council 

Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hampshire, 


OP8 JOINT HYPERMOBILITY IS COMMON AND STRONGLY GENETICALLY DETERMINED: 

RESULTS OF A FEMALE TWIN STUDY. 

AJ Hakim 1,2,3 , R Grahame 2 , TD Spector 1 , AJ MacGregor 1 . 1 

The Twin Research Unit, St Thomas’ 

Hospital, London, United Kingdom; 2 The Hypermobility Clinic, Centre for Rheumatology, University 

College London Hospitals, London, United Kingdom; 3 The Academic Rheumatology and 

Osteoporosis Unit, Whipps Cross University Hospital, London, United Kingdom 

25

OP9 ASSOCIATION BETWEEN DIETARY CAROTENOIDS AND RISK OF DEVELOPING 

INFLAMMATORY POLYARTHRITIS. 

DJ Pattison 1 , DPM Symmons 1 , M Lunt 1 , A Welch 2 , R Luben 2 , SA Bingham 3 , K-T Khaw 2 , NE Day 2 , AJ 

Silman 1 . 1 Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United 

Kingdom; 2 Department of Public Health & Primary Care, University of Cambridge, Cambridge, United 

Kingdom; 3 MRC Dunn Human Nutrition Unit, University of Cambridge, Cambridge, United Kingdom 

Young Investigator Award Winner 

OP10 PREDICTING PERSISTENCE OF NECK PAIN FOLLOWING A MOTOR VEHICLE ACCIDENT: 

A PROSPECTIVE STUDY OF PERSONS ATTENDING EMERGENCY DEPARTMENT. 

K Atherton 1 , GT Jones 1,2 , NJ Wiles 2,3 , AJ Silman 2 , FE Lecky 1 , SJ Hawes 4 , AJ Littlewood 1 , CJ Main 1 , GJ 

Macfarlane 1,2 . 1 

Unit of Chronic Disease Epidemiology, University of Manchester, Manchester, United 

Kingdom; 2 Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United 

Kingdom; 3 Division of Psychiatry, University of Bristol, Bristol, United Kingdom; 4 Department of 

Emergency Medicine, Wythenshawe Hospital, Manchester, United Kingdom 

OP11 HYPOTHALAMIC-PITUITARY-ADRENAL STRESS AXIS FUNCTION - THE RELATIONSHIP WITH 

CHRONIC WIDESPREAD PAIN AND ITS ANTECEDENTS: A POPULATION-BASED STUDY. 

J McBeth 1 , YH Chiu 1,5 , D Ray 2 , RK Morriss 3 , C Dickens 4 , A Gupta 1 , AJ Silman 1 , GJ Macfarlane 1,5 . 1 

ARC 

Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Endocrine Sciences Research 

Group, University of Manchester, Manchester, United Kingdom; 3 Department of Psychiatry, University of 

Liverpool, Liverpool, United Kingdom; 4 Department of Psychiatry, University of Manchester, Manchester, 

United Kingdom; 5 The Unit of Chronic Disease Epidemiology, University of Manchester, Manchester, 

United Kingdom. 

OP12 IS MUSCULOSKELETAL PAIN MORE COMMON NOW THAN 40 YEARS AGO? 

RESULTS FROM TWO POPULATION-BASED CROSS-SECTIONAL STUDIES. 

J McBeth 1 , EF Harkness 1 , AJ Silman 1 , GJ Macfarlane 1,2 . 1 

ARC Epidemiology Unit, The University of 

Manchester, Manchester, United Kingdom; 2 The Unit of Chronic Diseases Epidemiology, The University of 

Manchester, Manchester, United Kingdom 

Vascular injury (OP13 – OP18) Tinto/Moorfoot 

OP13 SYSTEMIC RHEUMATOID VASCULITIS - FACING EXTINCTION? 

RA Watts 1 , J Mooney 2 , SE Lane 2 , DGI Scott 2 . 1 

Department of Rheumatology, Ipswich Hospital NHS Trust, 

Ipswich, Suffolk, United Kingdom; 2 Department of Rheumatology, Norfolk & Norwich University Hospital, 

Norwich, Norfolk, United Kingdom 


OP14 THE HAEMOGLOBIN SCAVENGER RECEPTOR CD163 MEDIATES MACROPHAGE 

INTERLEUKIN-10 AND HAEM OXYGENASE-1 SYNTHESIS: AN INDUCIBLE CYTOPROTECTIVE 

PATHWAY AGAINST HAEMOGLOBIN-MEDIATED OXIDATIVE VASCULAR INJURY. 

P Philippidis, BJ Evans, JC Mason, KM Taylor, DO Haskard, C Landis. Eric Bywaters Centre for Vascular 

Inflammation, Imperial College, London, United Kingdom 


OP15 UPREGULATION OF MEMBRANE-BOUND COMPLEMENT REGULATORY PROTEINS BY 

ATORVASTATIN PROTECTS VASCULAR ENDOTHELIUM AGAINST COMPLEMENT-MEDIATED INJURY 

DURING HYPOXIA-REOXYGENATION. 

AR Kinderlerer 1 , R Mankoff 1 , PH Maxwell 2 , DO Haskard 1 , JC Mason 1 . 1 

BHF Cardiovascular Medicine Unit, 

The Eric Bywaters Centre for Vascular Inflammation, Imperial College London, London, United Kingdom; 

2 

Renal Unit, Faculty of Medicine, Imperial College London, London, United Kingdom 

26

OP16 RENAL ARTERY STENOSIS IN HYPERTENSIVE PATIENTS WITH ANTIPHOSPHOLIPID SYN- 

DROME (APS): THE EFFECTS OF ANTICOAGULATION. 

S Sangle, D D’Cruz, M Khamashta, GRV Hughes. Lupus Research Unit, The Rayne Institute, St 

Thomas’ Hospital, London, United Kingdom 

OP17 CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS 

IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV). 

EM Salisbury 1 , JS McLaren 1 , DRW Jayne 2 , RA Luqmani 1 . 1 

Rheumatic Diseases Unit, University of 

Edinburgh, Edinburgh, United Kingdom; 2 Addenbrooke’s NHS Trust, Cambridge, United Kingdom 

OP18 MOLECULAR PROFILE OF SYMPTOMATIC AND ASYMPTOMATIC CAROTID PLAQUES. 

EP Halligan 1 , M Sintler 2 , A Mahmood 2 , J Butler 1 , J Vorha 2 , GD Kitas 3 , J Lunec 1 . 1 

Cancer Studies and 

Molecular Medicine, Univesity of Leicester, Leicester, Leicestershire, United Kingdom; 2 Vascular 

Surgery, Selloak Hospital, Birmingham, United Kingdom; 3 Rheumatology, Dudley Group of 

Hospitals NHS Trust, Dudley, United Kingdom 

THERAPEUTICS (OP19 – OP24) Pentland 

OP19 THE ARMADA TRIAL: EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA ® ) OVER 30 

MONTHS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. 

ME Weinblatt 1 , EC Keystone 2 , DE Furst 3 , A Kavanaugh 4 , OG Segurado 5 , G Spencer-Green 6 , EK 

Chartash 6 . 1 

Brigham Women’s Hospital, Boston, MA, United States; 2 University of Toronto, 

Toronto, ON, Canada; 3 UCLA, Los Angeles, CA, United States; 4 The Center for Innovative Therapy, 

UCSD, San Diego, CA, United States; 5 Abbott Laboratories, Chicago, IL, United States; 6 Abbott 

Laboratories, Parsippany, NJ, United States 

OP20 ADALIMUMAB (HUMIRA ® ) INHIBITS RADIOGRAPHIC PROGRESSION IN RHEUMATOID 

ARTHRITIS (RA) PATIENTS WITH LONG-STANDING DISEASE: DATA AT TWO YEARS. 

E Keystone 1 , A Kavanaugh 2 , J Sharp 3 , G Spencer-Green 4 , OG Segurado 5 . 1 

University of Toronto, 

Toronto, ON, Canada; 2 The Centre for Innovative Therapy, UCSD, San Diego, CA, United States; 

3 

University of Washington, Seattle, WA, United States; 4 Abbott Laboratories, Parsippany, NJ, 

United States; 5 Abbott Laboratories, Chicago, IL, United States 

OP21 EFFICACY OF ANAKINRA IN ACTIVE ANKYLOSING SPONDYLITIS: A CLINICAL 

AND MAGNETIC RESONANCE IMAGING STUDY. 

AL Tan 1,3 , H Marzo-Ortega 1 , P O’Connor 2 , A Fraser 1 , P Emery 1 , D McGonagle 1,3 . 1 

Academic Unit of 

Musculoskeletal Disease, Leeds General Infirmary, Leeds, United Kingdom; 2 Department of 

Radiology, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of Rheumatology, 

Calderdale Royal Hospital, Halifax, United Kingdom 

OP22 PREDICTIVE VALUE OF SYNOVIAL CYTOKINE EXPRESSION FOR RESPONSE 

TO ANTI-TUMOUR-NECROSIS-FACTOR-α TREATMENT IN RHEUMATOID ARTHRITIS 

IN CLINICAL PRACTICE. 

MH Buch 1 , A English 1 , G Cunnane 2 , K Henshaw 1 , R Reece 1 , M Quinn 1 , SJ Bingham 1 , V Bejarano 1 , 

P Emery 1 . 1 

Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, West Yorkshire, 

United Kingdom; 2 Department of Rheumatology, St. James’ Hospital, Dublin, Ireland 

OP23 A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTI-CENTRE TRIAL OF 

COMBINATION THERAPY WITH METHOTREXATE PLUS CYCLOSPORIN V METHOTREXATE PLUS 

PLACEBO IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. 

AD Fraser 1 , A van Kuyk 2 , R Westhovens 3 , Z Karim 1 , A Gerards 2 , RBM Landewe 4 , S Steinfeld 5 , 

P Emery 1 , BAC Dijkmans 2 , DJ Veale 1 . 1 

Rheumatology and Rehabilitation Research Unit, University 

of Leeds, Leeds, West Yorkshire, United Kingdom; 2 VU University Medical Center, VU University, 

Amsterdam, The Netherlands; 3 Department of Rheuamtology, University of Leuven, Leuven, 

Belgium; 4 Department of Rheumatology, University Hospital Maastricht, Maastricht, The 

Netherlands; 5 Department of Rheuamtology, Erasme University Hospital, Brussels, Belgium 

27

OP24 A RANDOMISED CONTROLLED TRIAL OF INTRA-ARTICULAR TRIAMCINOLONE 

AND/OR PHYSIOTHERAPY IN SHOULDER CAPSULITIS. 

I Ryans 1 , A Montgomery 2 , R Galway 2 , WG Kernohan 3 , R McKane 1 . 1 

Rhematology Department, The Ulster 

Hospital, Dundonald, Belfast, Northern Ireland, United Kingdom; 2 Physiotherapy Department, The Ulster 

Hospital, Dundonald, Belfast, Northern Ireland, United Kingdom; 3 Faculty of Life and Health Sciences, 

University of Ulster, Jordanstown, Northern Ireland, United Kingdom 

BSR Plenary Oral Session 

Wednesday 21 April 2004, 14:00 – 16:00 

BSR PLENARY SESSION (OP25 - OP30) Pentland/Sidlaw 

OP25 TARGETING B CELLS WITH RITUXIMAB: AN EFFECTIVE AND WELL TOLERATED 

TREATMENT FOR ACTIVE RHEUMATOID ARTHRITIS (RA). 

JD Isaacs 1 , P Emery 2 . 1 

Department of Rheumatology, University of Newcastle-upon-Tyne, Newcastle, 

Newcastle-upon-Tyne, United Kingdom; 2 Academic Unit of Musculoskeletal Disease, Department of 

Rheumatology, Leeds General Infirmary, Leeds, United Kingdom 

OP26 HEBERDEN’S NODES: WHAT HEBERDEN DIDN’T SEE- A HIGH RESOLUTION MRI STUDY OF THE 

MICRO-ARCHITECTURAL ABNORMALITIES IN EARLY AND ESTABLISHED HAND OSTEOARTHRITIS. 

AL Tan 1 , A Grainger 2 , SF Tanner 3 , P Emery 1 , D McGonagle 1 . 1 

Academic Unit of Musculoskeletal Disease, 

University of Leeds, Leeds, United Kingdom; 2 Department of Radiology, Leeds General Infirmary, Leeds, 

United Kingdom; 3 Academic Unit of Medical Physics, University of Leeds, Leeds, United Kingdom 

OP27 PSORIATIC ARTHRITIS SYNOVITIS: A CRITICAL ROLE FOR IL-15 AND IL-18? 

DJ Kane 1 , A Gracie 2 , S Karanaman 2 , M Gogarty 3 , B Bresnihan 3 , O FitzGerald 3 , IB McInnes 2 . 

1 

Rheumatology, University of Newcastle, Newcastle, United Kingdom; 2 Centre for Rheumatic Diseases, 

Glasgow Royal Infirmary, Glasgow, United Kingdom; 3 Rheumatology, St. Vincent’s University Hospital, 

Dublin, United Kingdom 


OP28 VERY EARLY RHEUMATOID ARTHRITIS IS CHARACTERISED BY A UNIQUE AND TRANSIENT 

T CELL AND STROMAL CYTOKINE PROFILE. 

K Raza 1 , SJ Curnow 1 , EJ Taylor 1 , KY Lee 2 , AN Akbar 3 , J Lord 1 , GD Kitas 4 , CD Buckley 1 , C Gordon 1 , 

M Salmon 1 . 1 

Division of Immunity and Infection, MRC Centre for Immune Regulation, University of 

Birmingham, Birmingham B15 2TT, United Kingdom; 2 Department of Radiology, City Hospital, Dudley 

Road, Birmingham, B18 7QH, United Kingdom; 3 Department of Immunology and Molecular Pathology, 

Royal Free and University College Medical School, London, United Kingdom; 4 Department of 

Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, DY1 4SE, United Kingdom 

OP29 MODERATE ALCOHOL IS GOOD FOR WOMEN’S BONES. 

FMK Williams, LF Cherkas, TD Spector, AJ MacGregor. Twin Research and Genetic Epidemiology Unit, 

St Thomas’ Hospital, London, SE1 7EH, United Kingdom 

Michael Mason Prize Winner 

OP30 autoantibodies, lupus, and the science of sabotage 

A Rahman. Centre for Rheumatology, Department of Medicine, University College London, 

United Kingdom. 

28

BHPR Plenary Oral Session 


BHPR PLENARY SESSION (OP31 – OP36) Tinto/Moorfoot 

OP31 CONSERVATIVE HAND THERAPY TREATMENTS IN RHEUMATOID ARTHRITIS (RA) - 

A RANDOMISED CONTROLLED TRIAL. 

AV Chadwick 1 , CS Simpson 2 , K Murray 2 , J Spicer 2 , D Mulherin 2 , PW Jones 3 , R Mullis 1,4 , 

K Dziedzic 1,4 . 1 

Department of Physiotherapy Studies, Keele University, Keele, Staffs ST5 5BG, 

United Kingdom; 2 Department of Rehabilitation, Mid-Staffordshire General Hospitals NHS Trust, 

Stafford, Staffs, United Kingdom; 3 Department of Mathematics, Keele University, Keele, Staffs ST5 

5BG, United Kingdom; 4 Primary Care Sciences Research Centre, Keele University, Keele, Staffs ST5 

5BG, United Kingdom 

OP32 PAIN IS NOT ALWAYS THE PRIORITY - RHEUMATOID ARTHRITIS PATIENTS 

VALUE OTHER OUTCOMES. 

S Hewlett 1 , M Carr 2 , S Ryan 3 , J Kirwan 1 , P Richards 1 , P Creamer 4 , A Carr 5 , R Hughes 2 . 1 

Academic 

Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Rheumatology Department, St 

Peter’s Hospital, Chertsey, United Kingdom; 3 Rheumatology Department, Heywood Hospital, Stoke 

on Trent, United Kingdom; 4 Rheumatology Department, Southmead Hospital, Bristol, United 

Kingdom; 5 Rheumatology Department, Nottingham University, Nottingham, United Kingdom 

OP33 HOW DOES RHEUMATOID ARTHRITIS AFFECT FEMALE PATIENTS’ ABILITY 

TO CONTINUE HOUSEHOLD ACTIVITIES. RESULTS OF THE DEVELOPMENT AND 

VALIDATION OF A QUESTIONNAIRE. 

C Boys 1 , C Mayes 2 , A Young 2 , P Prouse 1 , A Stylianou 3 , J Done 3 . 1 

Rheumatology Department, North 

Hampshire Hospital, Basingstoke, Hampshire, United Kingdom; 2 Rheumatology Department, St 

Albans City Hospital, St Albans, Hertfordshire, United Kingdom; 3 Psychology Department, R&D 

Support Unit, University of Hertfordshire, Hatfield, Hertfordshire, United Kingdom 

OP34 PATIENTS’ AND RHEUMATOLOGISTS’ DIFFERENT VIEWS ON ANALGESIA IN RA. 

S Howden 1 , M Nicol 1 , DJ Martin 2 , D Jones 1 . 1 

Occupational Therapy Department, Queen Margaret 

University College, Edinburgh, Lothian, United Kingdom; 2 Physiotherapy Department, Queen 

Margaret University College, Edinburgh, Lothian, United Kingdom 

OP35 THE PATIENT’S EXPERIENCE OF ATTENDING EITHER A LUPUS OR A SCLERODERMA 

EDUCATION PROGRAMME: A QUALITATIVE EVALUATION. 

SJ Brown, NJ McHugh. RACE, Royal National Hospital for Rheumatic Diseases NHS Trust, Bath 

BA1 1RL, United Kingdom 

OP36 THE FUTURE OF SHARED CARE MONITORING OF DMARDS WITH THE ADVENT 

OF THE NEW GENERAL MEDICAL SERVICES GP CONTRACT - A SURVEY IN THE MERTHYR 

AND CYNON VALLEYS. 

E Thomas, F Hayes, C Rhys-Dillon. Department of Rheumatology, Prince Charles Hospital, Merthyr 

Tydfil, South Wales, United Kingdom 

29

Concurrent Oral Sessions 

Thursday 22 April 2004, 14:30 – 16:30 

HEALTH SERVICE AND EDUCATION RESEARCH (OP37 – OP44) Tinto/Moorfoot 

OP37 IMPROVED ACCESS AND TARGETING OF MUSCULOSKELETAL SERVICES: 

THE TEAMS PROGRAMME. 

P Maddison 1 , J Jones 1 , R Lewis 1 , L McSweeney 1 , C Norgain 1 , C Barton 1 , A Breslin 1 , J Fleur 1 , S Smith 1 , 

C Thomas 1 , C Tillson 2 . 1 

Rheumatology, Orthopaedics, Therapy Services and Pain Management, Ysbyty 

Gwynedd, Bangor, Gwynedd, United Kingdom; 2 Gwynedd Local Health Board, Eryldon, Caernarfon, 

Gwynedd, United Kingdom 

OP38 USING THE HEALTH ASSESSMENT QUESTIONNAIRE AND WELFARE BENEFITS ADVICE TO HELP 

PEOPLE DISABLED THROUGH ARTHRITIS TO ACCESS FINANCIAL SUPPORT. 

C Langley 1 , DS Memel 1 , JR Kirwan 2 , J Pollock 3 , S Hewlett 2 , D Gubbay 4 , J Powell 3 . 1 

Air Balloon Surgery, 

Bristol, United Kingdom; 2 Academic Rheumatology Unit, University of Bristol, Bristol, United Kingdom; 

3 

Faculty of Health and Social Care, University of the West of England, Bristol, United Kingdom; 4 Barton 

Hill Advice Service, Bristol, United Kingdom 

OP39 RCT OF PATIENT-INITIATED REVIEW VERSUS REGULAR PHYSICIAN-INITIATED FOLLOW-UP IN 

RHEUMATOID ARTHRITIS, EXTENDED TO 6 YEARS. 

S Hewlett 1 , J Kirwan 1 , K Mitchell 1 , M Hehir 1 , J Pollock 2 , D Memel 3 , PS Blair 4 , M Perry 1 . 1 

Academic 

Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Faculty of Health and Social Care, 

University of the West of England, Bristol, United Kingdom; 3 Air Balloon Surgery, Bristol, United 

Kingdom; 4 Division of Child Health, University of Bristol, Bristol, United Kingdom 

OP40 DEVELOPMENT OF E-LEARNING TUTORIALS IN RHEUMATOLOGY: EXPERIENCE 

FROM THE UNIVERSITY OF BRISTOL. 

RW Marshall 1,2 , JR Kirwan 1 . 1 

Rheumatology Unit, University Department of Clinical Science at South 

Bristol, Bristol, BS2 8HW, United Kingdom; 2 Rheumatology, Royal National Hospital for Rheumatic 

Diseases, Bath, BA1 1RL, United Kingdom 

OP41 COMPETENCE BASED ASSESSMENT OF SPECIALIST REGISTRARS IN RHEUMATOLOGY: 

ASSESSMENT OF OUT-PATIENT CONSULTATION SKILLS. 

CM Dowson, AB Hassell. West Midland Rheumatology Services and Training Committee (WMRSTC), 

Staffordshire Rheumatology Centre, Stoke-on-Trent, North Staffordshire, United Kingdom 

OP42 HOSPITAL SERVICES FOR LOW BACK PAIN : ARE THEY EFFICIENT? 

MJ Plant 1 , R Chadwick 3 , R Strachan 2 , M Murray 4 , E Carter 5 , S Puttick 5 , K Milligan 3 , C Greenough 4 . 

1 

Rheumatology, The James Cook University Hospital, Middlesbrough, United Kingdom; 2 Neurosurgery, 

The James Cook University Hospital, Middlesbrough, United Kingdom; 3 Pain Management, The James 

Cook University Hospital, Middlesbrough, United Kingdom; 4 Spinal Injuries, The James Cook University 

Hospital, Middlesbrough, United Kingdom; 5 Clinical Audit, The James Cook University Hospital, 

Middlesbrough, United Kingdom 

OP43 EVALUATION OF AN INTERACTIVE INTELLIGENT TELEPHONE BASED MONITORING 

SYSTEM FOR PATIENTS WITH RHEUMATOID. 

R Hampson, A Tierney, HA Capell, R Madhok. Centre for Rheumatic Diseases, Royal Infirmary, Glasgow, 


OP44 EARLY PHYSIOTHERAPY MANAGEMENT OF BACK PAIN IN PRIMARY CARE: A RANDOMISED 

CLINICAL TRIAL OF PHYSICAL TREATMENTS VERSUS A BRIEF PAIN MANAGEMENT PROGRAMME. 

EM Hay 1 , R Mullis 1 , M Lewis 1 , K Vohora 1 , C Main 2 , P Watson 3 , K Dzeidzic 1 , J Sim 1 , P Croft 1 . 1 

Primary Care 

Sciences Research Centre, Keele University, Keele, United Kingdom; 2 Department of Behavioral Medicine, 

Manchester University, Manchester, United Kingdom; 3 Department of Anaesthetics and Pain 

Management, University of Leicester, Leicester, United Kingdom 

30

RA PATHOGENESIS (OP45 – OP52) Fintry 

OP45 THE BALANCE OF SIGNALING MOLECULES DOWNSTREAM OF THE NOTCH RECEPTOR 

IN CD4+CD25 high REGULATORY T-CELLS IN RA RESEMBLES THE BALANCE OBSERVED IN 

ANERGIC CELLS. 

F Ponchel, SL Field, KE Snow, JD Isaacs, P Emery. Molecular Medicine Unit/Rheumatology Reserch 

Unit, University of Leeds, Leeds, West Yorkshire, United Kingdom 

OP46 OXDATIVE INACTIVATION OF CD45 PHOSPHATASE CONTRIBUTES TO THE 

DYSREGULATION OF T CELLS IN RA . 

DA Rider, AM McKendry, JE Goodall, SP Young. Rheumatology, University of Birmingham, 

Birmingham, West Midlands, United Kingdom 

OP47 ANGIOPOIETIN 2 IN INFLAMMATION, A PRIMARY ROLE FOR ANGIOGENESIS 

IN THE INVASIVE PROCESS? 

U Fearon 1 , T Markham 1 , RH Mullan 1 , L Golden-Mason 2 , T Duffy 1 , L Greenan 1 , B Bresnihan 1 , 

O FitzGerald 1 , DJ Veale 1 . 1 

Rheumatology, St Vincents University Hospital and The Conway Institute, 

Dublin, Ireland; 2 Liver Unit, St Vincents University Hospital, Dublin, Ireland 

OP48 SYNOVIAL HIF-2a EXPRESSION IS INVERSELY RELATED TO TISSUE OXYGEN 

LEVELS IN INFLAMMATORY ARTHRITIS. 

V Sandhu 1 , D Peston 2 , A Sandisson 2 , PC Taylor 1 . 1 

Kennedy Institute of Rheumatology Division, 

Imperial College, London, United Kingdom; 2 Charing Cross Hospital, Department of Pathology, 

London, United Kingdom 

OP49 BYSTANDER ACTIVATED LYMPHOCYTES : A PHENOTYPIC COMPARISON WITH 

RHEUMATOID SYNOVIAL LYMPHOCYTES. 

J Beech, P Amjadi, S Owen, A Foey, F Brennan. Kennedy Institute of Rheumatology Division, 



OP50 THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR QUINAPRIL SUPPRESSES 

INFLAMMATORY ARTHRITIS. 

N Dalbeth 1,2 , J Edwards 3 , MFC Callan 1,2 , FC Hall 1,4 . 1 

Weatherall Institute of Molecular Medicine, 

University of Oxford, Oxford, United Kingdom; 2 Department of Immunology, Imperial College 

London, London, United Kingdom; 3 Nuffield Department of Orthopaedic Surgery, Universty of 

Oxford, Oxford, United Kingdom; 4 University of Cambridge School of Clinical Medicine, 

Addenbrooke’s Hospital, Cambridge, United Kingdom 

OP51 DEFECTS IN THE GENERATION AND FUNCTION OF REGULATORY T CELLS IN 

RHEUMATOID ARTHRITIS: REVERSAL BY ANTI-TNFα THERAPY. 

MR Ehrenstein, JG Evans, A Singh, S Moore, DA Isenberg, C Mauri. Department of Medicine, 

University College London, London, United Kingdom 

OP52 PAR-2 IN THE PATHOGENESIS OF JOINT INFLAMMATION. 

EB Kelso 1 , I Elias-Jones 1 , L Dunning 2 , JC Lockhart 2 , WR Ferrell 1 , MD Hollenberg 3 , R Plevin 4 . 1 

Centre 

for Rheumatic Diseases, University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Biological 

Sciences, University of Paisley, Glasgow, Scotland, United Kingdom; 3 Department of Pharmacology, 

University of Calgary, Canada; 4 Department of Physiology & Pharmacology, Strathyclyde University, 

Scotland. 

GENOMICS (OP53 – OP60) Kilsyth 

OP53 SEQUESTOSOME 1 GENE MUTATIONS IN PAGET’S DISEASE OF BONE LEAD 

TO DISREGULATED NFKB SIGNALLING. 

A Daroszewska, A Duthie, LJ Hocking, G Lucas, RJ van ‘t Hof, SH Ralston. Department of 

Medicine and Therapeutics, University of Aberdeen, Aberdeen, Aberdeenshire, United Kingdom 

31

OP54 OX40L, BUT NOT OX40, IS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS. 

DS Cunninghame Graham, TJ Vyse. Rheumatology Section, Imperial College, Hammersmith Campus, 

Eric Bywaters Centre, London, United Kingdom 

OP55 HETEROGENEITY AMONGST PATIENTS WITH CHRONIC INFANTILE NEUROLOGICAL CUTA- 

NEOUS AND ARTICULAR (CINCA) SYNDROME. 

E Aganna, 1 JE Davidson, 2 G Cleary, 2 JA Sills, 2 A Bybee, 3 E Drewe, 4 GA Hitman, 1 P Woo, 5 PN Hawkins, 3 MF 

McDermott. 1 1 Centre for Diabetes & Metabolic Medicine, Queen Mary School of Medicine and Dentistry, 

London, United Kingdom; 2 Rheumatology, Royal Liverpool Children’s Hospital, Alder Hey, Liverpool, 

United Kingdom; 3 Centre for Amyloidosis, Royal Free Hospital, London, United Kingdom; 4 Molecular and 

Clinical Immunology, Queen’s Medical Centre, Nottingham, United Kingdom; 5 Rheumatology, Child 

Health, University College, London, United Kingdom 

OP56 HIGH RESOLUTION LINKAGE DISEQUILIBRIUM MAPPING IDENTIFIES ASSOCIATION TO SINGLE 

NUCLEOTIDE POLYMORPHISM MARKERS MAPPING TO A REGION OF LINKAGE ON CHROMOSOME 

17Q22 WITH RHEUMATOID ARTHRITIS. 

A Barton 1 , D Ward 1 , S Eyre 1 , A Hinks 1 , A Silman 1 , E Culbert 2 , S John 3 , J Worthington 1 . 1 

ARC-EU, University 

of Manchester, Manchester, United Kingdom; 2 Astra-Zeneca Pharmceuticals Ltd, Alderley Park, 

Macclesfield, Cheshire, United Kingdom; 3 CIGMR, University of Manchester, Manchester, United Kingdom 

OP57 THE BXSB INTERVAL ON CHROMOSOME 13 (BXS6) IS NECESSARY AND SUFFICIENT FOR HIGH 

TITRE GP70 AUTOANTIGEN SYNTHESIS AND CONCOMITANT AUTOANTIBODY PRODUCTION. 

JM Rankin 1 , MEK Haywood 1 , A McDermott 1 , S Izui 2 , B Morley 1 . 1 

Rheumatology Section, 

The Eric Bywaters Centre, Imperial College, London, United Kingdom; 2 Department of Pathology, 

C.M.U, Geneva, Switzerland 

OP58 MICROARRAY ANALYSIS OF CHROMOSOME 1 CONGENIC BXSB MICE REVEALS 

NOVEL LUPUS-SUSCEPTIBILITY GENE CANDIDATES. 

MEK Haywood, J Rose, G Fu, MJ Walport, BJ Morley. Rheumatology Section, Eric Bywaters Centre, 



OP60 THE IL1 GENE CLUSTER IS A MAJOR LOCUS DETERMINING SUSCEPTIBILITY TO 

ANKYLOSING SPONDYLITIS. 

AE Timms 1 , AM Crane 1 , A-M Sims 1 , H Cordell 2 , L Bradbury 1 , O Beynon 1 , GR Duff 5 , LR Cardon 4 , A Calin 3 , 

P Wordsworth 1 , MA Brown 1 . 1 

Institute of Musculoskeletal Sciences, The Botnar Research Centre, Oxford, 

United Kingdom; 2 Cambridge Institute of Medical Research, Addenbrookes Hospital, Cambridge, United 

Kingdom; 3 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 4 Wellcome Trust 

Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; 5 Division of Genomic 

Medicine, University of Sheffield, Sheffield, United Kingdom 

CONNECTIVE TISSUE DISEASE (OP61 – OP68) Sidlaw 

OP61 UPREGULATION OF THE MONOCYTE CHEMOATTRACTANT PROTEIN -1 LIGAND-RECEPTOR 

AXIS IN EARLY STAGE DIFFUSE CUTANEOUS SCLERODERMA. 

MT Carulli, V Ong, M Ponticos, X Shiwen, L Shand, DJ Abraham, CM Black, CP Denton. Centre for 

Rheumatology, Royal Free Hospital, London, United Kingdom 

OP62 A LONGITUDINAL ANALYSIS OF SKIN SCLEROSIS AND ORGAN-BASED ENDPOINTS 

IN A COHORT OF EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. 

LM Shand, M Hosseini, CM Black, CP Denton. Centre for Rheumatology, Royal Free and University 

College Medical School, London, United Kingdom 

32

OP63 ALTERED LIPID RAFT EXPRESSION AND ASSOCIATED SIGNALLING IN T LYMPHOCYTES 

FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 

EC Jury 1 , PS Kabouridis 2 , F Flores-Borja 2 , RA Mageed 2 , DA Isenberg 1 . 1 

Centre for Rheumatology, 

Royal Free and University College Medical School, University College London, London, United 

Kingdom; 2 Bone and Joint Research Unit, Bats and The London, Queen Mary’s School of Medicine 

and Dentistry, London, United Kingdom 

OP64 SEROLOGICAL INVESTIGATION OF AUTOANTIBODIES IN 577 FAMILIES WITH SYSTEMIC 

LUPUS ERYTHEMATOSUS. 

S Chadha, CA Roberton, P Charles, J Whittaker, TJ Vyse. 1 Rheumatology Section, Eric Bywaters 

Centre, Imperial College Faculty of Medicine, Hammersmith, London, United Kingdom; 2 Kennedy 

Institute of Rheumatology, Imperial College Faculty of Medicine, London, United Kingdom; 

3 

Epidemiology and Public Health, Imperial College Faculty of Medicine, St Mary’s, London, United 

Kingdom 

OP65 GENETIC DISSECTION OF BXSB LUPUS PHENOTYPE USING MICE CONGENIC 

FOR CHROMOSOME 1 DEMONSTRATES THAT SEPARATE INTERVALS DIRECT DIFFERENT 

ASPECTS OF DISEASE. 

MEK Haywood 1 , J Rose 1 , J Boyle 2 , AM McDermott 1 , JM Rankin 1 , S Izui 3 , MJ Walport 1 , BJ Morley 1 . 

1 

Rheumatology Section, Eric Bywaters Centre, Imperial College, London, United Kingdom; 

2 

Histopathology Department, Hammersmith Hospital, London, United Kingdom; 3 Department of 

Pathology, Centre Medical Universitaire, Geneva, Switzerland 

OP66 RECONSTITUTION OF C1q-DEFICIENCY WITH BONE MARROW DERIVED CELLS 

AMELIORATES THE AUTOIMMUNITY ASSOCIATED WITH C1q-DEFICIENCY. 

J Cortes-Hernandez 1 , L Fossati-Jimack 1 , S Izui 2 , F Petry 3 , M Loos 3 , MJ Walport 1 , M Botto 1 . 

1 

Rheumatology Section, Eric Bywaters Centre, Imperial College, London, London, United Kingdom; 

2 

Department of Pathology, University of Geneva, Geneva, Geneva, Switzerland; 3 Institute of 

Medical Microbiology and Hygiene, Johannes Gutenberg-University, Mainz, Mainz, Germany 

OP67 SEROLOGICAL CHANGES FOLLOWING B LYMPHOCYTE DEPLETION THERAPY 

IN SYSTEMIC LUPUS ERYTHEMATOSUS. 

MJ Leandro 1 , G Cambridge 1 , JCW Edwards 1 , M Teodorescu 2 , MR Ehrenstein 1 , DA Isenberg 1 . 

1 

Centre for Rheumatology, University College London, London, United Kingdom; 2 TheraTest Labs, 

Lombard, IL, United States 

OP68 QUALITY OF LIFE, FUNCTIONAL STATUS AND CLINICAL FEATURES AT PRESENTATION 

IN POLYMYALGIA RHEUMATICA(PMR): RESULTS FROM A MULTI-CENTRE PROSPECTIVE 

COHORT STUDY. 

B Dasgupta 1 , A Hutchings 1,2 , J Hollywood 1 , D Lamping 2 , C Pease 3 , K Chakravarty 4 , B Hazleman 5 , 

B Silverman 5 , E Choy 6 , DGI Scott 7 , B Bourke 8 , N Gendi 9 . 1 

Southend Hospital, Westcliff-on-sea, 

United Kingdom; 2 London School of Hygiene & Tropical Medicine, London, United Kingdom; 

3 

Leeds General Infirmary, Leeds, United Kingdom; 4 Harold Wood Hospital, Romford, Essex, United 

Kingdom; 5 Addenbrookes Hospital, Cambridge, United Kingdom; 6 King’s College London, London, 

United Kingdom; 7 Norfolk & Norwich Hospital, Norwich, United Kingdom; 8 St George’s Hospital, 

London, United Kingdom; 9 Basildon Hospital, Basildon, Essex, United Kingdom. 

33

BHPR Oral Presentations 

Friday 23 April 2004, 10:00 – 11:00, Fintry 

OP69 “CLINIC AT HOME” AN AUDIT OF A MULTIDISCIPLINARY SERVICE. 

Y Hough, A Campbell, J Novak, AE Griffiths, VE Abernethy, MP Lynch. 1 Rheumatology Department, 

St Helens & Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom 

OP70 PATIENT PERCEPTION OF REASON FOR FOLIC ACID SUPPLEMENTATION WHILE ON 

METHOTREXATE FOR RHEUMATOID ARTHRITIS (RA). 

M McDonald, R Ramachandran, E Garrity, A Tierney, R Hampson, HA Capell, R Madhok. Centre for 

Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom 

Poster Viewing Session 1 


CYTOKINS AND INFLAMMATOR MECHANISMS (1 – 5) 

1 TNF-α AND THE SPHINGOLIPID CASCADE: KEY PLAYERS IN THE SYSTEMIC INFLAMMATION AND 

ATHEROSCLEROSIS OF RA. 

LD Church, SP Young, PA Bacon. Department of Rheumatology, Division of Immunity and Infection, 

University of Birmingham, Birmingham, West Midlands, United Kingdom 

2 A NOVEL ROLE FOR SERUM AMYLOID-A (A-SAA) IN ANGIOGENESIS AND ADHESION MOLECULE 

EXPRESSION THROUGH AN NFKB-DEPENDENT SIGNAL TRANSDUCTION PATHWAY. 

RH Mullan, L Golden-Mason, T Markham, R O’Hara, O FitzGerald, B Bresnihan, DJ Veale, U Fearon. 

Rheumatology, St. Vincents University Hospital and The Conway Institute, Dublin, Ireland 

3 SYNDECAN-3 BINDS CXCL8 ON THE SYNOVIAL ENDOTHELIUM IN RHEUMATOID ARTHRITIS. 

AM Patterson 1 , L Gardner 1 , J Shaw 1 , E Loreau 2 , L Aguilar 2 , J Middleton 1 . 1 

LMARC, Keele University at 

Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom; 2 Endocube 

S.A.S., Prologue Biotech - BP-700, Rue Pierre et Marie Curie, 31319 Labege, France 

4 CHARACTERISATION OF THE RESPONSE TO SELF-hsp60 IN HEALTHY INDIVIDUALS. 

RC Duggleby 1 , MS Lillicrap 2 , JSH Gaston 1 , RA Whiston 1 . 1 

Medicine, University of Cambridge, Cambridge, 

United Kingdom; 2 Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom 

5 BYSTANDER-ACTIVATED LYMPHOCYTES IN INFLAMMATION: A NATURAL PROCESS? 

S Owen, P Amjadi, P Green, A Foey, F Brennan. Kennedy Institute of Rheumatology Division, Imperial 

College, London, United Kingdom 

CELL RECEPTOR-LIGAND INTERACTIONS (6 – 12) 

6 A ROLE FOR BOTH COMPLEMENT AND Fcγ RECEPTORS IN THE TRANSFER OF SOLUBLE IMMUNE 

COMPLEXES FROM ERYTHROCYTES TO MONOCYTE-DERIVED MACROPHAGES IN A DYNAMIC IN 

VITRO HUMAN MODEL. 

AL Hepburn 1 , JC Mason 2 , S Wang 2 , MJ Walport 1 , KA Davies 1 . 1 

Rheumatology Section, Imperial College 

London, Hammersmith Hospital, London, United Kingdom; 2 BHF Cardiovascular Medicine Unit, Imperial 

College London, Hammersmith Hospital, London, United Kingdom 

34

7 BIFUNCTIONAL ROLE FOR VEGF-INDUCED HEME OXYGENASE-1 IN VIVO: 

INDUCTION OF ANGIOGENESIS AND INHIBITION OF LEUKOCYTIC INFILTRATION. 

B Bussolati 1 , A Ahmed 2 , RC Landis 3 , F Di Carlo 1 , H Pemberton 1 , DO Haskard 3 , JC Mason 3 . 1 

Biology 

and Clinical Science, Torino University, Torino, Italy; 2 Reproductive and Vascular Biology, 

Birmingham University, Birmingham, United Kingdom; 3 The Eric Bywaters Centre, Imperial College 

London, Hammersmith Hospital, London, United Kingdom 

8 INVESTIGATION OF PLATELET GLYCOPROTEIN IIIa POLYMORPHISM IN PATIENTS WITH 

RHEUMATOID ARTHRITIS. 

AH Strang 1 , M McLaren 1 , A Rudd 1 , KD Morley 2 , JJF Belch 1 . 1 

Vascular Medicine, University of 

Dundee, Dundee, Tayside, United Kingdom; 2 Rheumatology, Ninewells Hospital, Dundee, Tayside, 


9 VEGF-INDUCED CYTOPROTECTION OF VASCULAR ENDOTHELIUM IS DIFFERENTIALLY REGU- 

LATED BY CYCLOSPORIN A AND RAPAMYCIN. 

JC Mason 1 , EA Lidington 1 , R Mankoff 1 , AR Kinderlerer 1 , M Ohba 2 , DO Haskard 1 . 1 

The Eric Bywaters 

Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom; 2 Institute of 

Molecular Oncology, Showa University, Tokyo, Japan 

10 LIGATION OF LEUKOCYTE FCγRII (CD32) BY AN ANTI-ENDOTHELIAL CELL (EC) ANTIBODY 

SYNERGISES WITH G-PROTEIN COUPLED RECEPTOR SIGNALLING TO AMPLIFY LEUKOCYTE 

ADHESION TO CYTOKINE-ACTIVATED UNDER PHYSIOLOGICAL FLOW. 

O Florey, JC Mason, DO Haskard. Eric Bywaters Centre, Imperial College, London, United Kingdom 

11 THE RA CANDIDATE SUSCEPTIBILITY GENE IkBL DOWNREGULATES 

INFLAMMATORY SIGNALLING. 

CD Ellis, D Mewar, FA Guesdon, AG Wilson. Division of Genomic Medicine, University of Sheffield, 

Sheffield, S Yorks, United Kingdom 

12 PERFORIN EXPRESSION IN EARLY INFLAMMATORY ARTHRITIS. 

CF Matthews 1 , P Maxwell 2 , GD Wright 1 , B Bresnihan 3 , O FitzGerald 3 , PW Hamilton 2 , MME Rooney 1 . 

1 

Department of Rheumatology, Musgrave Park Hospital, Belfast, County Antrim, United Kingdom; 

2 

Department of Quantitative Pathology, Queen’s University of Belfast, Belfast, County Antrim, 

United Kingdom; 3 Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland 

GENOMICS (13 – 27) 

13 THE DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE S GENE IN 

PSORIATIC ARTHRITIS USING PYROSEQUENCING. 

E Korendowych 1 , NJ McHugh 1 , J Lewis 1 , J Ravindran 1 , PA Owen 1 , S Gaudieri 2 . 1 

Department of 

Research and Clinical Effectiveness, Royal National Hospital for Rheumatic Diseases, Bath, United 

Kingdom; 2 Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital, Perth, 

WA, Australia 

14 INVESTIGATION OF CHROMOSOME 3q21 IN PSORIATIC ARTHRITIS. 

PYP Ho, J Bowes, S Eyre, P Bradburn, I Bruce, A Silman, J Worthington, A Barton. 

ARC-Epidemilogy Unit, University of Manchester, Manchester, United Kingdom 

15 INVESTIGATION OF CARD15 IN PATIENTS WITH PSORIATIC ARTHRITIS. 

PYP Ho, J Bowes, S Eyre, P Bradburn, I Bruce, A Silman, J Worthington, A Barton. 

ARC-Epidemiology Unit, University of Manchester, Manchester, United Kingdom 

16 FAILED TOTAL HIP REPLACEMENT CANDIDATE GENE ANALYSIS. 

HA Malik 2 , F Jury 1 , E Zeggini 1 , A Bayat 1 , WE Ollier 1 , PR Kay 2 . 1 

Centre for Integrated Genomic 

Medical Research, The University of Manchester, Manchester, United Kingdom; 2 The Centre for 

Hip Surgery, Wrightington Hospital, Wigan, Lancashire, United Kingdom 

35

17 POLYMORPHISMS OF WISP3 AND SUSCEPTIBILITY TO JUVENILE IDIOPATHIC ARTHRITIS. 

RM Lamb 1 , E Zeggini 2 , BPRG Study Group, W Thomson 1 , R Donn 1 . 1 

ARC/EU, University of Manchester, 

Manchester, United Kingdom; 2 CIGMR, University of Manchester, Manchester, 


18 GENOME WIDE SCREEN ANALYSIS IN MULTIPLEX FAMILIES WITH PRIMARY HIP OSTEOARTHRITIS: 

SUGGESTIVE LINKAGE TO CHROMOSOMES 2, 10 AND 11. 

GK Meenagh 1 , J Nixon 1 , GD Wright 1 , AE Hughes 2 . 1 

Department of Rheumatology, Musgrave Park 

Hospital, Belfast, United Kingdom; 2 Department of Medical Genetics, Queen’s University Belfast, Belfast 

City Hospital Trust, Belfast, United Kingdom 

19 LACK OF ASSOCIATION BETWEEN CORTICOTROPHIN-RELEASING HORMONE 

LOCUS AND RHEUMATOID ARTHRITIS. 

A Julià 1 , D Gallardo 2 , F Vidal 2 , C Tomàs 1 , P Barceló 1 , M Vilardell 3 , S Marsal 1 . 1 

Unitat de Recerca de 

Reumatologia, Hospital General i Universitari Vall d’Hebron, Barcelona, Spain; 2 Centre de Transfusions i 

Banc de Teixits de Barcelona, Servei Català de la Salut, Barcelona, Spain; 3 Servei de Medicina Interna, 

Hospital General i Universitari Vall d’Hebron, Barcelona, Spain 

20 A FUNCTIONAL HAPLOTYPE OF THE PADI4 GENE ASSOCIATED WITH RA IN A JAPANESE 

POPULATION IS NOT ASSOCIATED IN A UK POPULATION. 

J Bowes 1 , S Eyre 1 , K Spreckley 1 , A Hinks 1 , S John 2 , J Worthington 1 , A Barton 1 . 1 

ARC-EU, University of 

Manchester, Manchester, United Kingdom; 2 University of Manchester, Manchester, United Kingdom 

21 FUNCTIONAL LYMPHOTOXIN α 5’ POLYMORPHIC VARIANTS INFLUENCE PROMOTER ACTIVITY 

IN RHEUMATOID ARTHRITIS. 

C Molloy 1 , C Adams 1 , G O’Donoghue 1 , H Mulcahy 1 , S Busteed 2 , K O’Rourke 1 , C Silke 1 , F Shanahan 3 , MG 

Molloy 2 , F O’Gara 1 . 1 

Biomerit Research Centre, Microbiology, National University of Ireland (NUI), Cork, 

Ireland; 2 Rheumatology, NUI, Cork, Ireland; 3Medicine, NUI, Cork, Ireland 

22 GENE EXPRESSION PROFILING OF ISCHAEMIC HEART DISEASE IN RHEUMATOID ARTHRITIS. 

EP Halligan 1 , J Butler 1 , M Evans 1 , M Cooke 1 , F Falciani 3 , MJ Banks 2 , J Lunec 1 , GD Kitas 2 . 1 

Cancer Studies 

and Molecular Medicine, University of Leicester, Leicester, Leicestershire, United Kingdom; 

2 

Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom; 3 Biosciences, University 

of Birmingham, Birmingham, United Kingdom 

23 REFINEMENT OF THE CRH HAPLOTYPE IN RHEUMATOID ARTHRITIS. 

S Steer 1 , SA Fisher 2 , MS Fife 3 , B Lad 1 , J Grumley 1 , A Milicic 4 , P Wordsworth 4 , J Worthington 5 , ARC 

National Repository 5 , CM Lewis 2 . 1 

Rheumatology, Kings College, London, United Kingdom; 2 Division of 

Genetics and Development, Kings College, London, United Kingdom; 3 Paediatric and Adolescent 

Rheumatology, University College, London, United Kingdom; 4 Rheumatology, University of Oxford, 

Oxford, United Kingdom; 5 ARC Epidemiology Unit, University of Manchester, Manchester, 


24 FINE MAPPING OF NOVEL SUSCEPTIBILITY GENES FOR RHEUMATOID ARTHRITIS IN 

THE TELOMERIC MHC. 

AL Coote, RF Kilding, MM Iles, AM Mcdermott, AG Wilson. Division of Genomic Medicine, The 

University of Sheffield, Sheffield, United Kingdom 

25 ASSOCIATION OF MARKERS WITHIN THE FOXP3 GENE WITH RHEUMATOID ARTHRITIS (RA). 

A Hinks 1 , A Barton 1 , E Zeggini 2 , S Eyre 1 , S John 2 , J Worthington 1 . 1 

ARC-EU, University of Manchester, 

Manchester, United Kingdom; 2 CIGMR, University of Manchester, Manchester, United Kingdom 

36

26 ANALYSIS OF COMBINED US-UK RA WGS IDENTIFIES A SUSCEPTIBILITY LOCUS ON 

CHROMOSOME 1P. 

ND Shephard 1 , A Butterworth 1 , W Chen 2 , M Seldin 1 , A Silman 1 , B Ollier 3 , P Gregersen 4 , C Amos 2 , 

S John 3 , J Worthington 1 . 1 

ARC Epidemiology Unit, University of Manchester, Manchester, United 

Kingdom; 2 Epidemiology and Biomathematics, University of Texas, Houston, TX, United States; 

3 

Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United 

Kingdom; 4 Division of Biology and Human Genetics, North Shore University Hospital, New York, 

United States 

27 WHOLE GENOME LINKAGE SCAN IN RA MULTICASE FAMILIES, USING 11,245 SNPS. 

S John 1 , N Shephard 2 , E Zeggini 1 , M Cao 3 , W Chen 3 , N Vasavda 4 , G Liu 3 , N Gibson 4 , K Jones 3 , 

G Kennedy 3 , J Worthington 2 . 1 

Centre for Integrated Medical Genomic Research, University of 

Manchester, Manchester, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom; 3 Affymetrix, Inc., Santa Clara, CA, United States; 4Astrazeneca, 

Alderley Park, Macclesfield, United Kingdom 

RHEUMATOID ARTHRITIS: BIOLOGICS (28 – 47) 

28 IL-7 AND T-CELL DYSFUNCTION IN RA PATIENTS IN CLINICAL REMISSION. 

F Ponchel, AK Brown, SL Field, JD Isaacs, P Emery. Molecular Medicine Unit, Rheumatology 

Research Unit, University of Leeds, Leeds, West Yorkshire, United Kingdom 

29 ASSESSMENT OF FUNCTIONAL STATUS AMONG PATIENTS WITH ACTIVE RHEUMATOID 

ARTHRITIS IN A DOUBLE-BLIND TRIAL OF ETANERCEPT AND METHOTREXATE, ALONE AND 

COMBINED (TEMPO TRIAL). 

D van der Heijde 1 , L Klareskog 2 , J DeJager 3 , A Gough 4 , J Kalden 5 , M Malaise 6 , E Martin Mola 7 , 

K Pavelka 8 , J Sany 9 , L Settas 10 , J Wajdula 11 . 1 

U Hosp Maastricht, Maastricht, The Netherlands; 

2 

Karolinska Hosp, Stockholm, Sweden; 3 Gold Coast Rheumatology, Southport, Australia; 

4 

Harrogate District Hosp, Harrogate, United Kingdom; 5 U Erlangen-Nurnberg, Erlangen, Germany; 

6 

CHU Univ of Liege, Liege, Belgium; 7 La Paz Hosp, Madrid, Spain; 8 Inst of Rheumatology, Prague, 

Czech Republic; 9 Hosp Lapeyronie, Montpellier, France; 10 U Thessaloniki, Thessaloniki, Greece; 

11 

Wyeth Research, Collegeville, United States 

30 DOUBLE-BLIND COMPARATIVE STUDY OF RADIOGRAPHIC PROGRESSION OF 

ETANERCEPT (E) AND METHOTREXATE (MTX), ALONE AND COMBINED (E+MTX), 

IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (TEMPO TRIAL). 

D van der Heijde 1 , L Klareskog 2 , J DeJager 3 , A Gough 4 , J Kalden 5 , M Malaise 6 , E Martin Mola 7 , 

K Pavelka 8 , J Sany 9 , L Settas 10 , J Wajdula 11 . 1 

U Hosp Maastricht, Maastricht, The Netherlands; 

2 

Karolinska Hosp, Stockholm, Sweden; 3 Gold Coast Rheumatology, Southport, Australia; 

4 

Harrogate District Hosp, Harrogate, United Kingdom; 5 U Erlangen-Nurnberg, Erlangen, Germany; 

6 

CHU Univ of Liege, Liege, Belgium; 7 La Paz Hosp, Madrid, Spain; 8 Inst Rheumatology, Prague, 

Czech Republic; 9 Hosp Lapeyronie, Montpellier, France; 10 U Thessaloniki, Thessaloniki, Greece; 

11 

Wyeth Research, Collegeville, United States 

31 SWITCHING BIOLOGICS AFTER INITIAL ANTI-TUMOUR-NECROSIS-FACTOR-α FAILURE; 

SUCCESS WITH FURTHER TNF-α ANTAGONISM BUT FAILURE ON SUBSEQUENT 

INTERLEUKIN-1 RECEPTOR ANTAGONIST. 

MH Buch, SJ Bingham, Y Seto, V Bejarano, M Rynne, D Bryer, J White, P Emery. Academic Unit of 

Musculoskeletal Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom 

32 LEVELS OF CIRCULATING sCD23 FOLLOWING B LYMPHOCYTE DEPLETION THERAPY 

IN RHEUMATOID ARTHRITIS. 

G Cambridge, MJ Leandro, A Bhatia, JCW Edwards. Centre for Rheumatology, University College 

London, Arthur Stanley House, London W1T 5NJ, United Kingdom 

37

33 FATAL EXACERBATION OF RHEUMATOID ARTHRITIS (RA) ASSOCIATED FIBROSING ALVEOLITIS 

IN THREE PATIENTS TREATED WITH AZATHIOPRINE AND INFLIXIMAB. 

AJK Ostor 1 , MF Somerville 2 , SE Lane 1 , AYN Lim 1 , AJ Crisp 1 , DGI Scott 2 . 1 

Rheumatology Department, 

Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Rheumatology Department, Norfolk and 

Norwich University Hospital, Norwich, United Kingdom 

34 RELATIONSHIP OF ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) TO PHARMACODYNAMIC 

(PD) IN RHEUMATOID ARTHRITIS (RA) PATIENTS DURING PHASE II/III CLINICAL TRIALS. 

R Granneman 1 , Y Zhang 1 , P Noertersheuser 2 , R Velagapudi 3 , W Awni 1 , C Locke 1 , O Segurado 1 , T Toward 4 . 

1 

Abbott Laboratories, Abbott Park, IL, United States; 2 Abbott Laboratories, Ludwigshafen, Germany; 

3 

Abbott Laboratories, Parsippany, NJ, United States; 4 Abbott Laboratories, Maidenhead, Berkshire, 


35 THE EFFECT OF DISEASE DURATION ON CLINICAL OUTCOMES FOLLOWING ADALIMUMAB 

(HUMIRA ® ) THERAPY IN RA. 

P Emery 1 , R Fleischmann 2 , V Strand 3 , WG Reiss 4 , G Spencer-Green 5 , OG Segurado 6 . 1 

University of Leeds, 

Leeds, United Kingdom; 2 Southwestern Medical Centre at Dallas - Radiant Research, University of Texas, 

Dallas, TX, United States; 3 Stanford University, Portola Valley, CA, United States; 4 Abbott Laboratories, 

Parsippany, NJ, United States; 5Abbott Laboratories, Chicago, IL, United States 

36 BIOLOGICS IN CLINICAL PRACTICE - BETTER THAN EXPECTED? 

RN Jois, M Somerville, A Brooksby, K Gaffney, P Merry, DGI Scott. Department of Rheumatology, 

Norfolk and Norwich University Hospital, Norwich, United Kingdom 

37 ARE ALL ANTI-TNF AGENTS EQUAL? RESULTS OF MERSEY BIOLOGICS AUDIT. 

TC Barnes 1 , V Abernethy 2 . 1 

Dept Rheumatology, Royal Liverpool University Hospital, Liverpool, United 

Kingdom; 2 Dept Rheumatology, Whiston and St Helens Hospital, St. Helens, United Kingdom 

38 ANTI TNF: PATIENTS, POLITICS AND PRACTICALITIES OF ACCESS TO TREATMENT DURING 

THE LAST FOUR YEARS. 

MF Somerville, A Brooksby, K Gaffney, DGI Scott. Rheumatology Unit, Norfolk & Norwich University 

Hospital, Norwich, Norfolk, United Kingdom 

39 STEADY-STATE ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) FOLLOWING EVERY OTHER 

WEEK (EOW) DOSING OF 40mg SUBCUTANEOUS (SC) INJECTION, IN RHEUMATOID ARTHRITIS (RA) 

PATIENTS TREATED WITH AND WITHOUT CONCOMITANT METHOTREXATE (MTX). 

WM Awni 1 , P Cascella 2 , N Oleka 3 , RB Velagapudi 3 , H Kupper 4 , E Chartash 3 , R Granneman 1 , 

OG Segurado 1 , TJ Toward 5 . 1 Abbott Laboratories, Abbott Park, IL, United States; 2 Drug Development 

Resources LLC, Mountain Lakes, NJ, United States; 3 Abbott Laboratories, Parsippany, NJ, United States; 

4 

Abbott Laboratories, Ludwigshafen, Germany; 5 Abbott Laboratories, Maidenhead, Berks, 


40 SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA ® ) PLUS METHOTREXATE (MTX) 

IN RHEUMATOID ARTHRITIS (RA) PATIENTS. 

MH Schiff 1 , M Weisman 2 , DE Furst 3 , A Kavanaugh 4 , G Spencer-Green 5 , OG Segurado 6 . 1 

Denver Arthritis 

Clinic, Denver, CO, United States; 2 Cedars-Sinai Medical Center, Los Angeles, CA, United States; 3 UCLA, 

Los Angeles, CA, United States; 4 The Center for Innovative Therapy, UCSD, San Diego, CA, United 

States; 5 Abbott Laboratories, Parsippany, NJ, United States; 6 Abbott Laboratories, Chicago, IL, 

United States 

41 HOW WELL DO WE IDENTIFY RHEUMATOID ARTHRITIS (RA) PATIENTS ELIGIBLE FOR ANTI-TNF 

IN OUR ROUTINE CLINICS? 

M Leach, S Christy-Kilner, B Pal, PA Sanders. Department of Rheumatology, South Manchester University 

Hospitals, Manchester, M20 2LR, United Kingdom 

38

42 THE OXFORD EXPERIENCE WITH THE USE OF INFLIXIMAB IN THE TREATMENT OF 


ATY Chan, T Reed, J David. Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford, 


43 ADALIMUMAB IN CLINICAL PRACTICE-INITIAL EXPERIENCE AT A SINGLE UK CENTRE. 

AN Bennett, P Peterson, N Banya, J Grumley, G Panayi, B Kirkham. Department of Rheumatology, 

Guy’s & St Thomas’ Hospital Trust, UK, London, United Kingdom 

44 THE USE OF BIOLOGIC AGENTS FOR SEVERE INFLAMMATORY ARTHRITIS IN 

NORTHERN IRELAND. 

SA Wright 1 , K Brown 1 , D McCracken 2 , AJ Taggart 1 . 1 

Rheumatology, Musgrave Park Hospital, 

Belfast, Northern Ireland, United Kingdom; 2 Clinical Governance, Musgrave Park Hospital, Belfast, 

Northern Ireland, United Kingdom 

45 ANALYSING DECISIONS ABOUT THE CHANGE IN A PATIENT’S CLINICAL CONDITION 

AFTER A TRIAL TREATMENT WITH TNF-α AGENTS. 

L O’Hare, N Sheehy, F Kee, A Bell, O Fitzgerald. 1 Psychology, Queens University, Belfast, United 

Kingdom; 2 Psychology, Queens University, Belfast, United Kingdom; 3 Epidemiology and Public 

Health, Queens University, Belfast, United Kingdom; 4 Rheumatology, Queens University, Belfast, 

United Kingdom; 5 Rheumatology, St Vincent’s Hospital, Dublin, Ireland 

46 OBSERVATIONAL STUDY OF THE ROUTINE USE OF ANTI-TNF DRUGS IN THE TREATMENT 

OF RHEUMATOID ARTHRITIS IN A UK SETTING: IMPACTS ON QUALITY OF LIFE AND MOOD. 

M Koutantji 1 , JR Smith 2 , M Adams 2 , A Brooksby 3 , M Somerville 3 , DGI Scott 2,3 . 1 

Department of 

Surgical Oncology & Technology, Imperial College London, London, United Kingdom; 2 School of 

Medicine, Health Policy & Practice, University of East Anglia, Norwich, United Kingdom; 

3 

Department of Rheumatology, Norfolk & Norwich Univesity Hospital NHS Trust, Norwich, 


47 PATIENTS’ EXPERIENCE OF ANTI-TNFα THERAPY IN RHEUMATOID ARTHRITIS: 

A QUALITATIVE STUDY. 

NJ Marshall 1 , G Wilson 1 , K Lapworth 2 , LJ Kay 1 . 1 Musculoskeletal Department, Newcastle upon Tyne 

Hospitals NHS Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2 Clinical Effectiveness 

Department, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, Tyne and Wear, 


RHEUMATOID ARTHRITIS: THERAPY (48 – 71) 

48 USE OF HERBAL AND OVER-THE-COUNTER REMEDIES AND POTENTIAL INTERACTIONS 

WITH CONVENTIONAL MEDICATION IN RHEUMATOLOGY OUTPATIENTS. 

WA Holden 1 , J Joseph 2 , L Williamson 3 . 1 

Rheumatology, Nuffield Orthopaedic Centre, Oxford, 

United Kingdom; 2 Rheumatology, Nuffield Orthopaedic Hospital, Oxford, United Kingdom; 

3 

Rheumatology, Great Western Hospital, Swindon, United Kingdom 

49 ULTRASONOGRAPHY PREDICTS RESPONSE TO INTRAMUSCULAR METHYLPREDNISOLONE 

AND HYDROXYCHLOROQUINE IN PATIENTS WITH INFLAMMATORY HAND PAIN. 

Z Karim, MA Quinn, RJ Wakefield, AK Brown, PG Conaghan, P Emery. Academic Unit of 

Musculoskeletal Medicine, Department of Rheumatology, Leeds General Infirmary, Leeds, West 

Yorkshire, United Kingdom 

50 THE REGIONAL VARIATION AND DIFFERENTIAL RESPONSE OF SYNOVITIS TO THERAPY IN 

KNEE JOINT DISEASE IN EARLY INFLAMMATORY ARTHRITIS. 

AL Tan 1 , LA Rhodes 2 , SF Tanner 2 , A Radjenovic 2 , R Reece 1 , P O’Connor 3 , P Emery 1 , D McGonagle 1 . 

1 

Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 

2 

Academic Unit of Medical Physics, University of Leeds, Leeds, United Kingdom; 3 Department of 

Radiology, Leeds General Infirmary, Leeds, United Kingdom 

39

51 UNDERSTANDING NON-RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS: 

PREDICTING SUBSEQUENT OUTCOME. 

MH Buch, Y Seto, SJ Bingham, V Bejarano, D Bryer, J White, P Emery. Academic Unit of Musculoskeletal 

Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom 

52 AGGRESSIVE THERAPY WITH CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC 

DRUGS (DMARD) DOES NOT PREVENT DISEASE PROGRESSION IN PATIENTS WITH STABLE 

ESTABLISHED RHEUMATOID ARTHRITIS (RA): RESULTS OF A RANDOMISED OBSERVER-BLINDED 

CONTROLLED CLINICAL TRIAL. 

M Davis 1 , K Tricker 2 , C Roberts 3 , P Dawes 4 , A Hassell 4 , S Knight 5 , D Mulherin 6 , DL Scott 7 , D Symmons 2,5 . 

1 

Royal Cornwall NHS Trust, Truro, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom; 3 Biostatistics Group, University of Manchester, Manchester, United 

Kingdom; 4 University Hospital of North Staffordshire NHS Trust, Stoke on Trent, United Kingdom; 5 East 

Cheshire NHS Trust, Macclesfield, United Kingdom; 6 Mid-Staffordshire General Hospitals NHS Trust, 

Cannock, United Kingdom; 7 King’s College Hospital, London, United Kingdom 

53 ADDING LIGNOCAINE DOES NOT AFFECT SHORT OR MEDIUM-TERM OUTCOME IN 

INTRA-ARTICULAR STEROID INJECTIONS. 

C Rao, M Bukhari. Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, Lancashire, 


54 RANDOMISED PLACEBO-CONTROLLED TRIAL OF INTRAMUSCULAR (IM) DEPOT 

METHYLPREDNISOLONE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS. 

EH Choy 1 , GH Kingsley 1 , B Khoshaba 1 , N Pipitone 1 , L Dolan 2 , P Pitt 3 , B Dasgupta 4 , GS Panayi 1 , DL Scott 1 . 

1 

Academic Department of Rheumatology, GKT School of Medicine, London, United Kingdom; 

2 

Rheumatology, Queen Elizabeth Hospital, Greenwich, United Kingdom; 3 Rheumatology, Farnborough 

Hospital, Farnborough, United Kingdom; 4 Rheumatology, Southend Hospital, Southend, United Kingdom 

55 IS IT POSSIBLE TO PREDICT WHICH PATIENTS WITH RHEUMATOID ARTHRITIS (RA) 

WILL DERIVE RHEUMATOLOGICAL BENEFIT FROM STATIN THERAPY? 

DW McCarey, N Sattar, R Hampson, R Madhok, IB McInnes, HA Capell. Centre for Rheumatic Diseases, 

Royal Infirmary, Glasgow, United Kingdom 

56 COMBINATION VS MONOTHERAPY FOR POOR PROGNOSIS RHEUMATOID ARTHRITIS: 

A LONG-TERM FOLLOW-UP STUDY. 

V Bejarano, C Philip, G Michael, K Heather, E Paul. Academic Unit of Musculoskeletal Disease, University 

of Leeds, Leeds, United Kingdom 

57 SYSTEMATIC REVIEW OF EFFECTIVENESS OF FIVE STRATEGIES TO PREVENT NSAID-INDUCED 

GASTROINTESTINAL TOXICITY. 

L Hooper 1 , TJ Brown 1 , RA Elliott 2 , K Payne 3 , C Roberts 4 , D Symmons 5 . 1 

Cochrane Oral Health Group, 

University of Manchester, Manchester, United Kingdom; 2 School of Pharmacy, Manchester University, 

Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital, Manchester, United 

Kingdom; 4 School of Epidemiology and Health Sciences, Manchester University, Manchester, United 

Kingdom; 5 ARC Epidemiology Unit, Manchester University, Manchester, United Kingdom 

58 DEMOGRAPHIC TRENDS IN 5 COHORTS OF RHEUMATOID ARTHRITIS (RA) PATIENTS ENROLLED 

IN PROSPECTIVE DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) STUDIES 1986-2003. 

S Irvine 1 , G Roberts 1 , R Madhok 1 , DR Porter 2 , JA Hunter 2 , IB McInnes 1 , HA Capell 1 . 1 

Centre for Rheumatic 

Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 Rheumatology Department, Gartnavel General 

Hospital, Glasgow, United Kingdom 

59 EFFECT OF GENDER ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) PRESCRIPTION 

IN RHEUMATOID ARTHRITIS (RA). 

E Morrison 1 , R Hampson 2 , A Tierney 2 , L MacKenzie 2 , HA Capell 2 . 1 

Rheumatology, Southern General 

Hospital, Glasgow, United Kingdom; 2 Centre for Rheumatic Diseases, Royal Infirmary, Glasgow, 


40

60 LEFLUNOMIDE - EXPERIENCE WITH 300 PATIENTS. 

PN Platt. Rheumatology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom 

61 FREQUENCY AND TYPE OF PIGMENTATION IN PATIENTS RECEIVING MINOCYCLINE THER- 

PAY FOR RHEUMATOID ARTHRITIS (RA). 

G Roberts, HA Capell. Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United 

Kingdom 

62 THE USE AND MONITORING OF IMMUNE MODIFYING DRUGS IN DIFFERENT 

MEDICAL SPECIALITIES ACROSS WALES. 

H Cohen, C Aldridge, S Jones. Department of Rheumatology, University Hospital of Wales, Cardiff, 

S.Glamorgan, Wales, United Kingdom 

63 EFFICACY OF ARTROFOON IN RHEUMATOID ARHTRITIS: RESULTS OF A SIX-MONTH 

OPEN-LABEL STUDY. 

VI Petrov 1 , AR Babayeva 1 , JL Dugina 2 , AV Martyushev-Poklad 2 , MV Kachanova 2 , EV Tcherevkova 1 , 

OI Epstein 2 , SA Sergeeva 2 . 1 

Volgograd Medical University, Volgograd, Russian Federation; 2 NPF 

“Materia Medica Holding”, Moscow, Russian Federation 

64 SINGLE-BLIND RANDOMISED TRIAL OF COMBINATION ANTIBIOTIC THERAPY IN 


A Smith 1 , W Rogers 2 , J Soon-Shiong 2 , A Mitchell 2 , C Dore 3 , P Taylor 1 , C Mackworth-Young 1 . 

1 

Kennedy Institute of Rheumatology, London, United Kingdom; 2 Charing Cross Hospital, London, 

United Kingdom; 3 Statistics Department, MRC Clinical Trials Unit, London, United Kingdom 

65 AUDIT OF DRUG MONITORING FREQUENCY OF PATIENTS ON METHOTREXATE 

IN PRIMARY CARE COMPARED WITH HOSPITAL OUTPATIENTS CONTROLS. 

SK Pathare, NP Hurst. Rheumatic Diseases Unit, Western General Hospital, Edinburgh, Lothian, 


66 DMARDs TREATMENT AND BONE MINERAL DENSITY IN PATIENTS WITH 


LA Taukumova, AV Smirnov. 1 

Clinical Pharmacology, Institute of Rheumatology, Moscow, Russian 

Federation; 2 Radiology, Institute of Rheumatology, Moscow, Russian Federation 

67 THERMAL INFRARED-REFLECTIVE WRIST SLEEVE FOR RHEUMATOID ARTHRITIS: 

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY. 

J Currey 1 , P Lightman 1 , K Chakravarty 2 , S Petty-Saphon 3 . 1 

Rheumatology, Princess Alexandra 

Hospital NHS Trust, Harlow, CM20 1QX, United Kingdom; 2 Rheumatology, Harold Wood Hospital, 

Harold Wood, RM3 0BE, United Kingdom; 3 Spine-issimus Ltd, Saffron Walden, CB11 4JT, 


68 SUBCUTANEOUS METHOTREXATE (SC-Mtx) ADMINISTRATION IN RHEUMATOLOGY 

CLINIC AND IN THE HOME - CLINICAL AND PATIENT PERSPECTIVES. 

G Burbage, A Mee, K Lim. Dept. of Rheumatology, Sherwood Forest Hospitals NHS Trust, 

Kings Mill Hospital, Nottinghamshire, United Kingdom 

69 THE USE OF PARENTERAL METHOTREXATE IN THE TREATMENT OF RHEUMATIC DISEASE. 

RK Moitra, JM Ledingham. Rheumatology Department, Queen Alexandra Hospital, Portsmouth, 

Hampshire, United Kingdom 

70 CAN INTRAMUSCULAR METHOTREXATE FOR THE TREATMENT OF RHEUMATOID AND 

OTHER INFLAMMATORY ARTHRITIS BE ADMINISTERED IN THE COMMUNITY? 

SK Williams, S Church, GR Clarke. Department of Rheumatology, Harold Wood Hospital, 

Romford, Essex, United Kingdom 

41

71 METHOTREXATE MONITORING: A COUNTRYWIDE ANALYSIS OF MONITORING POLICIES AMONG 

RHEUMATOLOGISTS AND DERMATOLOGISTS IN THE REPUBLIC OF IRELAND. 

JG Ryan 1 , J Barry 2 , J Bourke 2 , M Phelan 1 . 1 

Departments of Rheumatology, South Infirmary- Victoria 

Hospital, Cork, Ireland; 2 Dermatology, South Infirmary- Victoria Hospital, Cork, Ireland 

CARTILAGE BIOLOGY (72 – 76) 

72 A NOVEL INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS) INHIBITOR INFLUENCES AGGRECAN 

mRNA LEVELS IN OSTEOARTHRITIC (OA) CHONDROCYTES. 

JE Johnston 1 , SJ Millward-Sadler 1 , N Boughton-Smith 2 , G Nuki 1 . 1 

Osteoarthritis Research Lab, Edinburgh 

University, Edinburgh, Scotland, United Kingdom; 2 Research And Development, AstraZeneca, 

Loughborough, Leicestershire, United Kingdom 

73 EFFECTS OF MECHANICAL STIMULATION ON MAP KINASES IN NORMAL AND OSTEOARTHRITIC 

HUMAN ARTICULAR CHONDROCYTES. 

Y Zhou, SJ Millward-Sadler, NS Khan, DM Salter, G Nuki. Osteoarticular Research Group, Medical 

College, University of Edinburgh, Edinburgh EH8 9AG, Scotland, United Kingdom 

74 INTEGRIN DEPENDENT UP-REGULATION OF PROTEOGLYCAN SYNTHESIS IN CULTURED 

NORMAL HUMAN ARTICULAR CHONDROCYTES FOLLOWING MECHANICAL STIMULATION IS LOST 

IN CHONDROCYTES FROM PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS. 

M Maruo Holledge, SJ Millward-Sadler, NS Khan, DM Salter, G Nuki. Osteoarticular Research Group, 

Medical College, University of Edinburgh, Edinburgh EH8 9AG, Scotland, United Kingdom 

75 CHANGE IN SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP) AFTER TOTAL 

KNEE REPLACEMENT FOR OSTEOARTHRITIS (OA). 

M Sharif 1 , JR Kirwan 2 , R Granell 2 , S Clarke 2 . 1 

Department of Anatomy, University of Bristol, Bristol, 

United Kingdom; 2 Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom 

76 INCREASED EXPRESSION OF CATABOLIC CYTOKINES AND THEIR RECEPTORS IN EARLY 

EQUINE ARTICULAR CARTILAGE DAMAGE. 

MJ Trickett, M Sharif, MJ Perry, CJ Fuller. Anatomy, University of Bristol, Bristol, United Kingdom 

BONE BIOLOGY (77 – 79) 

77 TARTRATE-RESISTANT ACID PHOSPHATASE: A POTENTIAL TARGET FOR THERAPEUTIC GOLD. 

AR Hayman 1 , TM Cox 2 . 1 

Clinical Veterinary Science, University of Bristol, Bristol, BS40 5DU, United 

Kingdom; 2 Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, CB2 2QQ, United 

Kingdom 

78 LIGAMENTS AND BONE JOIN AT SACRAL AND ILIAC ENTHESES BY DISCONTINUOUS 

ATTACHMENT ZONES DEFINED BY TENASCIN AND TYPE VI COLLAGEN. 

L Fairbairn, SJ Millward-Sadler, DM Salter, DL Gardner. Pathology, University of Edinburgh, Edinburgh, 


79 COMPARATIVE ANALYSIS OF STRUCTURES WITHIN THE OSTEOARTHRITIC KNEE JOINTS REVEALS 

MESENCHYMAL PROGENITOR CELL (MPC) ACTIVITY IN ALL TISSUES, IMPLICATIONS FOR THE ROLE 

OF THE MICROENVIRONMENT IN REPAIR. 

A English 1 , EA Jones 1 , K Henshaw 1 , D Corscadden 1 , J Holdsworth 2 , T Chapman 3 , R Reece 1 , P Emery 1 , 

D McGonagle 2 . 1 

Rheumatology and Rehabilitation Research Unit, University of Leeds, Leeds, Yorkshire, 

United Kingdom; 2 Rheumatology Department, Calderdale General Hospital, Halifax, Yorkshire, United 

Kingdom; 3 Orthopaedic Department, Calderdale General Hospital, Halifax, Yorkshire, United Kingdom 

42

BONE: GENES AND THE ENVIRONMENT (80 – 83) 

80 CADMIUM TOXICITY AND ITS HUMAN HEALTH IMPACT: A POSSIBLE CAUSE OF 

OSTEOMALACIA AND OSTEOPOROSIS IN POLLUTED AREAS. 

AA Elbeialy 1 , AM Bersy 2 , SM Zaky 3 , AM Kotb 4 , MM Emara 5 . 1 

Rheumatology, Al-Azhar Faculty of 

Medicine, Cairo, Cairo, Egypt; 2 Clinical Pathology, Al-Azhar Faculty of Medicine, Cairo, Cairo, 

Egypt; 3 Tropical Medicine, Al-Azhar Faculty of Medicine, Cairo, Cairo, Egypt; 4 Geophysics, Al-Azhar 

Faculty of Science, Cairo, Cairo, Egypt; 5 Chemistry, Al-Azhar Faculty of Science, Cairo, Cairo, Egypt 

81 POLYMORPHISMS OF THE TRANSFORMING GROWTH FACTOR β GENE ARE ASSOCIATED 

WITH BONE MASS AND INFANT GROWTH IN UK MEN BUT NOT WOMEN. 

E Dennison 1 , T Spector 2 , Y Mac 2 , T Andrew 2 , H Syddall 1 , C Cooper 1 . 1 

Medical Research Council 

Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United 

Kingdom; 2 Twin & Genetic Epidemiology Research Unit, St Thomas’ Hospital, London, United 

Kingdom 

82 LRP5 POLYMORPHISMS ARE LINKED AND ASSOCIATED WITH BONE MINERAL DENSITY. 

AM Koay 1 , PY Woon 1 , LJ Miles 1 , EL Duncan 2 , Y Zhang 1 , FAMOS Study Investigators 3 , JAH Wass 2 , 

MA Brown 1,2 . 1 

Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, 

Oxford, United Kingdom; 2 Metabolic Bone Unit, Nuffield Orthopaedic Centre, Oxford, United 

Kingdom; 3 Oxagen, Abingdon, United Kingdom 

83 VITAMIN D BINDING PROTEIN GENE (TAAA)n-Alu ELEMENT POLYMORPHISM AND ITS 

ASSOCIATION WITH BONE DENSITY AND OSTEOPOROSIS IN MEN. 

SP Tuck 1 , ZH Al-oanzi 1 , SS Varanasi 1 , N Raj 2 , GD Summers 2 , HK Datta 1 , RM Francis 1 . 1 

School of 

Clinical Medical Sciences, Medical School, Ubiversity of Newcastle, Newcastle upon Tyne, 

Newcastle, United Kingdom; 2 Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, 


CONNECTIVE TISSUE BIOLOGY (84 – 85) 

84 ROLE OF THE RAS/MEK/ERK SIGNALING PATHWAY AND ITS INHIBITORY REGULATION BY 

PROSTANOIDS IN THE FIBROTIC/WOUND HEALING RESPONSE. 

R Stratton, H Penn, G Taguri, X Shiwen, CM Black, DJ Abraham, A Leask. Centre for 

Rheumatology, Royal Free and University College School of Medicine, Royal Free Campus, London, 


85 EXPRESSION AND REGULATION OF ‘AGGRECANASE’ ENZYMES (ADAMTS-1, -4, -5) 

IN TENDON PATHOLOGY. 

AN Corps 1 , RL Harrall 1 , AHN Robinson 2 , BL Hazleman 1 , GP Riley 1 . 1 

Rheumatology Research Unit, 

Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Department of Orthopaedics & 

Trauma Surgery, Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom 

CRYSTAL DEPOSITION DISEASE (86 – 87) 

86 BASIC CALCIUM PHOSPHATE CRYSTAL-INDUCED SECRETION OF PRO-INFLAMMATORY 

CYTOKINES BY HUMAN MONOCYTE/MACROPHAGES LEADING TO ENDOTHELIAL ACTIVATION 

MEDIATED THROUGH PROTEIN KINASE Cα AND ε, MEK-1/2 MAP KINASE AND NFKB 

INTRACELLULAR SIGNALING PATHWAYS. 

I Nadra 1 , JC Mason 1 , GM McCarthy 2 , C Landis 1 , DO Haskard 1 . 1 

Eric Bywaters Centre for Vascular 

Inflammation, Imperial College, London, United Kingdom; 2 Department of Clinical Pharmacology, 

Royal College of Surgeons, Dublin, United Kingdom 

87 THE CROWNING GLORY OF CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD) 

DEPOSITION DISEASE. 

JE Brockbank, M Akil, C Romanowski. Royal Hallamshire Hospital, Sheffield, United Kingdom 

43

BONE MINERAL DENSITY (88 – 104) 

88 REDUCED BONE MASS IN RHEUMATOID ARTHRITIS PATIENTS COMPARED WITH 

AGE-MATCHED CONTROLS. 

B Heidari, S Azizian. 1 Department of Medicine, Shaheed Beheshti Hospital, Babol University of Medical 

Sciences, Babol, Mazandarn, Islamic Republic of Iran; 2 Department of Medicine, Shaheed Beheshti 

Hospital, Babol, Mazandarn, Islamic Republic of Iran 

89 EFFECT OF MEDICAL RISK FACTORS, MUSCLE STRENGTH AND FALLS HISTORY ON 

FRACTURE INCIDENCE. 

S Vasireddy 1 , K Kayan 1 , T Jalava 2 , C McGurk 1 , L Reaney 1 , J Kanis 1 , E McCloskey 1 . 1 

University of Sheffield, 

Sheffield, United Kingdom; 2 Leiras Oy, Helsinki, Finland 

90 EFFECT OF MEDICAL RISK FACTORS ON DXA MEASUREMENTS AND METACARPAL 

RADIOGRAPHIC INDICES. 

S Vasireddy, L Reaney, D Charlesworth, JA Kanis, EV McCloskey. University of Sheffield, Sheffield, 


91 MATERNAL VITAMIN D STATUS AND BODY COMPOSITION IN LATE PREGNANCY PREDICT 

CHILDHOOD LUMBAR SPINE VOLUMETRIC BONE DENSITY AT 9 YEARS. 

NCW Harvey 1 , MK Javaid 1 , P Taylor 2 , SR Crozier 1 , CR Gale 1 , EM Dennison 1 , KM Godfrey 1 , C Cooper 1 . 1 

MRC 

Environmental Epidemiology Unit, Southampton, United Kingdom; 2 Medical Physics and Bioengineering, 

Southampton General Hospital, Southampton, United Kingdom 

92 RELATIONSHIPS BETWEEN SF-36 AND BONE MINERAL DENSITY: THE HERTFORDSHIRE 

COHORT STUDY. 

E Dennison, H Syddall, H Gilbody, C Statham, A Aihie Sayer, C Cooper. Medical Research Council 

Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom 

93 PEAK BONE MASS IN EUROPEAN AND SOUTH ASIAN WOMEN OF PAKISTANI MUSLIM ORIGIN. 

DK Roy 1 , CM Swarbrick 1 , Y King 1 , SR Pye 1 , JE Adams 2 , J Berry 3 , AJ Silman 1 , TW O’Neill 1 . 1 

Arthritis Research 

Campaign Epidemiology Unit, University of Manchester, Manchester, Greater Manchester, United 

Kingdom; 2 Department of Imaging Science and Biomedical Engineering, University of Manchester, 

Manchester, Greater Manchester, United Kingdom; 3 Department of Medicine, Manchester Royal 

Infirmary, Manchester, Greater Manchester, United Kingdom 

94 DOES FRACTURE RISK ASSESSMENT INFLUENCE GP TREATMENTS OF PATIENTS WITH 

LOW TRAUMA FRACTURES? 

J Christopher 1 , M Goodwin 2 , C Jones 3 , P Thompson 1 . 1 

Rheumatology Unit, Poole Hospital NHS Trust, 

Poole, Dorset, United Kingdom; 2 Orthopedic Unit, Poole Hospital NHS Trust, Poole, Dorset, United 

Kingdom; 3 Osteoporosis Dorset, Bournemouth, Dorset, United Kingdom 

95 VITAMIN D STATUS IN PATIENTS WITH PAGET’S DISEASE. 

G Chung 1 , RW Keen 1,2 . 1 

Metabolic Unit, Royal National Orthopaedic Hospital, Stanmore, Middx, United 

Kingdom; 2 Department of Medicine, University College London, London, United Kingdom 

96 SELF REPORT OVERESTIMATES TRUE HEIGHT LOSS: RESULTS FROM THE 

NEWCASTLE THOUSAND FAMILIES STUDY. 

F Birrell 1,2,3 , M Pearce 1 , R Francis 1,2 , L Parker 1 . 1 

School of Clinical Medical Sciences, University of Newcastle 

upon Tyne, Newcastle upon Tyne, United Kingdom; 2 Musculoskeletal Unit, Freeman Hospital, Newcastle 

upon Tyne, United Kingdom; 3 Rheumatology, Wansbeck General Hospital, Ashington, United Kingdom 

97 THE PREVALENCE AND DISTRIBUTION OF OSTEOPOROSIS IN PATIENTS WITH END-STAGE KNEE 

OSTEOARTHRITIS (OA): MORE EVIDENCE FOR OA MITIGATING LOCAL BONE LOSS. 

E Lingard 1,2 , A Khan 2 , F Birrell 1,2,3 , R Francis 1,2 , R Peaston 2 , A McCaskie 1,2 . 1 

School of Clinical Medical 

Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 2 Musculoskeletal 

Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 3 Rheumatology, Wansbeck General 

Hospital, Ashington, United Kingdom 

44

98 THE PREVALENCE AND DISTRIBUTION OF OSTEOPOROSIS IN PATIENTS WITH END-STAGE 

HIP OSTEOARTHRITIS (OA): EVIDENCE FOR OA MITIGATING LOCAL BONE LOSS. 

F Birrell 1,2,3 , E Lingard 1,3 , A Khan 3 , R Francis 1,3 , R Peaston 3 , A McCaskie 1,3 . 1 

School of Clinical 

Medical Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 

2 

Rheumatology, Wansbeck General Hospital, Ashington, United Kingdom; 3 Musculoskeletal Unit, 

Freeman Hospital, Newcastle upon Tyne, United Kingdom 

99 SIZE-ADJUSTED MATERNAL CALCANEAL QUS CHANGE DURING PREGNANCY 

AND NEONATAL BONE MASS. 

MK Javaid 1 , SR Crozier 1 , P Taylor 1 , HM Inskip 1 , KM Godfrey 1 , C Cooper 1 . 1 

MRC Environmental 

Epidemiology Unit, Southampton, Hampshire, United Kingdom; 2 Medical Physics and 

Bioengineering, Southampton General Hospital, Southampton, Hampshire, United Kingdom 

100 DIRECT ACCESS BONE DENSITOMETRY AND SIGN GUIDELINES IN OSTEOPOROSIS: 

A PRIMARY CARE PERSPECTIVE. 

C Mitchell 1 , V Rajagopal 2 , E Brankin 1 , J Wright 1 , R Munro 2 . 1 

Coatbridge Local Healthcare 

Co-Operative, Coatbridge, Lanarkshire, United Kingdom; 2 Rheumatology Dept, Wishaw General, 

Wishaw, Lanarkshire, United Kingdom 

101 DIRECT ACCESS BMD IN MEN - IS THE PICK UP BETTER THAN IN WOMEN? 

H Gunawardena 1 , ECS Wong 1 , ND Harris 2 , AK Bhalla 1 . 1 

Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom; 2 Clinical Measurements, Royal National Hospital for 

Rheumatic Diseases, Bath, United Kingdom 

102 CLINICIAN SATISFACTION WITH A NURSE-LED PERIPHERAL DEXA SCAN SERVICE. 

A Adebajo, J Hitchcock, L Campbell. Rheumatology, Barnsley District General Hoapital NHS Trust, 

Barnsley, South Yorkshire, United Kingdom 

103 ACCESS TO DXA INFLUENCES PRESCRIBING CHOICES IN PRIMARY CARE, BUT DOES NOT 

SUBSTANTIALLY INCREASE COST. 

V Robins 1 , SM Stebbings 2 , R Darling 3 , L McHugh 4 . 1 

Medical School, University of Bristol, Bristol, 

United Kingdom; 2 Musculo-Skeletal Directorate, Southmead Hospital, Bristol, United Kingdom; 

3 

Riverbank Medical Centre, Weston-Super-Mare, Somerset, United Kingdom; 4 18, Upper Oldfield 

Park Surgery, Bath, Avon, United Kingdom 

104 CALCANEAL DXA - A USEFUL SCREENING TOOL? 

SY Khan, A Wood, K Mackay. Rheumatology Department, Queen Alexandra Hospital, Portsmouth, 


OSTEOPOROSIS: TREATMENT (105 – 107) 

105 SYSTEMIC MASTOCYTOSIS MAY PRESENT WITH OSTEOPOROSIS WHICH IMPROVES 

WITH BISPHOSPHONATES. 

AYN Lim, AJK Ostor, SA Love, AJ Crisp. Departments of Rheumatology and Metabolic Bone 

Diseases, Addenbrookes Hospital, Cambridge, Cambs, United Kingdom 

106 THE EFFECT OF 90MG OF PAMIDRONATE GIVEN ANNUALLY ON BONE MINERAL 

DENSITY IN POST-MENOPAUSAL OSTEOPOROSIS. 

EW Thomas 1 , H Cohen 1 , J Morgan 2 , D Hampton 2 , JC Martin 2 . 1 

Department of Rheumatology, 

University Hospital of Wales, Cardiff, United Kingdom; 2 Department of Rheumatology, Royal 

Glamorgan Hospital, Llantrisant, Rhondda Cynon Taf, United Kingdom 

107 PERCUTANEOUS VERTEBROPLASTY - A NEW DIMENSION TO TREATMENT 

FOR COMPLICATED OSTEOPOROSIS? 

T Sikdar, P Mathew, D Dutta, A Hussein. 1 Department of Radiology, Princess Alexandra Hospital, 

Harlow, United Kingdom; 2 Department of Orthopaerdics, Princess Alexandra Hospital, Harlow, 

United Kingdom; 3 Department of Anaesthesia, Princess Alexandra Hospital, Harlow, United 

Kingdom; 4 Department of Orthopaerdics, Princess Alexandra Hospital, Harlow, United Kingdom 

45

OSTEOARTHRITIS (108 – 132) 

108 PREVALENCE OF GENETIC HAEMOCHROMATOSIS AND IRON OVERLOAD AMONGST 

PATIENTS ATTENDING RHEUMATOLOGY AND JOINT REPLACEMENT CLINICS. 

S Donnelly 1 , NG Joshi 2 , D Thornburn 2 , A Cook 3 , G Reid 2 , M Neilson 2 , AJ Stanley 2 , HA Capell 1 . 1 

Centre for 

Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 Department of Gastroenterology, Royal 

Infirmary, Glasgow, United Kingdom; 3 Genetics Unit, Yorkhill Hospital, Glasgow, United Kingdom 

109 HAEMOCHROMATOSIS: IS IT WORTH LOOKING HARDER FOR IT? 

M Lloyd 1 , P Alton 2 , P Cusick 3 . 1 

Department of Rheumatology, Frimley Park Hospital, Frimley, Surrey, 

United Kingdom; 2 Department of Haematology, Frimley Park Hospital, Frimley, Surrey, United Kingdom; 

3 

Department of Clinical Biochemistry, Frimley Park Hospital, Frimley, Surrey, United Kingdom 

110 RADIOGRAPHIC FEATURES OF LUMBAR DISC DEGENERATION AND BONE MINERAL 

DENSITY IN MEN AND WOMEN. 

SR Pye 1 , DM Reid 2 , R Smith 2 , JE Adams 3 , AJ Silman 1 , TW O’Neill 1 . 1 

ARC Epidemiology Unit, University of 

Manchester, Manchester, United Kingdom; 2 Department of Medicine and Therapeutics, University of 

Aberdeen, Aberdeen, United Kingdom; 3 Clinical Radiology, Imaging Science and Biomedical Engineering, 

University of Manchester, Manchester, United Kingdom 

111 AEROBIC WALKING OR STRENGTHENING EXERCISE FOR OSTEOARTHRITIS OF THE KNEE? 

A SYSTEMATIC REVIEW. 

E Roddy, W Zhang, M Doherty. Academic Rheumatology, Nottingham City Hospital, Nottingham, 


112 EULAR RECOMMENDATIONS 2003: AN EVIDENCE BASED MEDICINE APPROACH TO 

THE MANAGEMENT OF KNEE OSTEOARTHRITIS. 

KM Jordan 1 , NK Arden 1 , M Doherty 2 , P Dieppe 3 , K Gunther 3 , H Hauselmann 3 , G Herrero-Beaumont 3 , 

P Kaklamanis 3 , S Lohmander 3 , B Leeb 3 , M Lequesne 3 , B Mazieres 3 , E Martin-Mola 3 , K Pavelka 3 , 

A Pendleton, 3 L Punzi 3 , U Serni 3 , B Swoboda 3 , G Verbruggen 3 , I Zimmerman-Gorska 3 , B Bannwarth 3 JWJ 

Bijlsma 3 , M Dougados 4 . 1 

MRC EEU, Southampton General Hospital, Southampton, Hampshire SO16 

6YD, United Kingdom; 2 Academic Rheumatology Unit, City Hospital, Nottingham, United Kingdom; 

3 

EULAR OA Task Force, Standing Committee for International Clinical Studies Including Therapeutic 

Trials (ESCISIT), Paris, France; 4 Institut de Rhumatologie, Hardy B, Hopital Cochin, 27, rue du Faubourg 

Saint-Jacques, 75014 Paris, France 

113 A COMPARISON OF QUANTITATIVE AND SEMI-QUANTITATIVE MRI SYNOVITIS SCORES 

IN KNEE OSTEOARTHRITIS. 

LA Rhodes 1 , AJ Grainger 2 , AM Keenan 3 , P Emery 3 , PG Conaghan 3 . 1 

Department of Medical Physics, 

University of Leeds, Leeds, West Yorkshire, United Kingdom; 2 Department of Radiology, University of 

Leeds, Leeds, West Yorkshire, United Kingdom; 3 Department of Rheumatology, Leeds General Infirmary, 

Leeds, West Yorkshire, United Kingdom 

114 HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS (OA): A COCHRANE REVIEW. 

N Bellamy, Jr 1 , J Campbell 2 , T Gee 1 , V Robinson 3 , G Wells 3 , R Bourne 2 . 1 

Centre of National Research on 

Disability and Rehabilitation Medicine (CONROD), University of Queensland, Herston, Brisbane, 

Queensland, Australia; 2 University of Western Ontario, London, ON, Canada; 3 University of Ottawa, 

Ottawa, ON, Canada 

46

115 EVIDENCE-BASED RECOMMENDATIONS FOR THE ROLE OF EXERCISE IN THE 

MANAGEMENT OF OSTEOARTHRITIS (OA) OF THE HIP OR KNEE. 

E Roddy 1 , W Zhang 1 , M Doherty 1 , N Arden 2 , J Barlow 3 , F Birrell 4 , A Carr 1 , K Chakravarty 5 , J Dickson 6 , 

E Hay 7 , G Hosie 6 , M Hurley 8 , K Jordan 2 , C McCarthy 9 , M McCurdo 10 , J Mead 11 , S Mockett 12 , J 

Nixon 13 , S O’Reilly 14 , G Peat 7 , A Pendleton 15 , S Richards 16 . 1 

Academic Rheumatology, Nottingham 

City Hospital, United Kingdom; 2 Rheumatology, Southampton General Hospital, United Kingdom; 

3 

Interdisciplinary Research Centre in Health, Coventry University, United Kingdom; 4 Rheumatology, 

University of Newcastle-upon-Tyne, United Kingdom; 5 Rheumatology, Haroldwood Hospital, 

Romford, United Kingdom; 6 Primary Care Rheumatology Society, United Kingdom; 7 Primary Care 

Sciences Research Centre, Keele University, United Kingdom; 8 Rehabilitation Research Unit, Kings 

College, London, United Kingdom; 9 The Centre for Rehabilitation Science, Manchester Royal 

Infirmary, United Kingdom; 10 Aging and Health, University of Dundee, United Kingdom; 11 Clinical 

Effectiveness, The Chartered Society of Physiotherapy, United Kingdom; 12 Physiotherapy Education, 

University of Nottingham, United Kingdom; 13 British Hip Society, The Royal College of Surgeons, 

United Kingdom; 14 Rheumatology, Derbyshire Royal Infirmary, United Kingdom; 15 Rheumatology, 

Belfast City Hospital, United Kingdom; 16 Rheumatology, Poole Hospital NHS Trust, United Kingdom 

116 RADIOGRAPHIC ASSESSMENT OF SEVERE JOINT DAMAGE IN OSTEOARTHRITIS. 

P Dieppe 1 , S Williams 1 , I Watt 1 , P Gregg 2 , P Juni 1 . 1 

MRC HSRC, University of Bristol, Bristol, United 

Kingdom; 2 British Orthopaedic Association, Royal College of Surgeons, London, United Kingdom 

117 A RANDOMIZED, DOUBLE-BLIND COMPARISON OF THE EFFICACY AND SAFETY OF 

VALDECOXIB 10 mg AND ROFECOXIB 25 mg IN INDIAN PATIENTS WITH OSTEOARTHRITIS. 

A Desai 1 , S Jagtap 2 , C Ballary 1 . 1 

Medical, Glenmark, Mumbai, Maharashtra, India; 2 Orthopaedics, 

Grant Medical College and J.J. Hospital, Mumbai, Maharashtra, India 

118 EFFICACY AND TOLERABILITY OF LUMIRACOXIB IN PATIENTS WITH OSTEOARTHRITIS: 

A POOLED ANALYSIS. 

R Fleischmann 1 , F Berenbaum 2 , V Sloan 3 , A Moore 4 , A Couturier 3 . 1 

University of Texas 

Southwestern Medical Center, Dallas, TX, United States; 2 Pierre and Marie Curie 

University-Saint-Antoine Hospital, Paris, France; 3 Novartis Pharmaceuticals Corporation, 

East Hanover, NJ, United States; 4 Novartis Pharma AG, Basel, Switzerland 

119 DOES GRADING IMPROVE BY OVERLAYING AN ACETATE LINE DRAWING ATLAS 

DIRECTLY OVER A RADIOGRAPH? 

CE Wilkinson, A Carr, M Doherty. Academic Rheumatology, University of Nottingham, 

Nottingham, United Kingdom 

120 RELATIONSHIP BETWEEN HEBERDEN’S NODES AND THE UNDERLYING 

RADIOGRAPHIC CHANGE. 

A Thaper, W Zhang, S Doherty, G Wright, M Doherty. Academic Rheumatology, Clinical Sciences 

Building, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom 

121 COMPARISON OF INVESTIGATOR-REPORTED AND PATIENT-REPORTED ADVERSE EVENT 

SEVERITY RATINGS AND THEIR RELATION TO OVERALL HEALTH AND QUALITY OF LIFE. 

PS Tugwell 1 , JJ Clinch 2 , JZ Shainhouse 3 , BA Kristjansson 4 , GA Wells 5 . 1 

Centre for Global Health, 

University of Ottawa, Ottawa, ON, Canada; 2 Clinical Epidemiology Program, Ottawa Health 

Research Institute, Ottawa, ON, Canada; 3 Clinical Research, Dimethaid Health Care Ltd., Markham, 

ON, Canada; 4 School of Psychology, University of Ottawa, Ottawa, ON, Canada; 5 Department of 

Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada 

122 THE A.C.T.I.V.E. (ARTHRITIS CARE TOWARDS IMPROVED VITALITY AND ENDURANCE) 

TRIAL: AN OBSERVATIONAL STUDY ON THE IMPACT OF VIOXX ® (ROFECOXIB) 12.5 mg OR 

25 mg/DAY ON PAIN CONTROL AND PHYSICAL FUNCTION IN ELDERLY PATIENTS WITH 

OSTEOARTHRITIS SYMPTOMS 

NR Bastien, 1 JJ Mansi, 1 A Turcotte. 2 1 Clinical Research, Merck Frosst Canada & Co., Kirkland, QC, 

Canada; 2 Centre de l’osteoporose et de Rhumatologie de Quebec, Sainte-Foy, QC, Canada 

47

123 EFFECT OF LUMIRACOXIB ON BLOOD PRESSURE AND FLUID RETENTION: 

A POOLED ANALYSIS. 

R Hirschberg 1 , O Della Casa Alberighi 2 , G Hoexter 2 . 1 

Harbor-UCLA Medical Center, Torrance, CA, 

United States; 2 Novartis Pharma AG, Basel, Switzerland 

124 DOES INCREASING THE GRADES OF THE KNEE OSTEOARTHRITIS LINE DRAWING ATLAS 

IMPROVE IT’S CLINIMETRIC PROPERTIES? 

CE Wilkinson, A Carr, M Doherty. Academic Rheumatology, University of Nottingham, Nottingham, 


125 CAN BASELINE CLINICAL SIGNS OF INFLAMMATION AND/OR SENSITIVE C-REACTIVE 

PROTEIN MEASUREMENT IDENTIFY RESPONDERS TO NSAIDs IN KNEE OA. 

A Sanghvi 1 , M Sharif 1 , I Al-Salem 2 , B Hameed 2 , JR Kirwan 2 . 1 

Department of Anatomy, University of 

Bristol, Bristol, United Kingdom; 2 Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, 


126 THE EFFECTS OF EARLY ENVIRONMENT AND GENE INTERACTIONS ON SPINAL OSTEOARTHRITIS. 

KM Jordan, H Syddall, EM Dennison, C Cooper, NK Arden. MRC Environmental Epidemiology Unit, 

Southampton General Hospital, Southampton, Hampshire, United Kingdom 

127 CARTILAGE OLIGOMERIC MATRIX PROTEIN AND AGGRECAN IN SYNOVIAL FLUID FROM 

PATIENTS WITH OSTEOARTHRITIS: MARKERS OF LOCAL OR SYSTEMIC CHARACTERISTICS? 

DF McWilliams 1 , Y Reehana 1 , B Carolyn 1 , D Michael 1 , H Dick 2 , S Tore 2,3 , Z Weiya 1 . 1 

Academic 

Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; 

2 

Dept Cell and Molecular Biology, Lund University, Lund, Sweden; 3 Dept Rheumatology, 

Lund University, Lund, Sweden 

128 SERUM BIOMARKERS IN MEDIAL TIBIOFEMORAL AND PATELLOFEMORAL 

OSTEOARTHRITIS OF THE KNEE. 

M Sharif 1 , JR Kirwan 2 , B Quilty 2 , S Clarke 2 , R Granell 2 , V Lock 2 , J Johansen 3 . 1 

Deopartment of Anatomy, 

University of Bristol, Bristol, United Kingdom; 2 Academic Rheumatology Unit, Bristol Royal Infirmary, 

Bristol, United Kingdom; 3 Department of Rheumatology, University of Copenhagen, Copenhagen, 

Denmark 

129 CRP LEVELS ARE RAISED IN PATIENTS WITH LONGSTANDING OSTEOARTHRITIS 

WHEN COMPARED WITH NORMAL CONTROLS. 

N Kumar, NJ Marshall, D Neely, SS Furniss, PN Platt, DJ Walker. 1 


Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Department of 

Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of 

Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom 

130 EVALUATION OF PATIENT SATISFACTION FOLLOWING TOTAL KNEE JOINT REPLACEMENT FOR 

OSTEOARTHRITIS. 

EA Lingard, KA Bettinson, AW McCaskie, ID Griffiths. Musculoskeletal Unit, Freeman Hospital, Newcastle 

upon Tyne, United Kingdom 

131 EXPRESSION PROFILING USING MICOARRAY TECHNOLOGY OF FAILED TOTAL 

HIP REPLACEMENTS. 

HA Malik 2 , B Rash 1 , N Delcroix 1 , P Day 1 , A Bayat 1 , WE Ollier 1 , PR Kay 2 . 1 


Medical Research, The University of Manchester, Manchester, United Kingdom; 2 Centre for Hip Surgery, 

Wrightington Hospital, Wigan, Lancashire, United Kingdom 

132 THE USE OF NON WEIGHT BEARING NEUROMUSCULAR EXERCISES IN ACUTE ANKLE 

LIGAMENT INJURY REHABILITATION. 

SH Voules, DW Hodgkinson. 1 Physiotherapy Department, Ipswich Hospital NHS Trust, Ipswich, Suffolk, 

United Kingdom; 2 Emergency Department, Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom 

48

FIBROMYALGIA (133 – 140) 

133 TREATMENT OF FIBROMYALGIA WITH THE DOPAMINE AGONIST ROPINIROLE: 

A PILOT, PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. 

AJ Holman 1 , RR Myers 1 , AM Gray 2 . 1 

Rheumatology, Pacific Rheumatology Associates, Renton, WA, 

United States; 2 Neurology & GI, GlaxoSmithKline, RTP, NC, United States 

134 PSYCHOLOGICAL STATUS IN PATIENTS WITH FIBROMYALGIA SYNDROME. 

SV Koliadenko, MA Stanislavchuk. Rheumatology, National Medical University, Vinnycia, Ukraine 

135 POWER SPEKTRUM ANALYSIS OF HEART RATE VARIABILITY IN THE PATIENTS 

WITH FIBROMYALGIA. 

MA Stanislavchuk 1 , VM Khomenko 2 . 1 

Rheumatology, Vinnytsia National Medical University, 

Vinnytsia, Ukraine; 2 Rheumatology, Vinnytsia District Hospital, Vinnytsia, Ukraine 

136 BODY COMPOSITION, PHYSICAL FUNCTION AND DISABLITY IN FEMALE ADULT 

PATIENTS WITH FIBROMYALGIA SYNDROME. 

KR Cowan 1 , SM Marcora 1 , JJ Jones 2 , PJ Maddison 2 , AB Lemmey 1 . 1 

School of Sport, Health and 

Exercise Sciences, University of Wales, Bangor, Gwynedd, United Kingdom; 2 Department of 

Rheumatology, Gwynedd Hospital, Bangor, Gwynedd, United Kingdom 

137 IS FIBROMYALGIA A UNIQUE RHEUMATIC DISORDER? 

GM Papadimitriou, KM Sotiriadou. 1 Internal Medicine Dept. University of Athens, Rheumatologist 

- Prof. University of Athens, Athens, Attiki, Greece; 2 Psychiatric Unit AGIOS Andreas Hospital, 

Psychiatrist Director of Psychiatric Unit, Patras, Ahaia, Greece 

138 IS THERE A LINK BETWEEN FIBROMYALGIA, HYPERVENTILATION SYNDROME AND 

OBSTRUCTIVE SLEEP APNOEA? 

AM Scott-Russell 1 , A Williams 2 , CA Dunne 1 . 1 

Rheumatology Department, Christchurch Hospital, 

Bournemouth, Dorset, United Kingdom; 2 Thoracic Department, Royal Bournemouth Hospital, 

Bournemouth, Dorset, United Kingdom 

139 A PILOT STUDY TO ESTABLISH THE BENEFITS OF A MULTIDISCIPLINARY FIBROMYALGIA 

PROGRAMME. 

W Farren, D Shead, F Caven, C Kemp, B Yates, R Mepstead, B Roychowdhury. Physiotherapy 

Department, Cumberland Infirmary, Carlisle, Cumbria, United Kingdom 

140 DO PATIENTS WITH FIBROMYALGIA UNDERGO UNNECESSARY OPERATIONS? 

AJ Kinder 1 , PT Dawes 2 , D Clement 3 , C Hollows 2 . 1 

Department of Rheumatology, Leicester Royal 

Infirmary, Leicester, United Kingdom; 2 Department of Rheumatology, Staffordshire Rheumatology 

Centre, Stoke-on-Trent, United Kingdom; 3 Research and Development, University Hospital of North 

Staffordshire, Stoke-on-Trent, United Kingdom 

SOFT TISSUE RHEUMATISM (141 – 145) 

141 PROGNOSTIC INDICATORS OF OUTCOME IN SHOULDER PAIN: RESULTS FROM 

AN ANALYSIS OF TWO PRAGMATIC, PRIMARY CARE-BASED RANDOMISED TRIALS. 

E Thomas 1,2 , DAWM van der Windt 2 , N Smidt 2 , K Dziedzic 1 , PR Croft 1 , LM Bouter 2 , EM Hay 1,3 . 

1 

Primary Care Sciences Research Centre, Keele University, Keele, North Staffordshire, United 

Kingdom; 2 EMGO Institute, Vrije Universiteit, Amsterdam, The Netherlands; 3 Staffordshire 

Rheumatology Centre, The Haywood, Stoke-on-Trent, North Staffordshire, United Kingdom 

142 GENERAL PRACTITIONERS ATTITUDES AND TRAINING IN ASSESSMENT AND 

MANAGEMENT OF SHOULDER PAIN - A QUESTIONAIRRE STUDY. 

I Ryans 1 , S McCann 2 , O McNally 2 , WG Kernohan 3 , D MacAuley 4 , R McKane 1 . 1 

Rheumatology 

Department, Ulster Hospital, Dundonald, Belfast, Co Down, United Kingdom; 2 Institute of 

Postgraduate Medical and Health Sciences, University of Ulster, Northern Ireland, United Kingdom; 

3 

Faculty of Life and Health Sciences, University of Ulster, Jordanstown, Northern Ireland, United 

Kingdom; 4 Department of Epidemiology, The Queen’s University, Belfast, United Kingdom 

49

143 THE EPIDEMIOLOGY OF ADHESIVE CAPSULITIS AMONG WORKING-AGED ADULTS 

IN THE GENERAL POPULATION. 

KE Walker-Bone 1 , IC Reading 2 , KT Palmer 2 , D Coggon 2 , C Cooper 2 . 1 

Rheumatology Department, Brighton 

and Sussex Medical School, Falmer, Brighton, East Sussex, United Kingdom; 2 MRC Environmental 

Epidemiology Unit, Southampton General Hospital, Southampton, Hampshire, United Kingdom 

144 ULTRASOUND EVALUATION OF SHOULDER PAIN AND RESTRICTION IN THE ELDERLY. 

J Rees1, I Wamuo1, W Jan2, T Gibson1. 1Department of Rheumatology, Guy’s and St Thomas’ 

Hospital, London, United Kingdom; 2Department of Radiology, Guy’s and St Thomas’ Hospital, London, 


145 ROLE OF ULTRASOUND GUIDED INJECTION OF SOFT TISSUE AND JOINTS AS A DIAGNOSTIC 

AND THERAPEUTIC PROCEDURE IN OUT-PATIENT BASED RHEUMATOLOGY PRACTICE. 

T Sikdar, K Chakravarty. 1 

Department of Radiology, Princess Alexandra Hospital, Harlow, United 

Kingdom; 2 Department of Rheumatology, Harold Wood Hospital, Harold Wood, United Kingdom 

PSYCHOLOGY (146 – 150) 

146 QUALITATIVE EVALUATION OF A PROGRAMME TO IMPROVE SELF-EFFICACY IN RA PATIENTS. 

J Taylor 1 , H Allen 2 , A Hayden 3 , R Baker 2 , C Musslewhite 4 , D Freshwater 4 , P Thompson 1 . 1 Rheumatology 

Unit, Poole Hospital NHS Trust, Poole, Dorset, United Kingdom; 2 Dorset Research and Development 

Support Unit, Poole Hospital, Poole, Dorset, United Kingdom; 3 ISECCA, The Surgery, Ringwood Rd, 

Dorset, United Kingdom; 4 Instutute of Health and Community Studies, Bournemouth University, 

Bournemouth, Dorset, United Kingdom 

147 COPING STRATEGIES USED BY PATIENTS WITH RHEUMATOID ARTHRITIS. 

R Belcher 1 , B Vernon 1 , LJ Kay 2 . 1 

The Medical School, University of Newcastle, Newcastle upon Tyne, Tyne 

& Wear, United Kingdom; 2 Department of Rheumatology, Newcastle Hospitals NHS Trust, Newcastle 

upon Tyne, Tyne & Wear, United Kingdom 

148 DISABILITY, ANXIETY, AND DEPRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS, 

PSORIASIS, AND CONTROL SUBJECTS. 

MJ Bridges 1 , NJ Reynolds 2 , LJ Kay 1 . 1 

Department of Rheumatology, Newcastle Hospital NHS Trust, 

Newcastle-upon-Tyne, Tyne and Wear, United Kingdom; 2 Department of Dermatology, University of 

Newcastle, Newcastle-upon-Tyne, Tyne and Wear, United Kingdom 

149 DEPRESSION IS MORE COMMON IN RHEUMATOID ARTHRITIS PATIENTS WITH A 

CARDIOVASCULAR COMORBIDITY: A CASE-CONTROLLED INVESTIGATION. 

GJ Treharne 1,2 , ED Hale 2 , AC Lyons 3 , DA Booth 1 , MJ Banks 2,4 , N Erb 2 , K Douglas 2 , DL Mitton 2,5 , GD Kitas 1,2,6 . 

1 

School of Psychology, University of Birmingham, Birmingham, United Kingdom; 2 Department of 

Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 3 School 

of Psychology, Massey University, Albany Campus, Auckland, New Zealand; 4 Department of Cardiology, 

Dudley Group of Hospitals NHS Trust, Dudley, West Midlands, United Kingdom; 5 School of Health 

Sciences, University of Birmingham, Birmingham, United Kingdom; 6 Department of Rheumatology, 

University of Birmingham, Birmingham, United Kingdom 

150 SEASONALITY AND CHANGES IN DEPRESSION, DISABILITY AND PHYSICAL SYMPTOMS OF 

RHEUMATOID ARTHRITIS: A LONGITUDINAL STUDY. 

GJ Treharne 1,2 , AC Lyons 3 , DA Booth 1 , GD Kitas 1,2,4 . 1 

School of Psychology, University of Birmingham, 

Birmingham, United Kingdom; 2 Department of Rheumatology, Dudley Group of Hospitals NHS Trust, 

Dudley, United Kingdom; 3 School of Psychology, Massey University, Albany Campus, Auckland, New 

Zealand; 4 Department of Rheumatology, University of Birmingham, Birmingham, United Kingdom 

50


Thursday 22 April 2004, 08:30 – 10:00 

HEALTH SERVICES RESEARCH (151 – 188) 

151 TRIAL EXCLUSIONS CAN DAMAGE OUR HEALTH: THE EXAMPLE OF NSAIDs. 

P Dieppe 1 , C Bartlett 1 , S Morrant 2 , T MacDonald 2 , P Davey 2 . 1 

MRC HSRC, University of Bristol, 

Bristol, United Kingdom; 2 MEMO, University of Dundee, Dundee, United Kingdom 

152 THE INFLUENCE OF RESOURCE LIMITATIONS ON THE USE OF BIOLOGIC AGENTS IN 

SOUTH WEST ENGLAND. 

SE Knights, H Averns. 1 Department of Rheumatology, North Bristol NHS Trust, Bristol, United 

Kingdom; 2 Department of Rheumatology, North Devon District Hospital, Barnstaple, North Devon, 


153 COST EFFECTIVENESS OF PREVENTION OF NSAID-INDUCED GASTROINTESTINAL TOX I C I T Y. 

RA Elliott 1 , L Hooper 2 , K Payne 3 , TJ Brown 2 , C Roberts 4 , D Symmons 5 . 1 

School of Pharmacy, 

Manchester University, Manchester, United Kingdom; 2 Cochrane Oral Health Group, University of 

Manchester, Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital, 

Manchester, United Kingdom; 4 School of Epidemiology and Health Sciences, University of 

Manchester, Manchester, United Kingdom; 5 ARC Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom 

154 COX II SELECTIVE INHIBITORS VERSUS TRADITIONAL NSAIDS: ARE WE 

USING THEM APPROPRIATELY? 

WF Ng, A Hall, A Steuer. Rheumatology, Wexham Park Hospital, Slough, SL2 4HL, United 

Kingdom 

155 A SURVEY OF 1152 PATIENTS ON NSAIDS - ARE ‘NICE’ GUIDELINES BEING FOLLOWED 

FOR PRESCRIBING COX-II INHIBITORS AND THE IMPLICATIONS FOR CLINICAL GOVERNANCE. 

J Francis, A Samanta, FE Nichol. Department of Rheumatology, University Hospitals of Leicester 

NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom 

156 THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA ® ) IN PATIENTS WITH 

RHEUMATOID ARTHRITIS: A UK ANALYSIS. 

N Bansback 1 , A Brennan 1 , N Sengupta 2 , F Pang 3 . 1 

School of Health and Related Research, 

University of Sheffield, Sheffield, South Yorkshire, United Kingdom; 2 Center for Pharmaceutical 

Appraisal & Outcomes Research, Abbott Laboratories Inc., Chicago, IL, United States; 3 Clinical 

Research, Abbott Laboratories Ltd., Maidenhead, Berkshire, United Kingdom 

157 A REGIONAL AUDIT OF THE USE OF COX-2 SELECTIVE NON-STEROIDAL 

ANTI-INFLAMMATORY DRUGS (NSAIDS) IN RHEUMATOLOGY CLINICS IN THE WEST 

MIDLANDS, ACCORDING TO NICE GUIDELINES. 

AN Price-Forbes 1 , R Callaghan 2 , ME Allen 2 , IF Rowe 1 . West Midlands Rheumatology Services and 

Training Committee. 1 Rheumatology, Worcestershire Royal Hospital, Worcester, United Kingdom; 

2 

Rheumatology, Walsgrave Hospital, Coventry, United Kingdom 

158 EVALUATION OF THE COST-EFFECTIVENESS OF ETORICOXIB IN PATIENTS AT RISK 

OF GI COMPLICATIONS IN THE UK. 

A Moore 1 , C Phillips 2 , J Pellissier 3 , S Crespi 4 , E Hunsche 5 . 1 

Pain Research, University of Oxford, 

Oxford, United Kingdom; 2 School of Health Science, University of Wales, Swansea, United 

Kingdom; 3 Health Economic Statistics, Merck & Co., Inc., Blue Bell, PA, United States; 4 Ernest 

Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States; 5 Outcomes Research, 

Merck & Co., Inc., Whitehouse Station, NJ, United States 

51

159 A SURVEY OF LONG-TERM NSAID USE IN PRIMARY CARE 1993 TO 2003: INDICATIONS, 

SIDE EFFECTS, AND COMPARISON WITH NICE GUIDELINES. 

T Leanne 1 , M John 1 , Q David 1 , T Paul 2 . 1 

Institute of Health and Community Studies, Bournemouth 

University, Bournemouth, Dorset, United Kingdom; 2 Rheumatology Unit, Poole Hospital NHS Trust, Poole, 

Dorset, United Kingdom 

160 NON-STEROIDAL ANTI-INFLAMMATORY USE IN GENERAL OUTPATIENT RHEUMATOLOGY 

SERVICE, AN AUDIT. ARE WE FOLLOWING DOCUMENTED GUIDELINES FOR PRESCRIBING 

COX2 AGENTS? 

N Quillinan, E O’Carroll, A Akadiri, G Kearns, P O’Connell. Department of Rheumatology, Beaumont 

Hospital, Dublin, Ireland 

161 REGIONAL AUDIT OF ANTI-TNF USE IN RHEUMATOID ARTHRITIS - ESSEX EXPERIENCE. 

K Chakravarty, T Bashir. Rheumatology, Harold Wood Hospital, Romford, Essex, United Kingdom 

162 A RESOURCE UTILISATION STUDY COMPARING HUMIRA ® (ADALIMUMAB) WITH REMICADE ® 

(INFLIXIMAB) FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS. 

B Hazleman 1 , A Ostor 1 , V Gurmin 2 , A Strickson 2 , F Pang 2 . 1 

School of Clinical Medicine, University of 

Cambridge, Cambridge, Cambridgeshire, United Kingdom; 2 Medical Division, Abbott Laboratories Ltd., 

Maidenhead, Berkshire, United Kingdom 

163 RHEUMATOLOGY PATIENT PREFERENCES FOR TIMING AND LOCATION OF OUTPATIENT CLINICS. 

KMJ Douglas 1 , T Potter 1 , K Obrenovic 2 , D Mitton 1 , GD Kitas 1 . 1 

Rheumatology Department, Dudley Group 

Hospitals, Dudley, West Midlands, United Kingdom; 2 Audit Department, Dudley Group Hospitals, Dudley, 

West Midlands, United Kingdom 

164 PRIORITY SETTING FOR TJR. 

EA Fargher, K Payne, LM Davies. Health Economics Research at Manchester (HER@M), University of 

Manchester, Manchester, United Kingdom 

165 COPYING LETTERS TO PATIENTS - AN OUTPATIENT QUESTIONNAIRE. 

SA Young Min, C Heycock, J Hamilton, C Kelly. Rheumatology, Queen Elizabeth Hospital, Gateshead, 

Tyne & Wear, United Kingdom 

166 MUSCULOSKELETAL SERVICE PROVISION IN THE UK - A SNAPSHOT. 

AK Gilbert, J Reeback, S Edwards. Rheumatology, ARMA (Arthritis and Musculoskeletal Alliance, 

41 Eagle Street, London, United Kingdom 

167 THE USE OF SOOTHING CLASSICAL MUSIC IN OUTPATIENTS WAITING AREA TO DECREASE THE 

LEVEL OF ANXIETY AND INCREASE RELAXATION IN RHEUMATOLOGY OUTPATIENTS. 

GA Hamad, L Williamson. 1 Rheumatology Department, Great Western Hospital, Swindon, Wiltshire, 

United Kingdom; 2 Rheumatology Department, Great Western Hospital, Swindon, Wiltshire, 


168 DRUG MONITORING CLINICS ? - A THING OF THE PAST. GUIDED SELF MANAGEMENT IS THE 

WAY FORWARD. 

R Chengebroyen, T Bashir, K Chakravarty. Rheumatology, Harold Wood Hospital, Romford, Essex, 


169 TOUCH SCREEN COLLECTION OF RA OUTCOME DATA IN CLINIC - 

A FEASIBLE AND VALID OPTION? 

MC Greenwood, AJ Hakim, DV Doyle. Academic Rheumatology and Osteoporosis Unit, Whipps Cross 

University Hospital, London, United Kingdom 

170 E-MAIL FACILITIES FOR PATIENTS AND GENERAL PRACTITIONERS: INNOVATIVE 

SERVICE DEVELOPMENT AT SOUTH MANCHESTER. 

B Pal. Rheumatology, Withington, Manchester, United Kingdom 

52

171 PRESCRIBING FOLLOWING OSTEOPOROTIC FRACTURE: DOES A PATIENT AND GENERAL 

PRACTITIONER CENTRED APPROACH INCREASE PRESCRIBING? 

SL Hider 1 , AA Ismail 1 , G Cook 3 , B Todd 2 , J Rogers 3 , A Hamilton 3 . 1 


Stepping Hill Hospital, Stockport, United Kingdom; 2 Department of Orthopaedics, Stepping Hill 

Hospital, Stockport, United Kingdom; 3 Department of Epidemiology, Stepping Hill Hospital, 

Stockport, United Kingdom 

172 THE COST EFFECTIVENESS AND ACCEPTABILITY OF SHARED CARE VS HOSPITAL 

TREATMENT FOR PATIENTS WITH MILD, STABLE, ESTABLISHED RHEUMATOID ARTHRITIS (RA). 

PK O’Neill 1 , EA Fargher 1 , K Tricker 1,2 , DPM Symmons 2 , LM Davies 1 . 1 

Health Economics Research at 

Manchester (HER@M), University of Manchester, Manchester, United Kingdom; 2 ARC 

Epidemiology Unit, University of Manchester, Manchester, United Kingdom 

173 THE USE OF A POINT-OF-CARE SYSTEM FOR CRP MEASUREMENT IN A 

RHEUMATOLOGY CLINIC. 

S Busteed 1 , K Hayden 2 , M Lawrence 1 , I Watson 2 , R Thompson 1 . 1 

Rheumatology, University Hospital 

Aintree, Liverpool, Merseyside, United Kingdom; 2 Biochemistry, University Hospital Aintree, 

Liverpool, Merseyside, United Kingdom 

174 INTER- AND INTRAOBSERVER VARIABILITY OF A NON-INSTRUMENTED, 

STANDARDISED PHYSICAL EXAMINATION IN A PRIMARY CARE POPULATION OF OLDER 

ADULTS WITH KNEE PROBLEMS. 

LRJ Wood 1 , GM Peat 1 , R Wilkie 1 , E Thomas 1 , EM Hay 1,2 , J Sim 1 . 1 Primary Care Sciences Research 

Centre, Keele University, Keele, Newcastle-under-Lyme, Staffs, United Kingdom; 2 Staffordshire 

Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, Staffs, United Kingdom 

175 THE IMPACT AND IMPLICATIONS OF NEW TREATMENTS IN ARTHRITIS: VALIDATION OF A 

QUESTIONNAIRE TO MEASURE THE ‘REAL LIFE’ EFFECTIVENESS OF MEDICATION. 

AJ Carr 1 , RA Hughes 2 , K Vincent 2 , M Carr 2 , C Thwaitesv. 1 

Academic Rheumatology, University of 

Nottingham, Nottingham, United Kingdom; 2 Rheumatology, Ashford and St Peter’s Hospital, 

Chertsey, United Kingdom 

176 REGIONAL VARIATIONS IN SELF-REPORTED LONGSTANDING MUSCULOSKELETAL 

CONDITIONS ARE ONLY PARTLY EXPLAINED BY SOCIAL CLASS: RESULTS FROM THE GENERAL 

HOUSEHOLD SURVEY. 

AM Clarke, DPM Symmons. Arthritis Research Campaign Epidemiology Unit, School of 

Epidemiology and Health Sciences, University of Manchester, Manchester, United Kingdom 

177 CAN THE RHEUMATOID ARTHRITIS QUALITY OF LIFE QUESTIONNAIRE BE EXTENDED TO 

PROVIDE GREATER INSIGHT INTO SPECIFIC PATIENT CONCERNS WITHOUT LOSING VALIDITY? 

MC Greenwood, AJ Hakim, DV Doyle. Academic Rheumatology and Osteoporosis Unit, Whipps 

Cross University Hospital, London, United Kingdom 

178 THE IMPACT OF SOCIAL DEPRIVATION ON HEALTH RELATED QUALITY OF LIFE AND 

FUNCTIONAL DISABILITY IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS. 

M Harrison 1 , K Tricker 2 , L Davies 2 , C Roberts 1 , D Symmons 1 . 1 


Manchester, Manchester, United Kingdom; 2 Health Economics Research at Manchester, University 

of Manchester, Manchester, United Kingdom; 3 Clinical Trials Unit, University of Manchester, 

Manchester, United Kingdom 

179 WHY WONT RESIDENTIAL HOME RESIDENTS WEAR HIP PROTECTORS? 

C Jones 1 , T Villar 2 , A Dawson 3 , P Thompson 2 . 1 

Osteoporosis Dorset, Bournemouth, Dorset, United 

Kingdom; 2 Poole Hospital NHS Trust, Poole, Dorset, United Kingdom; 3 Dorset Health Authority, 

Verwood, Dorset, United Kingdom 

53

180 DEGREE OF FUNCTIONAL DISABILITY DETERMINES THE USEFULNESS OF SPECIFIC 

HEALTH UTILITY MEASURES IN RA. 

AG Witney 1,2 , M Tavakoli 3 , K Vincent 4 , T Gareth 2 , DL Scott 4 , KD George 1,2 . 1 


University of Birmingham, Birmingham, West Midlands, United Kingdom; 2 Department of Rheumatology, 

Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom; 3 Department of Management, University 

of St Andrews, St Andrews, Fife, United Kingdom; 4 Department of Rheumatology, King’s College, 

London, London, United Kingdom 

181 ELBOW ASSESSMENT TOOL - DEVELOPMENT AND VALIDATION. 

P Sathyamoorthy, GJ Kemp, A Rawal, V1 Raynor, S1 Frostick. Department of Musculoskeletal Science, 

Royal Liverpool University Hospital, Liverpool, Mersey, United Kingdom 

182 PREDICTORS OF PRIMARY CARE CONSULTATION FOR KNEE-RELATED DISORDERS. 

A PROSPECTIVE STUDY. 

K Jordan, C Jinks, PR Croft. Primary Care Sciences Research Centre, Keele University, Keele, Staffs, 


183 SHOULDER AND KNEE PAIN: HOW WELL DO BSR ATTENDEES APPRECIATE PATIENT PRIORITIES? 

- THE SHEEP STUDY REVISITED. 

S Clarke 1 , DJ Sharp 2 , M Calnan 1 , PA Dieppe 1 . 1 

MRC Health Services Research Collaboration, University of 

Bristol, Bristol, Avon, United Kingdom; 2 Division of Primary Health Care, University of Bristol, Bristol, 

Avon, United Kingdom 

184 SINGLE PATIENT TRIALS IN RHEUMATOLOGY. 

S Brookes 1 , C Paterson 1 , C Pope 1 , P Creamer 2 , J Haines 2 , P Dieppe 1 . 1 

MRC HSRC, University of Bristol, 

Bristol, United Kingdom; 2 Department of Rheumatology, Southmead Hospital, Bristol, United Kingdom 

185 IS VIDEO ANALYSIS OF CLINICAL INTERVENTIONS IN TREATMENT TRIALS VALUABLE? 

EXPERIENCES FROM A LOW BACK PAIN STUDY. 

R Mullis 1 , K Dziedzic 1 , M Lewis 1 , V Cooper 2 , C Main 3 , P Watson 4 , P Croft 1 , E Hay 1 . 1 

Primary Care Sciences 

Research Centre, University of Keele, Keele, Staffordshire, United Kingdom; 2 Department of Postgraduate 

Medicine, University of Keele, Keele, Staffordshire, United Kingdom; 3 Department of Behavioural 

Medicine, University of Manchester/Hope Hospital, Salford, United Kingdom; 4 Department of 

Anaesthesia and Pain Management, University of Leicester, Leicester, United Kingdom 

186 SERVICE BARRIERS AND FACILITATORS TO IMPROVED MANAGEMENT OF OSTEOARTHRITIS. 

JA Chard 1 , PA Dieppe 1 , M Calnan 1 , P Conaghan 2 . 1 

MRC Hsrc, Department of Social Medicine, University 

of Bristol, Bristol, United Kingdom; 2 Department of Rheumatology, Leeds General Infirmary, Leeds, 


187 ISSUES OF GENERALISABILITY IN RANDOMISED CLINICAL TRIALS. 

M Lewis, R Mullis, J Hill, C Vohora, KS Dziedzic, EM Hay. Primary Care Sciences Research Centre, Keele 

University, Keele, Staffordshire, United Kingdom 

188 IMPROVED QUALITY OF REPORTING OF RANDOMIZED TRIALS IN EUROPEAN RHEUMATOLOGY 

JOURNALS PROMOTING CONSORT GUIDELINES. 

EA Sushchuk 1 , NN Stepanova 2 . 1 

Department of Hospital Therapeutics, Volgograd State Medical 

University, Volgograd, Russian Federation; 2 Rheumatology Department, Teaching City Hospital No.25, 

Volgograd, Russian Federation 

EPIDEMIOLOGY (189 – 196) 

189 PREDICTING THE ONSET OF NECK PAIN (WHIPLASH) FOLLOWING A MOTOR VEHICLE ACCIDENT. 

NJ Wiles 1,3 , GT Jones 1,2 , AJ Silman 1 , GJ Macfarlane 1,2 . 1 

ARC Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom; 2 Unit of Chronic Disease Epidemiology, University of Manchester, 

Manchester, United Kingdom; 3 Division of Psychiatry, University of Bristol, Bristol, United Kingdom 

54

190 THE PREVALENCE OF RHEUMATOID ARTHRITIS IN RURAL EGYPT. 

RR Abdel-Tawab 1 , AM Abdel-Nasser 1 , JA Mahmoud 1 , A Sammy 2 , M Abdel-Fattah 3 . 1 

Rheumatology 

& Rehabilitation, Minia University, Minia, Egypt; 2 Radiology, Minia University, Minia, Egypt; 

3Epidemiology, Minia University, Minia, Egypt 

191 PREVALENCE OF HAND PROBLEMS AND HAND PAIN IN OLDER PEOPLE: 

A SURVEY OF THE GENERAL POPULATION IN NORTH STAFFORDSHIRE. 

K Dziedzic, E Thomas, S Hill, R Wilkie, G Peat, P Croft. Primary Care Sciences Research Centre, 

Keele University, Keele, Newcastle, Staffs, United Kingdom 

192 ASSOCIATION OF HAND PARAESTHESIA WITH SPECIFIC JOB TASKS: RESULTS FROM 

A POPULATION STUDY IN NORTH STAFFORDSHIRE, UK. 

RJ Lacey, M Lewis, J Sim. Primary Care Sciences Research Centre, Keele University, Keele, Staffs 

ST5 5BG, United Kingdom 

193 A STUDY INTO THE INCIDENCE OF CANCER IN A COHORT OF PATIENTS WITH PRIMARY 

SJOGREN’S SYNDROME. 

MN Lazarus, DA Isenberg. Centre for Rheumatology, University College London, London, 


194 THE CHANGING PROFILE OF RHEUMATOLOGY ADMISSIONS IN A DISTRICT 

GENERAL HOSPITAL OVER THREE DECADES. 

NJ Allen 2 , JC Belfield 1 , GC Zaphiropolous 1 , K Chaudhuri 1 . 1 

Department of Rheumatology, University 

Hospitals of Coventry and Warwickshire, Coventry, Warwickshire, United Kingdom; 2 Department 

of Rheumatology, Kingston Hospital, Kingston, Surrey, United Kingdom 

195 PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH 


WF Ng, A Hall, A Steuer. Rheumatology, Wexham Park Hospital, Slough, SL2 4HL, United Kingdom 

196 LATERAL EPICONDYLITIS AMONG THE GENERAL POPULATION: A CASE-CONTROL STUDY. 

KE Walker-Bone 1 , KT Palmer 2 , IC Reading 2 , D Coggon 2 , C Cooper 2 . 1 


Brighton and Sussex Medical School, Brighton, East Sussex, United Kingdom; 2 MRC Environmental 

Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom 

NON-INFLAMMATORY MUSCULOSKELETAL DISORDERS (197 – 202) 

197 MUSCULO-SKELETAL REFLEX DYSFUNCTION IN THE JOINT HYPERMOBILITY SYNDROME. 

WR Ferrell 1 , RH Baxendale 2 , M Kusel 2 , N Tennant 3 , RD Sturrock 1 . 1 

Centre for Rheumatic Diseases, 

University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Institute of Biomedical & Life 

Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom; 3 Physiotherapy, Royal 

Infirmary, Glasgow, Scotland, United Kingdom 

198 HIGH PREVALENCE OF JOINT HYPERMOBILITY SYNDROME IN CLINIC REFERRALS 

TO A NORTH LONDON COMMUNITY HOSPITAL. 

R Grahame 1,2 , AJ Hakim 1,3 . 1 

The Hypermobility Clinic, Centre for Rheumatology, University College 

London Hospitals, London, United Kingdom; 2 Rheumatology, Willesden Community Hospital, 

London, United Kingdom; 3 The Academic Rheumatology and Osteoporosis Unit, Whipps Cross 

University Hospital, London, United Kingdom 

199 ‘REPETITIVE STRAIN INJURY’ IS RARE AMONG WORKING-AGED ADULTS AND IS NOT 

ASSOCIATED WITH KEYBOARD USE. 

KE Walker-Bone 1 , IC Reading 2 , KT Palmer 2 , D Coggon 2 , C Cooper 2 . 1 


Brighton and Sussex Medical School, Brighton, East Sussex, United Kingdom; 2 MRC Environmental 

Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United Kingdom 

55

200 CAUSES OF MUSCULOSKELETAL CHEST PAIN IN PATIENTS ADMITTED TO HOSPITAL 

WITH POSSIBLE MYOCARDIAL INFARCTION. 

J How, G Volz, J Hamilton, C Heycock, C Kelly. Medicine and Rheumatology, Queen Elizabeth Hospital, 

Gateshead, Tyne and Wear, United Kingdom 

201 SHOULD ALL PATIENTS WITH CARPAL TUNNEL SYNDROME BE SCREENED 

FOR THYROID DISEASE? 

E Suresh, IM Morris. 1 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom; 

2 

Department of Rheumatology, Kettering General Hospital, Kettering, United Kingdom 

202 TO SCAN OR NOT TO SCAN? THAT IS THE QUESTION.... 

S Bawa 1 , K Gaffney 1 , PG Kitchener 2 . 1 

Department of Rheumatology, Norfolk & Norwich University 

Hospital NHS Trust, Norwich, Norfolk, United Kingdom; 2 Department of Radiology, Norfolk & Norwich 

University Hospital NHS Trust, Norwich, Norfolk, United Kingdom 

EDUCATION RESEARCH (203 – 215) 

203 FACTORS INFLUENCING PATIENT’S PERCEPTION OF RISK ASSOCIATED WITH TAKING NSAIDs 

FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS. 

AM Metcalfe 1 , CM Clifford 1 , P Jobanputra 2 . 1 

School of Health Sciences, University of Birmingham, 

Birmingham, West Midlands, United Kingdom; 2 Rheumatology Dept., Selly Oak Hospital, University 

Hospital Birmingham (Teaching) NHS Trust, Birmingham, West Midlands, United Kingdom 

204 PATIENTS HAVE POSITIVE PERCEPTIONS OF INVOLVEMENT IN STRUCTURED MEDICAL 

STUDENT TEACHING. 

MS Lillicrap, V Dagley, AC Howe. School of Medicine, Health Policy and Practice, University of East 

Anglia, Norwich, United Kingdom 

205 AN EXPERT CONSENSUS OF APPROPRIATE PRACTICE AND COMPETENCY-BASED LEARNING 

OUTCOMES FOR RHEUMATOLOGISTS PERFORMING MUSCULOSKELETAL ULTRASONOGRAPHY. 

AK Brown 1 , RJ Wakefield 1 , Z Karim 1 , PJ O’Connor 2 , TE Roberts 3 , PG Conaghan 1 , A Grainger 2 , P Emery 1 . 

1 

Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 2 Department of 

Radiology, Leeds General Infirmary, Leeds, United Kingdom; 3 Medical Education Unit, School of 

Medicine, University of Leeds, Leeds, United Kingdom 

206 AN EXPERIENCE OF OSTEOPOROSIS EDUCATION SESSIONS. 

JT Morgan 1 , JC Martin 1 , R Tyrell 2 . 1 

Rheumatology, Pontypridd & Rhondda NHS Trust, Royal Glamorgan & 

Dewi Sant Hospital, Wales, United Kingdom; 2 Physiotherapy, Pontypridd & Rhondda NHS Trust, Royal 

Glamorgan & Dewi Sant Hospital, Wales, United Kingdom 

207 THE EFFICACY OF A SELF-MANAGEMENT INTERVENTION FOR HOSPITAL OUTPATIENTS 

WITH CHRONIC RA. 

TJ Pimm 1 , MA Byron 2 , DM Curson 1 , S Hill 1 , GH Aikman 1 , CH Bamford 1 , JA Hall 1 , JA Weinman 3 . 

1 

Department of Rheumatology, Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust, 

Aylesbury, United Kingdom; 2 Centre for Medical Education, University of Bristol, Bristol, United Kingdom; 

3 

Department of Psychology (at Guy’s), Institute of Psychiatry, London, United Kingdom 

208 CAN A SINGLE (RHEUMATOLOGY) REVISION SESSION HELP STUDENTS IN THEIR FINAL 

YEAR EXAMINATIONS? 

RW Marshall 1,2 , S Clarke 3 , D Coady 4 , JR Kirwan 1 . 1 

Rheumatology Unit, University Department of Clinical 

Science at South Bristol, Bristol, BS2 8HW, United Kingdom; 2 Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, BA1 1RL, United Kingdom; 3 MRC / HSRC, Canynge Hall, Whiteladies Road, 

Bristol, BS8 2PR, United Kingdom; 4 Rheumatology, Freeman Hospital, Newcastle-upon-Tyne, 


56

209 DO PATIENTS AND RHEUMATOLOGISTS HAVE THE SAME UNDERSTANDING OF WHAT IS 

SAID IN A CONSULTATION? 

MG Lee 3 , AG Witney 1,2 , GD Kitas 1,2 . 1 

Department of Rheumatology, University of Birmingham, 

Birmingham, West Midlands, United Kingdom; 2 Department of Rheumatology, Dudley Group of 

Hospitals NHS Trust, Dudley, United Kingdom; 3 School of Computer Science, University of 

Birmingam, Birmingham, West Midlands, United Kingdom 

210 RELATIONSHIP BETWEEN PERCEIVED CONFIDENCE AND ACTUAL PERFORMANCE IN 

AN OBJECTIVE STRUCTURED CLINICAL EXAMINATION OF SHOULDER AND KNEE JOINT 

ASSESSMENT. 

P Vivekananda-Schmidt 1 , DA Coady 2 , M Lewis 1 , MJ McLean 3 , L Kay 2 , D Walker 2 , AB Hassell 1 . 

1 

Primary Care Sciences Research Centre, Keele University, Keele, Staffordshire, United Kingdom; 

2 

Department of Rheumatology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 3 The 

Institute for the Advancement of University Learning, University of Oxford, Oxford, Oxfordshire, 


211 PERCEIVED CONFIDENCE AMONGST SENIOR HOUSE OFFICERS (SHOs) IN UNDERTAKING 

A REGIONAL MUSCULOSKELETAL EXAMINATION. 

DA Coady 1 , N McKay 2 , V Saravanan 3 , LJ Kay 1 . 1 

Rheumatology, Freeman Hospital, Newcastle upon 

Tyne, NE7 7DN, United Kingdom; 2 Rheumatology, Sunderland Royal Infirmary, Sunderland, Tyne 

and Wear, United Kingdom; 3 Rheumatology, Queen Elizabeth, Gateshead, Tyne and Wear, 


212 REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM (REMS): THE CORE 

SET OF CLINICAL SKILLS FOR MEDICAL STUDENTS. 

DA Coady, LJ Kay, DJ Walker. Rheumatology, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, 


213 EVALUATION OF A “REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM” 

(REMS) TEACHING VIDEO AMONGST FINAL YEAR MEDICAL STUDENTS IN TWO MEDICAL 

SCHOOLS. 

DA Coady 1 , RW Marshall 3,4 , S Clarke 2 , J Kirwan 4 , L Kay 1 , D Walker 1 . 1 

Rheumatology, Freeman 

Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom; 2 MRC / HSRC, Canynge Hall, 

Whiteladies Road, Bristol, BS8 2PR, United Kingdom; 3 Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, BA1 1RL, United Kingdom; 4 Rheumatology Unit, University Department 

of Clinical Science at South Bristol, Bristol, BS2 8HW, United Kingdom 

214 DOES A REGIONAL EXAMINATION OF THE MUSCULOSKELETAL SYSTEM (REMS) VIDEO 

DESIGNED FOR MEDICAL STUDENTS CONTAIN ENOUGH DETAIL FOR GENERAL PRACTICE 

REGISTRARS (GPRs)? 

EM Wise 2 , DA Coady 1 , LJ Kay 1 , DJ Walker 1 . 1 

Department of Rheumatology, The Freeman Hospital, 

Newcastle upon Tyne, United Kingdom; 2 Northumbria Vocational Training Scheme, Newcastle 

upon Tyne, United Kingdom 

215 THE USE OF PROSPECTIVE DIARIES TO CAPTURE WHICH MUSCULOSKELETAL 

CONDITIONS GENERAL PRACTICE REGISTRARS (GPRs) SEE. 

EM Wise 1 , DA Coady 2 , TD Van Zwanenberg 1 , DJ Walker 3 . 1 


Musculoskeletal Unit, The Freeman Hospital, Newcastle upon Tyne, United Kingdom; 

2 

Northumbria Vocational Training Scheme, Newcastle upon Tyne, United Kingdom; 3 Department 

of General Practice, Postgraduate Institute for Medicine & Dentistry, Newcastle upon Tyne, 


57

SCLERODERMA (216 – 233) 

216 OXIDISED LOW DENSITY LIPOPROTEIN AND HOMOCYSTEINAEMIA ARE RISK FACTORS FOR 

MACROVASCULAR DISEASE IN SYSTEMIC SCLEROSIS. 

M Ho 2 , AH Strang 1 , M McLaren 1 , F Daly 1 , C Eastmond 3 , G Nuki 4 , JJF Belch 1 . 1 

University Department of 

Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom; 2 Dept. of Rheumatology, 

Northampton General Hospital NHS Trust, Northampton, United Kingdom; 3 Dept. of Rheumatology, 

Aberdeen Royal Infirmary, Aberdeen, United Kingdom; 4 Rheumatic Diseases Unit, Western General 

Hospital, Edinburgh, United Kingdom 

217 CTGF: A POTENTIAL MARKER OF FIBROSIS IN SCLERODERMA? 

M Dziadzio 1 , W Usinger 2 , H Penn 1 , C Black 1 , D Abraham 1 , C Denton 1 , R Stratton 1 . 1 

Rheumatology, Royal 

Free Hospital, London, United Kingdom; 2 FibroGen, San Francisco, CA, United States 

218 QUALITY OF LIFE WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS. 

AE Gliddon 1 , CJ Dore 2 , PJ Maddison 3 , the Quins Trial Study Group. 1 School of Sport, Health & Exercise 

Science, University of Wales, Bangor, Bangor, Gwynedd, United Kingdom; 2 MRC Clinical Trials Unit, 

London, United Kingdom; 3 Rheumatology Department, Ysbyty Gwynedd Hospital, Bangor, Gwynedd, 


219 A PILOT STUDY ASSESSING THE RESPONSE OF SINGLE DOSE SILDENAFIL CITRATE (VIAGRA) 

IN THE TREATMENT OF RAYNAUDS’ PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS. 

N Kumar 1 , J Allen 2 , A Murray 2 , B Griffiths 1 . 1 

Department of Rheumatology, Musculoskeletal Unit, 

Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Regional Medical Physics Department, 

Freeman Hospital, Newcastle-upon-Tyne, United Kingdom 

220 PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS - SCREENING GUIDELINES IN PRACTISE. 

S Busteed, RJ Moots, RN Thompson. Rheumatology, University Hospital Aintree, Liverpool, Merseyside, 


221 PULMONARY ARTERIAL HYPERTENSION IN FIBROTIC AND NON-FIBROTIC SSC PATIENTS - 

RESPONSE TO THERAPY. 

A Kawald, M Williams, C Elliott, CM Black, GJ Coghlan. 1 Department of Academic Rheumatology, Royal 

Free Hospital, London NW3 2QG, United Kingdom; 2 Department of Cardiology, Royal Free Hospial, 

London NW3 2QG, United Kingdom 

222 A COMPARISON OF FINGER AND EARLOBE OXIMETRY IN PATIENTS WITH SYSTEMIC SCLEROSIS. 

K Isdale 1 , BR O’Driscoll 2 , AL Herrick 1 . 1 

University of Manchester Rheumatic Diseases Centre, Hope 

Hospital, Salford, United Kingdom; 2 Respiratory Medicine, Hope Hospital, Salford, United Kingdom 

223 CALCINOSIS IN SYSTEMIC SCLEROSIS - ARE WE UNDERESTIMATING ITS PREVALENCE? 

K Brennan 1 , S Jackson 2 , AL Herrick 1 . 1 

University of Manchester Rheumatic Diseases Centre, Hope 

Hospital, Salford, United Kingdom; 2 Radiology, Hope Hospital, Salford, United Kingdom 

224 RENAL INVOLVEMENT IN INDIAN SCLERODERMA PATIENTS - A SINGLE CENTER STUDY. 

R Gupta 1 , R Grover 1 , V Marwaha 1 , VK Singhal 2 . 1 

Clinical Immunology & Rheumatology Service, 

Department of Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India; 2 Rheumatology 

Department, Army Hospital (Research & Referral), New Delhi, Delhi, India 

225 MONOCYTE CHEMOATTRACTANT PROTEIN-3 (MCP-3) OVEREXPRESSION IN SCLERODERMA: 

REGULATION BY TGFβ. 

VH Ong, M Carulli, G Lindahl, S Xu, DJ Abraham, CM Black, CP Denton. Centre for Rheumatology, Royal 

Free and University College Medical School, London, United Kingdom 

226 DNA BINDING-ACTIVITY OF CCAAT-BINDING FACTOR (CBF) IS STRONGLY ENHANCED IN 

ACTIVATED LUNG FIBROBLASTS FROM PATENTS WITH SYSTEMIC SCLEROSIS. 

GE Lindahl 1 , X Shiwen 1 , RC Chambers 2 , CP Denton 1 , DJ Abraham 1 , CM Black 1 , GJ Laurent 2 . 

1 

Rheumatology, Royal Free and UCL Medical School, London, United Kingdom; 2 Centre for Respiratory 

Research, Dept Medicine, UCL Medical School, London, United Kingdom 

58

227 DYSREGULATED METALLOPROTEINASE EXPRESSION IN A TRANSGENIC MOUSE 

MODEL OF SCLERODERMA. 

CP Denton 1 , K Lazaridis 2 , X Shiwen 1 , DJ Abraham 1 , A Chantry 2 , D Edwards 2 , CM Black 1 . 1 


Rheumatology, Royal Free and University College Medical School, Hampstead, London, United 

Kingdom; 2 School of Biological Sciences, University of East Anglia, Norwich, United Kingdom 

228 GENE EXPRESSION PROFILING DELINEATES CONSTITUTIVELY ACTIVATED TARGETS OF 

TGFβ IN A TRANSGENIC MODEL OF SCLERODERMA. 

CP Denton, G Lindahl, VH Ong, X Shiwen, E Renzoni, DJ Abraham, CM Black. Centre for 

Rheumatology, Royal Free and University College Medical School, Hampstead, London, 


229 DYSREGULATION OF THE EXPRESSION OF TGFβ ACCESSORY RECEPTORS IN THE 

SSC FIBROBLAST. 

AM Holmes, X Shi-Wen, CM Black, DJ Abraham. Rheumatology Dept., UCL-Royal Free Campus, 


230 SYNERGISTIC ENHANCEMENT OF MATRIX REMODELING IN LUNG FIBROBLASTS AFTER 

CO-STIMULATION WITH ET-1 AND THROMBIN: IMPLICATIONS FOR PULMONARY FIBROSIS 

IN SCLERODERMA. 

X Shiwen 1 , A Leask 1 , CP Denton 1 , M Eastwood 2 , R Stratton 1 , A Holmes 1 , R duBois 3 , DJ Abraham 1 , 

CM Black 1 . 1 

Rheumatology, Royal Free and University College Medical School, London, United 

Kingdom; 2 Tissue Engineering Research, University of Westminster, London, United Kingdom; 

3 

Interstitial Lung Disease Unit, Imperial College School of Medicine, London, United Kingdom 

231 THE ROLE OF TH3 (TGF-β PRODUCING) T CELLS IN SYSTEMIC SCLEROSIS. 

NG Taguri, M Ponticos, DJ Abraham, CM Black. Centre for Rheumatology, Royal Free and 

University College Medical School, London, United Kingdom 

232 ENDOTHELIN-1 PROMOTES MYOFIBROBLAST INDUCTION THROUGH THE ETA 

RECEPTOR VIA RAC/PI3 KINASE/AKT AND CONTRIBUTES TO THE CONTRACTILE PHENOTYPE 

OF SCLERODERMA FIBROBLASTS. 

A Leask 1 , X Shi-wen 1 , CP Denton 1 , A Holmes 1 , M Eastwood 2 , E Renzoni 3 , M Dashwood 1 , RM 

duBois 3 , CM Black 1 , DJ Abraham 1 . 1 

Rheumatology, Royal Free and University College Medical 

School, London, United Kingdom; 2 Tissue and Engineering Research, University of Westminster, 

London, United Kingdom; 3 Interstitial Lung Disease Unit, Imperial College of Medicine, London, 


233 MICROVASCULAR PERICYTES EXPRESS THE MESENCHYMAL STEM CELL MARKER 

STRO-1 AND THE FIBROBLAST SPECIFIC ANTIGEN, THY-1. 

VS Rajkumar, CM Black, DJ Abraham. Rheumatology, Royal Free & University College Medical 

School, London, United Kingdom 

INFLAMMATORY MUSCLE DISEASE (234 – 235) 

234 INTER-RATER RELIABILITY OF TWO DISEASE ACTIVITY ASSESSMENT TOOLS IN PATIENTS 

WITH IDIOPATHIC INFLAMMATORY MYOPATHY. 

SM Sultan 1 , E Allen 2 , C Oddis 3 , J Vencovsky 4 , I Lundberg 5 , DA Isenberg 1 . 1 

Rheumatology, University 

College London, London, United Kingdom; 2 Medical Statistics, University College London, London, 

United Kingdom; 3 University of Pittsburgh, Pittsburgh, United States; 4 Institute of Rheumatology, 

Prague, Czech Republic; 5 Karolinska Institute, Stockholm, Sweden 

235 DIFFERENCES ARE DEMONSTRATED IN THE ASSOCIATION OF MALIGNANCY BETWEEN 

POLYMYOSITIS AND DERMATOMYOSITIS. 

H Chinoy 1 , F Salway 2 , SJ Alan 2 , OE William 2 , CG Robert 1 . 1 

Rheumatic Diseases Centre, Hope 

Hospital, Salford, Lancs, United Kingdom; 2 ARC Epidemiology Unit, Stopford Building, University 

of Manchester, Manchester, Lancs, United Kingdom 

59

SJÖGREN’S SYNDROME (236 – 239) 

236 HEALTH CARE USAGE IN PRIMARY SJÖGREN’S SYNDROME. 

R Callaghan 1 , A Prabu 1 , C Gordon 1 , A Clarke 2 , S Bowman 1 . 1 

Rheumatology Department, Division of 

Immunity & Infection, The University of Birmingham, Birmingham, United Kingdom; 2 Department of 

Medicine, McGill University, Montreal, QC, Canada 

237 A STUDY INTO THE INCIDENCE OF AUTOIMMUNE DISEASES IN A COHORT OF PATIENTS 

WITH PRIMARY SJOGREN’S SYNDROME. 

MN Lazarus, DA Isenberg. Centre for Rheumatology, University College London, London, 


238 SYMPTOMS OF OCULAR AND ORAL DRYNESS IN AN UNSELECTED POPULATION OF PATIENTS 

ATTENDING A RHEUMATOLOGY CLINIC. 

G Hamad, E Price. Department of Rheumatology, Great Western Hospital, Swindon, Wiltshire, 


239 HLA GENOTYPES IN PRIMARY SJÖGREN’S SYNDROME COMPARED TO A NORTH EAST OF 

ENGLAND CONTROL GROUP. 

C Morley 1 , V Carter 2 , G Cavanagh 2 , NJ Marshall 1 , ID Griffiths 1 . 1 

Rheumatology Department, Freeman 

Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2 Histocompatibility and 

Immunogenetics Department, National Blood Service, Newcastle upon Tyne, Tyne and Wear, 


SLE AND ANTIPHOSPHOLIPID SYNDROME (240 – 264) 

240 SPONTANEOUS AUTOIMMUNITY AND ITS EPISTATIC MODIFICATION IN 129 AND C57BL/6 MICE 

- IMPLICATIONS FOR AUTOIMMUNITY DESCRIBED IN GENE-TARGETED MICE. 

J Cortes-Hernandez, AE Bygrave, KL Rose, J Warren, TH Cook, MJ Walport, T Vyse, M Botto. 

Rheumatology Section, Eric Bywaters Centre, Imperial College, London, London, United Kingdom 

241 TNF HAPLOTYPES WITH SEROLOGICAL SUBSETS OF SLE. 

NJ McHugh 1 , PA Owen 2 , B Cox 2 , J Dunphy 2 , KI Welsh 3 . 1 

Rheumatology, Royal National Hospital for 

Rheumatic Diseases, Bath, Banes, United Kingdom; 2 BIRD Diagnostics, Bath Institute for Rheumatic 

Diseases, Bath, Banes, United Kingdom; 3 Clinical Genomics, National Heart and Lung Institute, London, 


242 A COMBINATION OF LOSS OF SLE SUSCEPTIBILITY INTERVALS AND ACQUISITION OF 

SUPPRESSOR LOCI RESULTS IN DISEASE RESISTANCE IN BXSB/LONG-LIVED MICE. 

MEK Haywood 1 , J Rose 1 , S Izui 2 , BJ Morley 1 . 1 

Rheumatology Section, Eric Bywaters Centre, Imperial 

College, London, United Kingdom; 2 Department of Pathology, Centre Medical Universitaire, Geneva, 


243 RE-THROMBOSIS AND BLEEDING IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS ON 

ORAL ANTICOAGULATION AT A TARGET INR 2.0-3.0. A LONGITUDINAL COMPARISON WITH 

PATIENTS WITH INHERITED THROMBOPHILIA AND AORTIC VALVE REPLACEMENTS. 

PRJ Ames 1 , A Ciampa 2 , M Maurizio 3 , S Giovanna 3 , B Vincenzo 3 , I Luigi 3 . 1 

Academic Department of 

Rheumatology, Leeds General Infirmary, Leeds, United Kingdom; 2 Unita’ Semplice di Emostasi e 

Trombosi, Ospedale A. Moscati, Avellino, Italy; 3 Unita’ Semplice di Emostasi e Trombosi, Ospedale A 

Cardarelli, Naples, Italy 

244 COELIAC ARTERY STENOSIS AND ANTIPHOSPHOLIPID ANTIBODIES. 

G Obermoser, IS Lau, S Sangle, D D’Cruz, GRV Hughes. Lupus Research Unit, The Rayne Institute, 

St Thomas’ Hospital, London, United Kingdom 

60

245 CARDIOVASCULAR RISK FACTORS IN ANTIPHOSPHOLIPID SYNDROME WITH 

HYPERTENSION AND RENAL ARTERY STENOSIS. 

N Horwood, S Sangle, DP D’Cruz, MA Khamashta, I Abbs, GRV Hughes. Lupus Research Unit, 

Rayne Institute, St Thomas’ Hospital, London SE1 7EH, United Kingdom 

246 SURVEY OF ATTITUDES AND OPINIONS HELD BY PATIENTS WITH SLE AT NORTHWICK 

PARK HOSPITAL. 

J Andrews, U Martin, CS Higgens. Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex, 


247 PREVALENCE OF HYPERTENSION IN 600 PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME. 

S Sangle, D D’Cruz, M Khamashta, GRV Hughes. Lupus Research Unit, The Rayne Institute, St 

Thomas’ Hospital, London, United Kingdom 

248 LIVEDO RETICULARIS, PREGNANCY MORBIDITY AND NEGATIVE ANTIPHOSPHOLIPID 

ANTIBODIES: A PRELIMINARY REPORT. 

S Sangle, D D’Cruz, GRV Hughes. Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, 


249 CARDIAC LUPUS - MANY SHADES OF ONE COLOUR. 

M Fonseka, M Nisar. Rheumatology, Queen’s Hospital, Burton-on-Trent, United Kingdom 

250 HYPERTENSION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. 

MA Baron, Y Karim, MJ Cuadrado, L Bertolaccini, MA Khamashta, GRV Hughes. 1 Lupus Research 

Unit, St. Thomas’ Hospital, London, England, United Kingdom; 2 Immunology Department, St. 

Thomas’ Hospital, London, England, United Kingdom; 3 Lupus Research Unit, St. Thomas’ Hospital, 

London, England, United Kingdom; 4 Lupus Research Unit, St. Thomas’ Hospital, London, England, 

United Kingdom; 5 Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom; 

6 

Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom 

251 PREMATURE CARDIOVASCULAR DISEASE IN SLE: A STUDY FROM A TERTIARY 

REFERRAL CENTRE. 

S Nair, DP D’Cruz, MA Khamashta, GRV Hughes. Lupus Research Unit, Rayne Institute, 

St.Thomas’s Hospital, London, United Kingdom 

252 A MULTICENTRE RANDOMISED CONTROLLED TRIAL OF CYCLOSPORIN A (CYA) VERSUS 

AZATHIOPRINE (AZA) IN PATIENTS WITH SEVERE SLE: AN INTERIM ANALYSIS. 

B Griffiths 1 , P Emery 2 , D Isenberg, M Akil, R Thompson, P Maddison, I Griffiths 1 , A Lorenzi 2 , 

S Miles 2 , D Situnayake 3 , LS Teh, M Plant, C Hallengrew, K Chakravarty, T Tait, C Gordon 3 . 

1 

Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2 Academic Unit 

of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of 

Rheumatology, University of Birmingham, Birmingham, United Kingdom 

253 THE PREVALENCE OF AN ABNORMAL ANKLE-BRACHIAL INDEX IN PRIMARY 

ANTIPHOSPHOLIPID SYNDROME. 

MA Baron, DP D’Cruz, MA Khamashta, GRV Hughes. The Lupus Research Unit, The Rayne 

Institute, St Thomas’ Hospital, London, United Kingdom 

254 AUDIT ON CARDIOVASCULAR RISK IN SLE. 

FM Erkeller-Yuksel 1 , HD Sinclair 2 , JA Griffin 1 , MR Persey 1 , J MacGowan 2 . 1 

Rheumatology, Chase 

Farm Hospital, Enfield, Middlesex, United Kingdom; 2 Rheumatology, North Middlesex University 

Hospital, London, United Kingdom 

255 ARTERIAL DISEASE IN ANTIPHOSPHOLIPID SYNDROME WITH HYPERTENSION AND RENAL 

ARTERY STENOSIS: A STUDY OF ENDOTHELIN LEVELS. 

N Horwood, S Sangle, K Mepani, ML Bertolaccini, D D’Cruz, MA Khamashta, I Abbs, GRV Hughes. 

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, United Kingdom 

61

256 DOES ANTINUCLEAR ANTIBODY ELISA MISS SIGNIFICANT CONNECTIVE TISSUE DISEASE ? 

AYN Lim, G Maguire, G Wood, DS Kumararatne, JSH Gaston. 1 Department of Rheumatology, 

Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Department of Clinical Immunology, 



Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 5 Department of Rheumatology, 

Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom 

257 DOUBLE BLIND, CROSSOVER, RANDOMISED TRIAL COMPARING LOW MOLECULAR WEIGHT 

HEPARIN VERSUS PLACEBO IN THE TREATMENT OF CHRONIC HEADACHE IN PATIENTS WITH 

ANTIPHOSPHOLIPID ANTIBODIES. 

G Sanna 1 , MJ Cuadrado 2 , M Sharief 3 , MA Khamashta 4 , GRV Hughes 5 . 1 

Rheumatology, Homerton 

University Hospital, London, England, United Kingdom; 2 Lupus Rearch Unit, St. Thomas’ Hospital, 

London, England, United Kingdom; 3 Neurology, St. Thomas’ Hospital, London, England, United Kingdom; 

4 

Lupus Research Unit, St. Thomas’ Hospital, London, England, United Kingdom; 5 Lupus Research Unit, 

St. Thomas’ Hospital, London, England, United Kingdom 

258 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND QUALITY OF LIFE IN SYSTEMIC 

LUPUS ERYTHEMATOSUS. 

S Khanna 1 , H Pal 2 , RM Pandey 3 , R Handa 4 . 1 

All India Institute of Medical Sciences, New Delhi, India; 

2 

Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India; 3 Department of 

Biostatistics, All India Institute of Medical Sciences, New Delhi, India; 4 Department of Medicine, All India 

Institute of Medical Sciences, New Delhi, India 

259 PREVALENCE OF ANTITHYROID ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME. 

P Harrison 1 , GT Swana 2 , MR Swana 3 , ML Bertolaccini 1 , MA Khamashta 1 , DP D’Cruz 1 , GRV Hughes 1 . 1 Lupus 

Research Unit, The Rayne Institute, London, United Kingdom; 2 Immunology Department, St.Thomas’ 

Hospital, London, United Kingdom; 3 Immunology Department, University College London Hospital, 


260 ATYPICAL CO-LOCALISATION OF CD45 AND LYN TO LIPID RAFT SIGNALLING DOMAINS 

CORRELATES WITH B-LYMPHOCYTE HYPER RESPONSIVENESS IN PATIENTS WITH LUPUS. 

F Flores-Borja 1 , PS Kabouridis 1 , E Jury 2 , D Isenberg 2 , RA Mageed 1 . 1 

Bone and Joint Research Unit, 

St Bartholomew’s and The Royal London, Queen Mary School of Medicine, London, United Kingdom; 

2 

Centre for Rheumatology, University College London, London, United Kingdom 

261 A SINGLE MUTATION OF AN ARGININE RESIDUE ALTERS THE BINDING AFFINITY OF A HUMAN 

MONOCLONAL ANTIBODY TO DIFFERENT ANTIGENS. 

N Lambrianides 1,2 , A Rahman 1,2 , L Mason 2 , D Latchman 1 , D Isenberg 2 . 1 

Medical Molecular Biology Unit, 

Institute of Child Health, University College London, London, United Kingdom; 2 Centre for 

Rheumatology, University College London, London, United Kingdom 

262 ANTIBODIES AGAINST OXIDISED THE COMPLEX LOW DENSITY LIPOPROTEIN-BETA - 2 - 

G LYCOPROTEIN-I MAY HAVE A PRO- ATHEROGENIC ROLE IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. 

PRJ Ames 1 , J Delgado-Alves 2 , D Lopez 3 , L Lopez 3 , E Matsuura 4 , A Margarita 5 , L Iannaccone 5 , 

V Brancaccio 5 . 1 

Academic Department of Rheumatology, Leeds General Infirmary, Leeds, United 

Kingdom; 2 Department of Internal Medicine, Curry Cabral Hospital, Lisbon, Portugal; 3 Science and 

Research, Corgenix Ltd, Denver, CO, United States; 4 Department of Biochemistry, Okayama School of 

Medicine, Okayama, Japan; 5 Angiohaemostasis Unit, Ospedale A. Cardarelli, Naples, Italy 

263 STABLE TRANSFECTION OF CHO CELLS TO EXPRESS WHOLE HUMAN IgG ANTIPHOSPHOLIPID 

ANTIBODIES. 

N Lambrianides 1,2 , I Giles 1,2 , D Latchman 1 , D Isenberg 2 , A Rahman 1,2 . 1 

Medical Molecular Biology Unit, 

Institute of Child Health, University College London, London, United Kingdom; 2 Centre for 


62

264 TREATMENT OF REFRACTORY LUPUS NEPHRITIS WITH B LYMPHOCYTE DEPLETION. 

MJ Leandro, MR Ehrenstein, JCW Edwards, J Manson, G Cambridge, DA Isenberg. Centre for 


VASCULITIS (265 – 270) 

265 PREDICING TEMPORAL ARTERITIS IN PEOPLE WITH PRESENTING POLYMYALGIC 

SYMPTOMS. 

CT Pease, G Haugeberg, AW Morgan, BB Bhakta. Academic Unit of Musculoskeletal Disease, 

University of Leeds, Leeds, United Kingdom 

266 PREDICTING DURATION OF ORAL PREDNISOLONE TREATMENT IN PEOPLE WITH 

POLYMYALGIA RHEUMATICA. 

CT Pease, G Haugeberg, BB Bhakta. 1 Academic Unit of Musculoskeletal Disease, University of 

Leeds, Leeds, United Kingdom; 2 Academic Unit of Musculoskeletal Disease, University of Leeds, 

Leeds, United Kingdom; 3 Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, 


267 THE PREVALENCE AND ASSOCIATIONS OF AN ABNORMAL ANKLE-BRACHIAL PRESSURE 

INDEX IN SYSTEMIC VASCULITIS: A PILOT STUDY. 

M Mora, C Noronha, B Grima, MA Baron, M Liz, MA Khamashta, GRV Hughes, DP D’Cruz. The 

Lupus Research Unit, St Thomas’ Hospital, London, United Kingdom 

268 DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) 

IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE. 

JS McLaren, CJ Hall, RA Luqmani. Rheumatic Diseases Unit, University of Edinburgh, Edinburgh, 


269 WEGENER’S GRANULOMATOSIS: COMPARISON OF OUTCOME IN PATIENTS TREATED 

WITH LOW DOSE IV CYCLOPHOSPHAMIDE, ORAL CYCLOPHOSPHAMIDE OR OTHER 

CYTOTOXIC AGENTS. 

AN Bennett, C Noronha, JD Rees, DP D’Cruz, GRV Hughes. Lupus Research Unit, St Thomas’ 

Hospital, London, United Kingdom 

270 THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES IN A COHORT OF PATIENTS WITH 

SYSTEMIC VASCULITIS. 

J Rees, S Lanca, PV Marques, JA Gómez-Puerta, MA Khamashta, DP D’Cruz, GRV Hughes. 

The Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, United Kingdom 

PAEDIATRIC RHEUMATOLOGY (271 – 278) 

271 SUBGROUP CLASSIFICATION OF CHILDREN WITH JIA USING THE ILAR SCHEME DOES 

NOT CHANGE OVER 12 MONTHS OF OBSERVATION. 

N Adib 1 , J Davidson 2 , E Baildam 3 , M Lay 1 , A Silman 1 , W Thomson 1 . 1 

ARC Epidemiology Unit, 

Manchester University Medical School, Manchester, United Kingdom; 2 Rheumatology, Royal 

Liverpool Children’s Hospital, Liverpool, United Kingdom; 3 Rheumatology, Royal Manchester 

Childrens Hospital, Manchester, United Kingdom 

272 CONFIRMATION OF ASSOCIATION OF HLA-DRB1*13 WITH UVEITIS IN JUVENILE 

IDIOPATHIC ARTHRITIS. 

E Zeggini 1 , W Thomson 2 , P Wordsworth 3 , MA Hall 3 , JC Packham 4 . 1 


Medical Research, University of Manchester, Manchester, United Kingdom; 2 ARC Epidemiology 

Unit, University of Manchester, Manchester, United Kingdom; 3 Nuffield Orthopaedic Centre, 

University of Oxford, Oxford, United Kingdom; 4 Staffordshire Rheumatology Centre, Haywood 

Hospital, Stoke on Trent, United Kingdom 

63

273 A USER PERSPECTIVE OF THE RHEUMATOLOGY ADOLESCENT PLANNER - AN AID TO 

TRANSITIONAL CARE FORADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS. 

D O’Connor, KL Shaw, JE McDonagh. Medical School, University of Birmingham, Birmingham, West 

Midlands, United Kingdom 

274 TRANSITIONAL CARE IN JUVENILE IDIOPATHIC ARTHRITIS: PROFESSIONAL, PATIENT AND 

PARENT VIEWS OF BEST PRACTICE AND FEASIBILITY. 

KL Shaw, TR Southwood, JE McDonagh, on Behalf of the BPRG, CCAA, LHT & AC Funded by ARC. 

Institute of Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom 

275 WHAT’S IN A NAME? DISEASE KNOWLEDGE IN JUVENILE IDIOPATHIC ARTHRITIS. 

KL Shaw, TR Southwood, JE McDonagh, on Behalf of the BPRG, CCAA, LHT, AC. Funded by the ARC. 

1 

Institute of Child Health, University of Birmingham, Birmingham, West Midlands, United Kingdom 

276 RAYNAUD’S PHENOMENON IN CHILDHOOD: 33 PATIENTS FOLLOW UP. 

JJ Bethencourt, S Bustabad, JC Quevedo, S Machin, T Gonzalez. Rheumatology, Hospital Universitario 

de Canarias, La Laguna, Santa Cruz de Tenerife, Spain 

277 THE STATUS OF VITAMINS A, E, C, B 12 AND FOLATE FOR CHILDREN WITH JUVENILE 

IDIOPATHIC ARTHRITIS AND ITS CONNECTION WITH AN ANEMIC SYNDROME. 

VM Dudnyk, OO Pentiuk, LM Stanislavchuk. Children Diseases, National Medical University, Vinnycia, 

Ukraine 

278 NUTRITIONAL STATUS IN JUVENILE IDIOPATHIC ARTHRITIS. 

G Cleary 1 , L Gillian 2 , F Annan 3 , JA Sills 1 , JE Davidson 1 . 1 

Department of Rheumatology, Royal Liverpool 

Children’s Hospital, Liverpool, United Kingdom; 2 Centre for Medical Statistics and Health Evaluation, 

University of Liverpool, Liverpool, United Kingdom; 3 Department of Nutrition and Dietetics, Royal 

Liverpool Children’s Hospital, Liverpool, United Kingdom 

CASE REPORTS (279 – 295) 

279 REVERSING MYOCARDIAL MICROVASCULAR DISEASE IN RHEUMATOID ARTHRITIS. 

K Raza 1 , M Banks 2 , GD Kitas 2 . 1 

Division of Immunity and Infection, MRC Centre for Immune Regulation, 

University of Birmingham, Birmingham B15 2TT, United Kingdom; 2 Departments of Rheumatology and 

Cardiology, Dudley Group of Hospitals NHS Trust, Dudley, DY1 4SE, United Kingdom 

280 REGRESSION OF NEPHROTIC SYNDROME DUE TO REACTIVE AMYLOIDOSIS IN A PATIENT WITH 

ANKYLOSING SPONDYLITIS FOLLOWING COLCHICINE THERAPY. 

S Jain 1 , DS Mathur 1 , V Ravindran 2 . 1 

Division of Rheumatology, Department of Medicine, S M S Medical 

College and Teaching Hospitals, Jaipur, Rajasthan, India; 2 Division of Rheumatology, Department of 

Medicine, Epsom General Hospital, Epsom, Surrey, United Kingdom 

281 RHEUMATOLOGISTS AND BREASTS: FOUR CASES OF GRANULOMATOUS MASTITIS. 

N Raj 1 , RD MacMillan 2 , CM Deighton 3 . 1 

Rheumatology, Nottingham City Hospital, Nottingham, 

United Kingdom; 2 Surgery, Nottingham City Hospital, Nottingham, United Kingdom; 3 Rheumatology, 

Derbyshire Royal Infirmary, Derby, United Kingdom 

282 TWO CASES OF LIFE-THREATENING METHOTREXATE TOXICITY INDUCED BY ACUTE 

RENAL FAILURE. 

AH Strang, T Pullar. Rheumatology, Ninewells Hospital & Medical School, Dundee, Tayside, 


283 RITUXIMAB TREATMENT FOR RECALCITRANT RHEUMATOID PLEUROPERICARDIAL 

DISEASE -CASE REPORT. 

SN Kamath, AB Hassell, A Brownfield, J Fisher, PT Dawes. Haywood Hospital, Staffordshire 

Rheumatology Centre, Stoke on Trent, Staffordshire, United Kingdom 

64

284 OPEN LABEL PILOT STUDY OF INFLIXIMAB IN YOUNG ADULTS WITH JUVENILE 

IDIOPATHIC ARTHRITIS. 

E Rankin 1 , L Waterhouse 1 , D Carruthers 2 . 1 

Rheumatology, University Hospital Birmingham NHS 

Trust, Birmingham, United Kingdom; 2 Rheumatology, City Hospital NHS Trust, Birmingham, 


285 ELEVATION IN CREATINE KINASE (CK): CASES HIGHLIGHTING IMPORTANT RELATED 

ISSUES. 

LM Thomas, AL Thomas, JM Ledingham. Rheumatology Department, Queen Alexandra Hospital, 

Portsmouth, Hants, United Kingdom 

286 LIPOMA ARBORESCENS - IS IT A RARE CONDITION? 

AR Clewes 1 , VV Kaushik 1 , JK Dawson 1 , VE Abernethy 1 , O Harris 2 , BG Bolton-Maggs 3 . 1 

Department 

of Rheumatology, St Helens and Knowsley NHS Trust, St Helens, Merseyside, United Kingdom; 

2 

Department of Radiology, St Helens and Knowsley NHS Trust, St Helens, Merseyside, United 

Kingdom; 3 Department of Orthopaedics, St Helens and Knowsley NHS Trust, St Helens, 

Merseyside, United Kingdom 

287 SEVERE HERPES ZOSTER ON INFLIXIMAB TREATMENT. 

S Stevens, AJ Kinder, J Francis, P Sheldon. Rheumatology, Leicester Royal Infirmary, Leicester, 


288 POLYMYOSITIS WITH NORMAL CREATINE PHOSPHOKINASE. 

B Galarraga 1 , T Pullar 1 , M Garton 2 . 1 

Rheumatic Diseases Unit, Ninewells Hospital and Medical 

School, Dundee, United Kingdom; 2 Rheumatic Diseases Unit, Perth Royal Infirmary, Perth, 


289 EOSINOPHILIC GASTROENTERITIS AND RHEUMATOID ARTHRITIS. 

WF Ng 1 , P Cohen 2 , S Hamdulay 1 , A Hepburn 1 , M Carpani 3 , JC Mason 1 . 1 

Rheumatology, 

Hammersmith Hospital, London, United Kingdom; 2 Histopathology, Hammersmith Hospital, 

London, United Kingdom; 3 Gastroenterology, Hammersmith Hospital, Du Cane Road, London, 


290 AN UNUSUAL CAUSE OF A ‘DRY TAP’: LIPOMA ARBORESCENS. 

J Francis 1 , A Kinder 1 , PJ Sheldon 1 , K Jeyapalan 2 . 1 

Rheumatology, University Hospitals of Leicester 

NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom; 2 Radiology, University Hospitals of 

Leicester NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom 

291 GENERALIZED MORPHEA IN A PATIENT WITH SYSTEMIC SCLEROSIS. 

GA Mittal 1 , W Williams 2 , PJ Maddsion 1 . 1 

Rheumatology, Ysbyty Gwynedd, Bangor, Gwynedd, 

United Kingdom; 2 Rheumatology, Ysbyty Glan Clwyd, Rhyl, Denbighshire, United Kingdom 

292 XRAY AND MRI IMAGING IN CAMURATI-ENGELMANN DISEASE. 

R Callaghan 1 , J Chandy 2 , J Coppock 2 . 1 

Rheumatology Department, Selly Oak Hospital, Birmingham, 

United Kingdom; 2 Rheumatology Department, Walsgrave Hospital, Coventry, United Kingdom 

293 SEVERE MYOPERICARDITIS ASSOCIATED WITH JUVENILE ANKYLOSING SPONDYLITIS. 

R Bessant, C Li, C Pilkington. Centre for Rheumatology, University College London Hospitals, 


294 AMYOPATHIC DERMATOMYOSITIS WITH LUNG INVOLVEMENT. 

SE Woodham, J Joseph. Department of Rheumatology, The Hillingdon Hospital, Uxbridge, 

Middlesex, United Kingdom 

295 RECURRENCE OF NON HODGKINS LYMPHOMA (NHL) PRESENTING AS SCIATICA. 

LM Thomas, JM Ledingham. Rheumatology Department, Queen Alexandra Hospital, Portsmouth, 

Hants, United Kingdom 

65


Friday 23 April 2004, 08:30 – 10:00 

SPONDYLARTHROPATHIES: CLINICAL ASPECTS (296 – 319) 

296 FIVE YEAR OUTCOME FOLLOWING THE ONSET OF INFLAMMATORY POLYARTHRITIS IN THOSE 

WITH AND WITHOUT PSORIASIS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER. 

C Morgan 1 , S Mottram 1 , D Bunn 2 , DPM Symmons 1 , AJ Silman 1 . 1 

ARC Epidemiology Unit, Manchester 

University, Manchester, United Kingdom; 2 NOAR, Norfolk and Norwich University Hospital, Norwich, 


297 AN INVESTIGATION OF PIIINP AS A MARKER OF HEPATIC FIBROSIS IN PSORIASIS : 

DOES THE ARTHRITIS AFFECT PIIINP LEVELS? 

K Lindsay, A Gough, A Layton, M Goodfield, S Fraser. 1 

Rheumatology, Harrogate District Hospital, 

Harrogate, West Yorkshire, United Kingdom; 2 Dermatology, Harrogate District Hospital, Harrogate, 

West Yorkshire, United Kingdom; 3 Dermatology, Leeds General Infirmary, Leeds, West Yorkshire, 


298 ULTRASONOGRAPHY IN PATIENTS WITH PSORIATIC ARTHRITIS: CORRELATION WITH OTHER 

OBJECTIVE DISEASE ACTIVITY MEASURES. 

Z Karim 1 , RJ Wakefield 1 , A Fraser 1 , S Jarret 1 , M Quinn 1 , AK Brown 1 , BAC Dijkmans 2 , P Emery 1 , D Veale 1 . 

1 

Academic Unit of Musculoskeletal Medicine, Department of Rheumatology, Leeds General Infirmary, 

Leeds, West Yorkshire, United Kingdom; 2 Rheumatology, VU University Medical Centre, Amsterdam, 

The Netherlands 

299 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES ARE A MARKER OF DISEASE SEVERITY IN 

PSORIATIC ARTHRITIS. 

E Korendowych, PA Owen, J Lewis, CR Carmichael, J Ravindran, NJ McHugh. Department of Research 

and Clinical Effectiveness, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom 

300 MEASUREMENT OF ENTHESITIS IN PSORIASIS AND PSORIATIC ARTHRITIS: COMPARISON 

OF THE NEWCASTLE ENTHESITIS INDEX AND THE MAASTRICHT ANKYLOSING SPONDYLITIS 

ENTHESITIS SCORE. 

MJ Bridges 1 , NJ Reynolds 2 , LJ Kay 1 . 1 

Department of Rheumatology, Newcastle Hospitals NHS Trust, 

Newcastle upon Tyne, Tyne & Wear, United Kingdom; 2 Department of Dermatology, University of 

Newcastle, Newcastle upon Tyne, Tyne & Wear, United Kingdom 

301 THE INFLUENCE OF TOBACCO SMOKING ON DISEASE ACTIVITY AND FUNCTIONAL STATUS IN 

ANKYLOSING SPONDYLITIS. 

LP Robertson 1 , E Stanley 2 , MJ Davis 2 . 1 

Rheumatology Unit, Bristol Royal Infrimary, Bristol, Avon, 

United Kingdom; 2 Dept of Rheumatology, Royal Cornwall Hospital, Truro, Cornwall, United Kingdom 

302 FUNCTIONAL IMPAIRMENT IN PSORIATIC ARTHRITIS. 

L Williamson, N Dalbeth, JL Dockerty, R Weatherall, P Wordsworth. 1 Rheumatology Department, Nuffield 

Orthopaedic Centre, Oxford, Oxon, United Kingdom; 2 ICRF/NHS Centre for Statistics in Medicine, 

Institute of Health Sciences, Oxford, Oxon, United Kingdom 

303 SACROILIAC JOINT INVOLVEMENT IN PSORIASIS: CLINICAL, RADIOLOGICAL AND COMPUTED 

TOMOGRAPHY FINDINGS. 

AM Abdel-Nasser 1 , OA Khalil 2 . 1 

Rheumatology & Rehabilitation, Minia University, Minia, Egypt; 

2 

Radiolology, Minia University, Minia, Egypt 

66

304 CAN EARLY DIAGNOSIS AND MANAGEMENT OF COSTOCHONDRITIS REDUCE ACUTE 

CHEST PAIN ADMISSIONS? 

JE Freeston 1 , Z Karim 1 , K Lindsay 1 , AKS Gough 1,2 . 1 

Rheumatology, Harrogate District Hospital, 

Harrogate, North Yorkshire, United Kingdom; 2 Academic Department of Rheumatology, Leeds 

General Infirmary, Leeds, West Yorkshire, United Kingdom 

305 USING A MODIFIED SHARP SCORE TO ASSESS RADIOLOGICAL PROGRESSION IN 


J Ravindran 1 , C Carmichael 1 , C Balakrishnan 2 , S Jones 3 , E Korendowych 1 , N McHugh 1 . 

1 

Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 

2 

Rheumatology, P.D.Hinduja National Hospital and Medical Research Centre, Mumbai, India; 

3 

Rheumatology, University of Wales, Cardiff, United Kingdom 

306 ASSESSING INFLAMMATION AND PREDICTING RADIOLOGICAL OUTCOME IN EARLY PSO- 

RIATIC ARTHRITIS: ROLE OF ESR, CRP, SERUM AMYLOID A AND CARTILAGE OLIGOMERIC 

MATRIX PROTEIN. 

DJ Kane 1 , T Saxne 2 , JP Doran 3 , B O’ Shea 3 , B Bresnihan 3 , O FitzGerald 3 . 1 

Rheumatology, University 

of Newcastle, Newcastle, United Kingdom; 2 Rheumatology, University of Lund, Lund, Sweden; 

3Rheumatology, St Vincent’s University Hospital, Dublin, Ireland 

307 THE IMPACT OF ANKYLOSING SPONDYLITIS ON QUALITY OF LIFE AND ABILTY TO WORK. 

N Barkham, KO Kong, A Fraser, A Tennant, P Emery. Academic Unit of Musculoskeletal Disease, 

University of Leeds, Leeds, United Kingdom 

308 THE VALUE OF SERUM TYPE III PROCOLLAGEN AMINOPEPTIDE(P3NP) IN MONITORING 

METHOTREXATE INDUCED LIVER FIBROSIS IN PSORIATIC ARTHRITIS. 

CE Buckley, PA Sanders. Rheumatology Department, South Manchester University Hospitals, 

Manchester, M20 2LR, United Kingdom 

309 BASDAI ASSESSMENT FOR ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS. 

S Mackenzie, S Miah, D Kane, H John, S Roger. 1 

Centre for Rheumatic Diseases, Division of 

Immunology, Infection and Inflammation, University of Glasgow, Glasgow, Scotland, United 

Kingdom; 2 Rheumatology, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom 

310 PROFILE OF PATIENTS WITH ANKYLOSING SPONDYLITIS ATTENDING A DISTRICT GENERAL 

HOSPITAL - HOW MANY MIGHT BE SUITABLE FOR TREATMENT WITH ANTI-TNF THERAPY? 

J Novak, A Griffiths, JK Dawson, VE Abernethy. Rheumatology Department, St Helens and 

Knowsley Hospitals, St Helens, WA9 3DA, United Kingdom 

311 THE INCIDENCE OF LONG-TERM METHOTREXATE HEPATOTOXICITY IN 


K Lindsay, A Gough, M Goodfield, A Layton, S Fraser. 1 

Rheumatology, Harogate District Hospital, 

Harrogate, West Yorkshire, United Kingdom; 2 Dermatology, Harrogate District Hospital, Harrogate, 

West Yorkshire, United Kingdom; 3 Dermatology, Leeds General Infirmary, Leeds, West Yorkshire, 

United Kingdom; 4 Rheumatology, Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom 

312 AS YOU LIKE IT THE POTENTIAL SIZE OF THE UK AS POPULATION MERITING 

ANTI-TNFα TREATMENT. 

PJ Cornell, J Haynes, SCM Richards. Rheumatology, Poole Hospital NHS Trust, Poole, Dorset, 


313 NAIL DISEASE IN PSORIATIC ARTHRITIS: CLINICALLY IMPORTANT, POTENTIALLY 

TREATABLE AND OFTEN OVERLOOKED. 

L Williamson, N Dalbeth, JL Dockerty, B Gee, R Weatherall, P Wordsworth. 1 Rheumatology 

Department, Nuffield Orthopaedic Centre, Oxford, Oxon, United Kingdom; 2 Dermatology 

Department, Churchill Hospital, Oxford, Oxon, United Kingdom; 3 ICRF/NHS Centre for Staistics in 

Medicine, Institute of Health Sciences, Oxford, Oxon, United Kingdom 

67

314 CHANGE IN PATIENT-ASSESSED HEALTH FOLLOWING PHYSICAL THERAPY FOR ANKYLOSING 

SPONDYLITIS (AS): A STRUCTURED REVIEW. 

KL Haywood, AM Garratt, PT Dawes. 1 Unit of Health-Care Epidemiology, Department of Public Health, 

University of Oxford, Oxford, United Kingdom; 2 Unit of Health-Care Epidemiology, Department of Public 

Health, University of Oxford, Oxford, United Kingdom; 3 Staffordshire Rheumatology Centre, University 

Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, Staffordshire, United Kingdom 

315 THE SPONDYLOARTHROPATHY OF INFLAMMTORY BOWEL DISEASE. 

S Salman, AA Abdulla. 1 Rheumatoloy Dept., Faculty of Medicine University of Baghdad, Iraq, Baghdad, 

Iraq; 2 Rheumatoloy Dept, Faculty of Medicine, University of Baghdad, Iraq, Baghdad, Iraq 

316 MUSCLE MASS AND FUNCTION IN ANKYLOSING SPONDYLITIS PATIENTS. 

F Casanova 1 , SM Marcora 1 , ER Williams 1 , AB Lemmey 1 , J Jones 2 , P Maddison 2 . 1 

School of Sport, Health 

and Exercise Sciences, University of Wales, Bangor, Gwynedd, United Kingdom; 2 Rheumatology 

Department, Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom 

317 SPINAL OSTEOTOMY FOR THE CORRECTION OF SEVERE DEFORMITY IN ANKYLOSING 

SPONDYLITIS. 

K Dani, MJ M, SD Roger. 1 

Centre for Rheumatic Diseases, Division of Immunology, Infection and 

Inflammation, Faculty of Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom; 2 Spinal 

Deformity Centre, Edinburgh Royal Infirmary, Edinburgh, Scotland, United Kingdom 

318 PATTERN OF PRESENTATION OF SINGLE JOINT EFFUSION AMONG PATIENTS ATTENDING 

A DISTRICT GENERAL HOSPITAL. 

A Salih, A Cox, E Williams. Rheumatology Department, Warrington Hospital, Warrington, Cheshire, 


319 ELIGIBILITY FOR ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS: WHAT’S THE REAL 

SITUATION? 

RF Mascarenhas 1 , MJ Davis 1 , LP Robertson 2 . 1 

Rheumatology, Royal Cornwall Hospital, Truro, Cornwall, 

United Kingdom; 2 Rheumatology, United Bristol Healthcare Trust, Bristol, United Kingdom 

SPONDYLARTHROPATHIES: AETIOPATHOGENESIS (320 – 327) 

320 MAPPING THE NON-B27 MHC ASSOCIATIONS OF ANKYLOSING SPONDYLITIS (AS). 

A-M Sims 1 , M Bernardo 2 , J Broxholme 3 , I Herzberg 1 , L Bradbury 1 , A Calin 4 , BP Wordsworth 1 , C Darke 5 , 

MA Brown 1 . Botnar Research Centre, Nuffield Orthopaedic Centre, Oxford, United Kingdom; 2 Oxford 

Transplant Centre, Churchill Hospital, Oxford, United Kingdom; 3 Wellcome Trust Centre for Human 

Genetics, Oxford, United Kingdom; 4 Royal National Hospital for Rheumatic Diseases, Bath, United 

Kingdom; 5 Welsh Blood Service, Pontyclun, United Kingdom 

321 EVIDENCE FOR A TNF α HAPLOTYPE ASSOCIATION WITH PSORIATIC ARTHRITIS INDEPENDENT 

OF HLA-Cw6. 

J Ravindran 1 , A Lagan 2 , T Ahmed 3 , P Owen 1 , E Korendowych 1 , C Carmichael 1 , J Lewis 1 , K Welsh 2 , 

N McHugh 1 . 1 

Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; 

2 

Clinical Genomics, National Heart and Lung Institute, London, United Kingdom; 3 Gastroenterology Unit, 

Radcliffe Infirmary, Oxford, United Kingdom 

322 HLA-B27 ALLELES ASSOCIATED WITH SUSCEPTIBILITY TO ANKYLOSING SPONDYLITIS (AS) 

EXHIBIT DIFFERENT PHENOTYPES IN A CELL LINE DEFECTIVE IN ANTIGEN PROCESSING. 

JC Goodall, JSH Gaston. Medicine, Cambridge University, Cambridge, Cambridgeshire, United Kingdom 

323 APPENDECTOMY IS A RISK FACTOR FOR SERONEGATIVE SPONDYLOARTHROPATHIES. 

R Scarpa 1 , F Manguso 1 , A Oriente 1 , R Peluso 1 , M Atteno 1 , F Ayala 2 , P Punzetto 1 , D Di Minno 1 , S Iervolino 1 , 

A D’Arienzo 1 . 1 

Clinical and Experimental Medicine, Federico II University, Federico II University, NA, Italy; 

2 

Systematic Pathology, Federico II University, Federico II University, NA, Italy 

68

324 CHARACTERIZATION OF AUTOREACTIVE IL-4 PRODUCING T CELLS ISOLATED FROM 

PATIENTS WITH SPONDYLOARTHROPATHY (SpA). 

LB Jarvis, MK Matyszak, JSH Gaston. Department of Medicine, University of Cambridge, 

Cambridge, United Kingdom 

325 PHENOTYPIC CHARACTERIZATION OF NATURAL KILLER CELLS AND RECEPTORS IN 

SPONDYLOARTHRITIS. 

ATY Chan, S Kollnberger, A McMichael, P Bowness. Human Immunology Unit, Weatherall Institute 

of Molecular Medicine, Oxford, United Kingdom 

326 METHOTREXATE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS INCREASES 

APOPTOSIS THROUGH DECREASE OF Bcl-2 PRODUCTION AND ACTIVATION OF CASPASE-3. 

MJ Benito, B Bresnihan, D Kane, O FitzGerald. Rheumatology, St. Vincent’s University Hospital, 

Dublin, Ireland 

327 OSTEOPROTEGERIN (OPG) AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR 

KAPA-BETA-LIGAND (RANKL) IN THE SERA OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS): 

CORRELATIONS WITH METROLOGY, FUNCTIONAL AND ACTIVITY INDEXES. 

A Cauli, G Dessole, R Pala, A Vacca, A Mameli, G Passiu, A Mathieu. 2nd Rheumatology Unit, 

University of Cagliari, Cagliari, Italy 

SPONDYLARTHROPATHIES: THERAPY (328 – 331) 

328 INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF ACTIVE 

ANKYLOSING SPONDYLITIS: A DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL USING 

MAGNETIC RESONANCE IMAGING. 

H Marzo-Ortega 1 , D Mc Gonagle 1,2 , S Jarrett 1 , G Haugeberg 3 , E Hensor 1 , P O’Connor 4 , AL Tanv, PG 

Conaghan 1 , A Greenstein 1 , P Emery 1 . 1 

Academic Unit of Musculoskeletal Disease, Department of 

Rheumatology, University of Leeds, Leeds, West Yorkshire, United Kingdom; 2 Department of 

Rheumatology, Calderdale General Hospital, Halifax, West Yorkshire, United Kingdom; 3 Oslo City 

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; 4 Department of Radiology, 

Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom 

329 AN OPEN STUDY OF PULSE PAMIDRONATE THERAPY IN SEVERE ANKYLOSING 

SPONDYLITIS, AND ITS EFFECT ON BIOCHEMICAL MARKERS OF BONE TURNOVER. 

AP Cairns 1 , SA Wright 1 , AJ Taggart 1 , SM Coward 2 , GD Wright 1 . 1 


Musgrave Park Hospital, Belfast, Northern Ireland, United Kingdom; 2 Department of Biochemistry, 

Musgrave Park Hospital, Belfast, Northern Ireland, United Kingdom 

330 A CLINICAL AND MAGNETIC RESONANCE IMAGING ASSESSMENT OF THE EFFICACY 

OF INFLIXIMAB AT A DOSE OF 3MG/KG IN COMBINATION WITH METHOTREXATE IN THE 

TREATMENT OF PSORIATIC ARTHRITIS. 

H Marzo-Ortega 1 , D Mc Gonagle 1,2 , AL Tan 1 , L Rhodes 3 , S Tanner 3 , PG Conaghan 1 , P O’Connor 4 , 

A Fraser 1 , D Veale 5 , P Emery 1 . 1 

Academic Unit of Musculoskeletal Disease, University of Leeds, 

Leeds, West Yorkshire, United Kingdom; 2 Department of Rheumatology, Calderdale General 

Hospital, Halifax, West Yorkshire, United Kingdom; 3 Academic Unit of Medical Physics, Leeds 

General Infirmary, Leeds, West Yorkshire, United Kingdom; 4 Department of Radiology, Leeds 

General Infirmary, Leeds, West Yorkshire, United Kingdom; 5 Department of Rheumatology, 

St Vincent’s University Hospital, Dublin, Ireland 

331 ANTI-TNFα THERAPY IN PSORIASIS AND PSORIATIC ARTHRITIS: CLINICAL AND 

ANGIOGENIC RESPONSES. 

T Markham 1 , U Fearon 1 , S Rogers 2 , L Golden-Mason 3 , B Bresnihan 1 , O FitzGerald 1 , DJ Veale 1 . 

1 

Rheumatology, St. Vincents University Hospital and The Conway Institute, Dublin, Ireland; 

2 

Dermatology, ST. Vincents University Hospital, Dublin, Ireland; 3 Liver Unit, St.Vincents University 

Hospital, Dublin, Ireland 

69

MISCELLANEOUS RHEUMATIC DISEASE (332 – 336) 

332 BAKER’S CYST - AN AUDIT OF MISSED OPPORTUNITY. 

RS Tattersall, JT Bourne. Rheumatology and General Medicine, Chesterfield and North Derbyshire Royal 

Hospital, Chesterfield, Derbyshire, United Kingdom 

333 IS IT NECESSARY TO DO CELL COUNTS ON SYNOVIAL FLUID? 

S Abdullah, S YoungMin, CA Kelly, C Heycock, S Hudson, J Hemmings, JD Hamilton. 1 Department of 

Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom; 2 Department of 

Microbiology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom 

334 INTER AND INTRAOBSERVER ERROR IN RECORDED OBSERVATIONS AND DIRECT GROSS 

ANALYSIS OF SYNOVIAL FLUID. 

S Abdullah, S Young Min, CA Kelly, CR Heycock, JD Hamilton. Department of Rheumatology, Queen 

Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom 

335 OCULAR TOXICITY AND HYDROXYCHLOROQUINE : AUDIT OF CURRENT PRACTICE. 

SI Yeo, AN Bennett, T Gibson. Rheumatology Department, Guy’s & St. Thomas’ Hospital, London, 


336 LONG TERM OUTCOME FROM SEPTIC ARTHRITIS ON FIVE-YEAR FOLLOW-UP. 

A PROSPECTIVE STUDY. 

MN Gupta, M Field. Centre for Rheumatic Diseases, Royal Infirmary, Glasgow, Strathclyde, United Kingdom 

RHEUMATOID ARTHRITIS: AETIOPATHOGENESIS (337 – 341) 

337 MATRIX METALLOPROTEINASE GENOTYPE IS ASSOCIATED WITH FUNCTIONAL STATUS IN 


E Dennison 1 , K Walker Bone 1 , N Patodi 2 , I Reading 1 , L Dunleavey 2 , S Ye 2 . 1 

Medical Research Council 

Environmental Epidemiology Unit, Southampton General Hospital, Southampton, Hants, United 

Kingdom; 2 Human Genetics Division, Southampton General Hospital, Southampton, Hants, 


338 CD56 BRIGHT NK CELLS: “NATURAL INFLAMMATORY CELLS”? 

N Dalbeth 1,2 , R Gundle 3 , R Davies 4 , M Callan 1,2 . 1 

Department of Immunology, Imperial College London, 

London, United Kingdom; 2 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, 

Oxford, United Kingdom; 3 Department of Orthopaedics, Nuffield Orthopaedic Centre, Oxford, United 

Kingdom; 4 Chest Unit, Churchill Hospital, Oxford, United Kingdom 

339 INACTIVATION OF XANTHINE OXIDOREDUCTASE IS ASSOCIATED WITH INCREASED ACUTE 

ANTIGEN-INDUCED ARTHRITIS. 

R Klocke 1,2 , A Mani 3 , KP Moore 3 , CJ Morris 1 , DR Blake 1,2 , PI Mapp 1 . 1 

Department of Pharmacy & 

Pharmacology/School for Health, University of Bath, Bath, United Kingdom; 2 Royal National Hospital for 

Rheumatic Diseases, NHS Trust, Bath, United Kingdom; 3 Centre for Hepatology, Department of Medicine, 

Royal Free & University College Medical School, UCL, London, United Kingdom 

340 THE ASSOCIATION OF THE “SHARED EPITOPE” WITH SYNOVIAL IMMUNOHISTOCHEMICAL 

CHANGES IN EARLY RHEUMATOID ARTHRITIS. 

CF Matthews 1 , P Maxwell 2 , GD Wright 1 , D Middleton 3 , B Bresnihan 4 , O FitzGerald 4 , PW Hamilton 2 , MME 

Rooney 1 . 1 

Department of Rheumatology, Musgrave Park Hospital, Belfast, County Antrim, United 

Kingdom; 2 Department of Quantitative Pathology, Queen’s University of Belfast, Belfast, County Antrim, 

United Kingdom; 3 Department of Tissue Typing, Belfast City Hospital, Belfast, County Antrim, United 

Kingdom; 4 Department of Rheumatology, St Vincent’s University Hospital, Dublin, County Dublin, Ireland 

70

341 THE ASSOCIATION BETWEEN HLA GENES AND RADIOLOGICAL EROSIONS IN MALAYSIAN 

PATIENTS WITH RHEUMATOID ARTHRITIS. 

SS Yeap 1 , A Mohd 1 , G Kumar 2 , KF Kong 3 , EML Goh 1 , SK Chow 1 , ME Phipps 3 . 1 

Department of 

Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2 Department of 

Radiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 3 Department of 

Allied Health Sciences, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 

RHEUMATOID ARTHRITIS: CLINICAL ASPECTS (342 – 357) 

342 CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN ADULTS & CHILDREN WITH ARTHRITIS IN 

A DISTRICT GENERAL HOSPITAL SETTING. 

K Hurley 1 , SS Hamdulay 2 , A Steuer 2 , A Hall 2 , H Chapel 1 , BL Ferry 1 . 1 

Immunology, Wexham Park 

Hospital, Slough, United Kingdom; 2 Rheumatology, Wexham Park Hospital, Slough, 


343 THE PREDICTIVE VALUE OF ANTIBODIES TO CYCLIC CITRULLINATED PEPTIDE IN VERY 

EARLY INFLAMMATORY ARTHRITIS. 

K Raza 1 , GM Breese 2 , KY Lee 3 , T Potter 2 , CD Buckley 1 , C Gordon 1 , M Salmon 1 , GD Kitas 2 . 1 

MRC 

Centre for Immune Regulation, Division of Immunity and Infection, University of Birmingham, 

Birmingham B15 2TT, United Kingdom; 2 Department of Rheumatology, Dudley Group of Hospitals 

NHS Trust, Dudley, DY1 4SE, United Kingdom; 3 Department of Radiology, City Hospital, Dudley 

Road, Birmingham B18 7QH, United Kingdom 

344 STRUCTURAL DAMAGE AS MEASURED BY RADIOGRAPHS ACCELERATES BETWEEN 

YEARS TWO AND THREE IN EARLY RHEUMATOID ARTHRITIS - IMPORTANT IMPLICATIONS 

FOR TREATMENT AND TRIAL DESIGN. 

J Dixey 1 , C Sollymossy 1 , P Jones 2 , A Young 1 , T McCourt 1 , L Waterhouse 1 . 1 

On Behalf of the 

Early Rheumatoid Arthritis Study (ERAS), St Albans City Hospital, St Albans, Hertfordshire, 


345 CAN WE PREDICT DEVELOPMENT OF RA IN ‘PRE-RHEUMATOID’ PATIENTS? 

SN Kamath 1 , PT Dawes 1 , S Griffiths 1 , PW Jones 2 , A Brownfield 1 , J Fisher 1 , DL Mattey 1 . 1 

Haywood 

Hospital, Staffordshire Rheumatology Centre, Stoke on Trent, Staffordshire, United Kingdom; 

2 

Department of Mathematics, Keele University, Stoke on Trent, Staffordshire, United Kingdom 

346 INFLUENCES OF SEROPOSITIVITY AND GENDER ON DISEASE ACTIVITY SCORE (DAS) 

IN EARLY RHEUMATOID ARTHRITIS (RA). 

L Connell, R Ramachandran, R Madhok, H Capell. Centre for Rheumatic Diseases, Royal Infirmary 

on Behalf of the MASCOT Group, Glasgow, United Kingdom 

347 AN AUDIT OF VITAMIN D LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS. 

A Sinclair, N McAvoy, EA Murphy. Department of Rheumatology, Wishaw General Hospital, 

Wishaw, ML2 0DP, United Kingdom 

348 INVESTIGATION OF GROWTH HORMONE SECRETION AND SENSITIVITY IN 


GA Mittal 1,4 , S Marcora 4 , AB Lemmey 4 , A Wayte 2 , PJ Maddison 1,4 , A Wilton 3,4 . 1 

Rheumatology, 

Ysbyty Gwynedd, Bangor, Gwynedd, United Kingdom; 2 Clinical Chemistry, Ysbyty Gwynedd, 

Bangor, Gwynedd, United Kingdom; 3 Endocrinology, Ysbyty Gwynedd, Bangor, Gwynedd, United 

Kingdom; 4 School of Sports, Health and Exercise Sciences, University of Wales, Bangor, Gwynedd, 


349 RESPONSE RATES TO JOINT INJECTION THERAPY IN RHEUMATOID ARTHRITIS. 

C Rao, MAS Bukhari. Rheumatology, Royal Lancaster Infirmary, Lancaster, Lancashire, 


71

350 ARE FLEXION/EXTENSION VIEWS OF THE CERVICAL SPINE NECESSARY IN PATIENTS WITH 

RHEUMATOID ARTHRITIS? 

ASM Jawad 1 , A Malhorta 2 , Z Chan 2 , M Adler 1 , O Chan 2 . 1 

Rheumatology Department, The Royal London 

Hospital, London, E1 4DG, United Kingdom; 2 Radiology Department, The Royal London Hospital, 

London, E1 4DG, United Kingdom 

351 OCCURRENCE AND RISK FACTORS FOR FALLS IN RHEUMATOID ARTHRITIS. 

C Armstrong1, CM Swarbrick2, SR Pye2, TW O’Neill1,2. 1Department of Rheumatology, Hope Hospital, 

Salford, United Kingdom; 2ARC Epidemiology Unit, University of Manchester, Manchester, United 

Kingdom 

352 AUDIT OF INFLUENZA VACCINE UPTAKE BY RHEUMATOID ARTHRITIS (RA) PATIENTS. 

L Connell, M McDonald, HA Capell. Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, 


353 DIETARY INTAKE AND NUTRITIONAL STATUS OF PATIENTS WITH RHEUMATOID ARTHRITIS. 

P Judd, L Goodacre, J Goodacre. Lancashire School of Health and Postgraduate Medicine, University of 

Central Lancashire, Preston, Lancs, United Kingdom 

354 WHICH PATIENTS WITH EARLY RA DEVELOP FAST PROGRESSIVE DISEASE? PROGNOSTIC 

FACTORS FOR SEVERE FUNCTIONAL LOSS FROM AN INCEPTION COHORT WITH 9 YEAR FOLLOW UP. 

N Bansback 1 , A Brennan 1 , A Young 2 , C Sollymossy 2 , J Dixey 2 , H Dart 2 . 1 

Operational Research, School of 

Health and Related Research, Sheffield, United Kingdom; 2 Early Rheumatoid Arthritis Study (ERAS), 

St Albans City Hospital, St Albans, Hertfordshire, United Kingdom 

355 CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENT’S WHO MAINTAIN THE THE 

REMISSION WITHOUT DMARD’s. 

R Gupta, V Marwaha, R Grover, A Kumar. Clinical Immunology & Rheumatology Service, Department of 

Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India 

356 OUTCOME OF A LARGE SECONDARY CARE INCEPTION COHORT OF EARLY RA PATIENTS USING 

A STANDARDISED TREATMENT PROTOCOL: SETTING STANDARDS FOR OUTCOME IN EARLY RA WITH 

CONVENTIONAL DISEASE MODIFYING THERAPIES. 

MA Quinn, PG Conaghan, MJ Green, S Jarret, A-M Keenan, H King, P Emery. Rheumatology, Leeds 

Musculoskeletal Institute, Leeds, West Yorkshire, United Kingdom 

357 THE IMPACT OF THE PUBLICATION OF SIGN GUIDELINES ON MANAGEMENT OF EARLY 

RHEUMATOID ARTHRITIS (RA). 

E Suresh, NL Maiden, VB Dhillon, ER McRorie. 1 Rheumatic Diseases Unit, Western General Hospital, 

Edinburgh, United Kingdom; 2 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United 

Kingdom; 3 Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom; 4 Rheumatic 

Diseases Unit, Western General Hospital, Edinburgh, United Kingdom 

RHEUMATOID ARTHRITIS: ASSESSMENT (358 – 366) 

358 VA L I D ATING PATIENT BASED DISEASE ACTIVITY SCORE (PDAS) IN RHEUMATOID ARTHRITIS (RA). 

B Khoshaba 1 , DJ Cooper 2 , AJ MacGregor 3 . 1 

Academic Department of Rheumatology, Guy’s King’s St 

Thomas Hospitals School of Medicine, London, United Kingdom; 2 Information Services, Guy’s King’s 

St Thomas Hospitals School of Medicine, London, United Kingdom; 3 Department Rheumatology, 

Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom 

359 USING PATIENT SELF-ASSESSMENT IN RHEUMATOID ARTHRITIS TO CONSTRUCT A PATIENT 

DISEASE ACTIVITY SCORE (PDAS). 

B Khoshaba 1 , DJ Cooper 2 , AJ MacGregor 3 , DL Scott 1 , EHS Choy 1 . 1 

Academic Department of 

Rheumatology, Guy’s, King’s College and St Thomas Hospitals School of Medicine, London, United 

Kingdom; 2 Department of Information Services, Guy’s, King’s College and St Thomas Hospitals School of 

Medicine, London, United Kingdom; 3 Norfolk and Norwich Hospital University NHS Trust, Depatment of 

Rheumatology, Norwich, United Kingdom 

72

360 SELF-MONITORING OF BLOODS AND SYMPTOMS IN PATIENTS WITH RHEUMATOID 

ARTHRITIS RECEIVING METHOTREXATE. 

KM Mitchell 1,3 , AL Mandeville 1 , J Manson 2 , A Olaleye 2 , M Shipley 2 , SP Newman 1 . 1 


Behavioural and Social Sciences in Medicine, University College London, London, United Kingdom; 

2 

Department of Rheumatology, University College Hospitals NHS Trust, London, United Kingdom; 

3 

Department of Psychology, Thames Valley University, London, United Kingdom 

361 RHEUMATOID ARTHRITIS IN INDIA: ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE 

IN RELATION TO DISEASE ACTIVITY. 

GS Bedi 1 , N Gupta 1 , H Pal 2 , RM Pandey 3 , R Handa 4 . 1 

Undergraduate Student, All India Institute of 

Medical Sciences, New Delhi, Delhi, India; 2 Dept. of Psychiatry, All India Institute of Medical 

Sciences, New Delhi, Delhi, India; 3 Dept. of Biostatistics, All India Institute of Medical Sciences, 

New Delhi, Delhi, India; 4 Clinical Immunology & Rheumatology Service, All India Institute of 

Medical Sciences, New Delhi, Delhi, India 

362 MUSCLE STRENGTH INDEX IS AN OBJECTIVE INDICATOR OF THE EFFECTIVENESS OF 

TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS. 

NB Ursol 1 , MA Stanislavchuk 2 . 1 

Rheumatology, Khmelnytsky District Hospital, Khmelnytsky, 

Ukraine; 2 Rheumatology, National Medical University, Vinnytcia, Ukraine 

363 ULTRASONOGRAPHY OF THE MCP’S: AN OBJECTIVE DISEASE ACTIVITY MEASURE IN 

PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. 

Z Karim, MA Quinn, PG Conaghan, RJ Wakefield, AK Brown, A Fraser, P Emery. Academic Unit of 

Musculoskeletal Medicine, Department of Rheumatology, Leeds General Infirmary, Leeds, West 


364 FOOT INVOLVEMENT, DISEASE ACTIVITY AND DISABILITY IN RHEUMATOID ARTHRITIS. 

SJ Farrow, B Khoshaba, DL Scott, EHS Choy. Academic Department of Rheumatology, Guy’s, 

King’s College and St Thomas Hospitals School of Medicine, London, United Kingdom 

365 IS DAS 28 OBJECTIVE ENOUGH FOR MEASURING DISEASE ACTIVITY IN RHEUMATOID 

ARTHRITIS BEFORE STARTING BIOLOGICAL THERAPIES? : AN ULTRASOUND STUDY 

RJ Wakefield, Y Seto, KO Kong, D Loeuille, MH Buch, D Bryer, V Bejarano, AK Brown, Z Karim, P 

Emery. Department of Rheumatology, Academic Unit of Musculoskeletal Diseases, Leeds General 

Infirmary, Leeds, United Kingdom 

366 A COMPARATIVE STUDY OF DISEASE SEVERITY, TREATMENT MODALITIES AND 

DEPRESSION IN AUSTRALIAN AND BRITISH CAUCASIAN PATIENTS WITH RHEUMATOID 

ARTHRITIS. 

CE Neville 1 , W Hassan 2 , K Gibson 1 . 1 

Rheumatology, Liverpool Hopsital, South West Sydney, NSW, 

Australia; 2 Rheumatology, University Hospitals of Leicester, Leicester, Leicestershire, United 

Kingdom 

RHEUMATOID ARTHRITIS: CARDIOVASCULAR (367 – 382) 

367 THE INFLUENCE OF ELEVATED CRP AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 

ON CARDIOVASCULAR MORTALITY IN PATIENTS WITH INFLAMMATORY POLYARTHRITIS. 

NJ Goodson 1 , M Lunt 1 , D Bunn 2 , AJ Silman 1 , DPM Symmons 1 . 1 

ARC Epidemiology Unit, 

Manchester University, Manchester, United Kingdom; 2 Norfolk Arthritis Register, Norfolk and 

Norwich University Hospital, Norwich, United Kingdom 

368 CARDIOVASCULAR MORBIDITY AND MORTALITY IN AN INCEPTION COHORT OF 


NJ Goodson 1 , M Lunt 1 , JS Marks 2 , DPM Symmons 1 . 1 


Manchester, Manchester, United Kingdom; 2 Department of Rheumatology, Stepping Hill Hospital, 

Stockport, United Kingdom 

73

369 COMORBIDITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGIC 

THERAPY - RESULTS FROM THE BSR BIOLOGICS REGISTER. 

K Hyrich, K Watson, D Symmons, A Silman, the BSR Biologics Register. ARC Epidemiology Unit, 

University of Manchester, Manchester, United Kingdom 

370 SMALL AND LARGE ARTERY COMPLIANCE IN RHEUMATOID ARTHRITIS. 

AR Clewes 1 , SA Hulme 2 , MP Lynch 1 , JK Dawson 1 . 1 

Department of Rheumatology, St Helens and Knowsley 

NHS Trust, St Helens, Merseyside, United Kingdom; 2 Department of Diabetes, Whiston Hospital, Prescot, 


371 DIFFERENCES IN PREDICTED CARDIOVASCULAR RISK BETWEEN PATIENTS WITH RHEUMATOID 

ARTHRITIS AND THEIR SAME SEX SIBLING. 

N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , DJ Walker 1 , PN Platt 1 . 1 


Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Department of 

Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of 

Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom 

372 RELATIONSHIP BETWEEN DISEASE CHARACTERISTICS OF RHEUMATOID ARTHRITIS AND CAUSE 

OF DEATH. RESULTS FROM AN INCEPTION COHORT OF 1388 PATIENTS. 

G Koduri 1 , A Young 1 , M Batley 1 , E Kulinskaya 2 , S Stafford 1 . 1 

On Behalf of the Early Rheumatoid Arthritis 

Study (ERAS), St Albans City Hospital, St Albans, Hertfordshire, United Kingdom; 2 Health Research and 

Development Support Unit, University of Hertfordshire, Hatfield, Hertfordshire, United Kingdom 

373 ACCELERATED EARLY ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS: SMOKING EFFECT ON 

CAROTID INTIMAL-MEDIAL THICKNESS. 

Y Sherer 1 , R Gerli 2 , G Vaudo 3 , G Schiallaci 3 , B Gilburd 1 , A Giordano 2 , EB Bucci 2 , R Allegruci 2 , S Marchesi 3 , 

E Mannarino 3 , Y Shoenfeld 1 . 1 

Department of Medicine B and Center of Autoimmune Diseases, Sheba 

Medical Center, Tel-Hashomer, Israel; 2 Section of Internal Medicine & Oncological Sciences, Center for 

the Study of Rheumatic Diseases, University of Perugia, Perugia, Italy; 3 Section of Internal Medicine, 

Angiology & Atherosclerosis Diseases, Department of Clinical & Experimental Medicine, University of 

Perugia, Perugia, Italy 

374 DIFFERENCES IN CAROTID ARTERY INTIMA MEDIA THICKNESS BETWEEN INDEX CASES WITH 

RHEUMATOID ARTHRITIS AND THEIR SAME SEX SIBLINGS. 

N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , DJ Walker 1 , PN Platt 1 . 1 


Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 2 Deaprtment of Biochemistry, Royal Victoria 

Infirmary, Newcastle-upon-Tyne, United Kingdom; 3 Department of Cardiology, Freeman Hospital, 

Newcastle-upon-Tyne, United Kingdom 

375 VASCULAR ABNORMALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. 

YK Otkalenko 1 , MA Stanislavchuk 1 , OS Otkalenko 2 . 1 

Rheumatology, National Medical University, Vinnycia, 

Ukraine; 2 Ultrasonography, Vinnytcia District Hospital, Vinnytcia, Ukraine 

376 BODY MASS INDEX (BMI) AND RELEVANCE TO ASSESSMENT OF DISEASE ACTIVITY IN 

RHEUMATOID ARTHRITIS (RA). 

RA Munro 1 , R Hampson 2 , R Madhok 2 , HA Capell 2 . 1 

Rheumatology, Wishaw General Hospital, Lanarkshire, 

United Kingdom; 2 Centre for Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom 

377 STROKE AND RHEUMATOID ARTHRITIS: A RETROSPECTIVE, MATCHED CASE-CONTROL STUDY. 

PD Mudd 1 , RW Heycock 1 , J Hamilton 2 , CA Kelly 2 , DH Barer 1 . 1 

Stroke Research Unit, Queen Elizabeth 

Hospital, Gateshead, Tyne and Wear, United Kingdom; 2 Department of Rheumatology, Queen Elizabeth 

Hospital, Gateshead, Tyne and Wear, United Kingdom 

74

378 A PILOT STUDY IN THE USE OF THE ROSE ANGINA QUESTIONNAIRE IN THE ASSESSMENT 

OF ISCHAEMIC HEART DISEASE IN THE RHEUMATOID PATIENT. 

N Kumar 1 , NJ Marshall 1 , D Neely 2 , SS Furniss 3 , PN Platt 1 , DJ Walker 1 . 1 

Department of 

Rheumatology, Musculoskeletal Unit, Freeman Hospital, High Heaton, Newcastle-upon-Tyne, 

United Kingdom; 2 Department of Biochemistry, Royal Victoria Infirmary, Newcastle-upon-Tyne, 

United Kingdom; 3 Department of Cardiology, Freeman Hospital, High Heaton, 


379 HEALTH SCREENING INTERVENTIONS ARE PARTIALLY SUCCESSFUL IN REDUCING 

CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS. 

AM Meadows, NJ Sheehan. Department of Rheumatology, Edith Cavell Hospital, Peterborough, 

Cambridgeshire, United Kingdom 

380 PULMONARY ARTERY PRESSURES MEASURED WITH DOPPLER ECHOCARDIOGRAPHY IN 

RHEUMATOID ARTHRITIS PATIENTS OVER A FIVE YEAR PERIOD. 

AR Clewes 1 , A Burkart 2 , LM Crolla 2 , MP Lynch 1 , JK Dawson 1 . 1 


St Helens and Knowsley NHS Trust, St Helens, Merseyside, United Kingdom; 2 Cardiorespiratory 

Department, Whiston Hospital, Prescot, Merseyside, United Kingdom 

381 A HIGH PREVALENCE OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN A 

RHEUMATOID POPULATION. 

GS Bhatia 1 , MD Sosin 1 , KA Grindulis 2 , FH Khattak 2 , GY Lip 1 , RC Davis 1 . 1 

University Department of 

Medicine & Department of Cardiology, University of Birmingham and Sandwell & West 

Birmingham Hospitals NHS Trust, Birmingham, United Kingdom; 2 Department of Rheumatology, 

Sandwell Hospital, Sandwell & West Birmingham Hospitals NHS Trust, West Bromwich, West 

Midlands, United Kingdom 

382 THE EFFECTS OF PSYCHOLOGICAL AND POSTURAL STRESS ON CARDIOVASCULAR AND 

INFLAMMATORY ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. 

JJCS Veldhuijzen van Zanten 1,3 , C Ring 1 , D Carroll 1 , GD Kitas 2,3 . 1 

School of Sport and Exercise 

Sciences, University of Birmingham, Birmingham, United Kingdom; 2 School of Medicine, University 

of Birmingham, Birmingham, United Kingdom; 3 Department of Rheumatology, Dudley Group of 

Hospitals NHS Trust, Dudley, United Kingdom 

RHEUMATOID ARTHRITIS: MANAGEMENT (383 – 386) 

383 THE VALUE OF ANTI-CCP ASSAYS IN AN OUTPATIENT RHEUMATOLOGY CLINIC. 

R Ramachandran 1 , A Farrell 2 , M Thomas 2 , R Madhok 1 , HA Capell 1 . 1 

Centre for Rheumatic Diseases, 

Royal Infirmary, Glasgow, United Kingdom; 2 Department of Clinical Immunology, Western 

Infirmary, Glasgow, United Kingdom 

384 PATIENT-INITIATED REVIEWS AND PHYSICIAN-INITIATED REVIEWS IN RA: 

HOW APPROPRIATE ARE THEY? 

M Hehir 1 , S Hewlett 1 , J Kirwan 1 , K Mitchell 1 , J Pollock 2 , D Memel 3 , PS Blair 4 . 1 

Academic 

Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Dept Health and Social Care, 

University of the West of England, Bristol, United Kingdom; 3 Air Balloon Surgery, Bristol, United 

Kingdom; 4 Div Child Health, University of Bristol, Bristol, United Kingdom 

385 AGGRESSIVE TREATMENT OF RHEUMATOID ARTHRITIS FOR THE BUSY CLINICIAN. 

TC Barnes, V Gupta, EJ Tunn, RC Bucknall, KW Nelson. Rheumatology, Royal Liverpool University 

Hospital, Liverpool, United Kingdom 

386 CHANGES IN DEMOGRAPHIC AND DISEASE PATTERNS AMONG PATIENTS WITH 

RHEUMATOID ARTHRITIS ENTERING LARGE CLINICAL TRIALS OVER A 20 YEAR PERIOD. 

R Ramachandran, E Garrity, R Madhok, HA Capell. Centre for Rheumatic Diseases, Royal Infirmary, 

Glasgow, United Kingdom 

75

BHPR (387 – 437) 

387 A LIFESTYLE MANAGEMENT FOR ARTHRITIS PROGRAMME: SHORT-TERM OUTCOMES 

FOR PEOPLE WITH INFLAMMATORY ARTHRITIS. 

A Hammond, J Bryan, A Hardy. Rheumatology, Derbyshire Royal Infirmary, Derby, Derbyshire, 


388 THE IMPACT OF OSTEOARTHRITIS ON PERSONAL RELATIONSHIPS AND SEXUAL ACTIVITY. 

J Hill, N Reay. Academic and Clinical Unit Musculoskeletal Nursing, Academic Unit of Musculoskeletal 

Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom 

389 RELATIONSHIP BETWEEN CAUSAL BELIEFS OF KNEE OSTEOARTHRITIS AND PAIN, FUNCTION, 

MOOD AND SELF-EFFICACY. 

HL Mitchell 1 , JA Weinman 2 , NE Walsh 1 , MV Hurley 1 . 1 

Rehabilitation Research Unit, GKT School of 

Medicine and Dentistry, London, United Kingdom; 2 Department of Psychological Medicine, GKT School 

of Medicine and Dentistry, London, United Kingdom 

390 RHEUMATOLOGY TELEPHONE HELPLINES: PATIENT AND HEALTH PROFESSIONAL 

REQUIREMENTS. 

SJ Brown 1 , CS McCabe 1 , S Hewlett 2 , JA McDowell 3 , J Cushnaghan 4 , AM Breslin 5 , S Stafford 6 , CR 

Carmichael 7 . 1 

RACE, Royal National Hospital for Rheumatic Diseases, Bath BA1 1RL, United Kingdom; 

2 

University of Bristol, Bristol, United Kingdom; 3 Hereford Hospitals NHS Trust, Hereford, United Kingdom; 

4 

Lymington Hospital, Lymington, United Kingdom; 5 Ysbyty Gwynedd, Bangor, United Kingdom; 6 The 

Royal Hampshire County Hospital, Winchester, United Kingdom; 7 Research and Development Support 

Unit, Royal United Hospital, Bath, United Kingdom 

391 BELIEFS ABOUT CAUSES OF RHEUMATOID ARTHRITIS(RA) OF PATIENTS AND THEIR SPOUSES. 

M Carr 1 , R Hughes 1 , A Carr 2 , M Hankins 3 , C Thwaites 1 , J Weinman 3 . 1 

Rheumatology, St Peters Hospital, 

Chertsey, United Kingdom; 2 Rheumatology, Nottingham University, Nottingham, United Kingdom; 

3 

Psychology, GKT School of Medicine, London, United Kingdom 

392 OFF-THE-SHELF CONTOURED ORTHOSES DEMONSTRATE COMPARABLE MECHANICAL 

PROPERTIES TO CUSTOM-MADE FOOT ORTHOSES AT LESS COST. 

AC Redmond 1 , KB Landorf 2 , A-M Keenan 1 , P Emery 1 . 1 

Academic Unit of Musculoskeletal Disease, 

University of Leeds, Leeds, W. Yorks, United Kingdom; 2 School of Exercise and Health Sciences, 

University of Western Sydney, Sydney, NSW, Australia 

393 PATIENT-INITIATED REVIEW: SPECIFIC HELPLINE SUPPORT IS REQUIRED. 

K Mitchell 1 , S Hewlett 1 , J Kirwan 1 , M Hehir 1 , D Memel 2 , PS Blair 3 , S Tipler 1 , J Haynes 4 , J Pollock 5 . 

1 

Academic Rheumatology, University of Bristol, Bristol, United Kingdom; 2 Air Balloon Surgery, Bristol, 

United Kingdom; 3 Division of Child Health, University of Bristol, Bristol, United Kingdom; 4 Rheumatology 

Dept, Southmead Hospital, Bristol, United Kingdom; 5 Dept Health and Social Care, University of the 

West of England, Bristol, United Kingdom 

394 INTERIM RESULTS OF A RANDOMISED PLACEBO-CONTROLLED TRIAL OF PHYSIOTHERAPY 

TREATMENT FOR ROTATOR CUFF TENDINOPATHIES. 

JT Wies 1 , M Latham 2 , T Viljoen 2 , BL Hazleman 1 , CA Speed 1 . 1 

Rheumatology Research Unit, Addenbrookes 

NHS Trust, Cambridge, Cambridgeshire, United Kingdom; 2 Oupatients Physiotherapy Department, 

Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom 

395 A STANDARDISED PHYSIOTHERAPY REGIME VERSUS SOFT TISSUE MANIPULATION IN FROZEN 

SHOULDER: A RANDOMISED CONTROLLED PILOT STUDY. 

JT Wies 1 , M Latham 2 , T Viljoen 2 , H Humphreys 2 , BL Hazleman 1 , CA Speed 1 . 1 

Rheumatology Research Unit 

- E6, Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom; 2 Outpatient Physiotherapy 

Department, Addenbrookes NHS Trust, Cambridge, Cambridgeshire, United Kingdom 

76

396 WHAT’S IT LIKE TO HAVE RHEUMATOID ARTHRITIS? RESEARCHING AN 

EDUCATIONAL WEBSITE. 

JC Carter, DR Blake. Research and Clinical Effectiveness, Royal National Hospital for Rheumatic 

Diseases, Bath, Somerset, United Kingdom 

397 UPPER LIMB SENSORIMOTOR DYSFUNCTION AND FUNCTIONAL PERFORMANCE IN 


LM Bearne, AF Coomer, MV Hurley. Physiotherapy Division, Guys, Kings & St Thomas’s School of 

Biomedical Sciences, Kings College London, London, SE1 1UL, United Kingdom 

398 PATIENTS’ PERSPECTIVE OF QUALITY OF LIFE FOLLOWING COMMENCEMENT OF NEW 

BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS. 

NJ Marshall. Musculoskeletal Department, Newcastle upon Tyne Hospitals NHS Trust, Newcastle 

upon Tyne, Tyne & Wear, United Kingdom 

399 A STUDY TO EXPLORE THE INFLUENCES WHICH DRIVE CLINICAL DECISION MAKING 

AMONGST RHEUMATOLOGY NURSES. 

DJ Bryer. Regional Rheumatology Centre, Leeds Teaching Hospitals NHS Trust, Leeds, West 


400 PROPRIOCEPTIVE ACUITY OF THE LUMBAR SPINE IN LOW BACK PAIN AND NON-LOW 

BACK PAIN SUBJECTS. 

DR Phillips 1 , MV Hurley 2 , CA Davey 1 , MA Mullee 3 . 1 

School of Health Professions & Rehabilitation 

Sciences, University of Southampton, Southampton, United Kingdom; 2 Rehabilitation Research 

Unit, King’s College London, London, United Kingdom; 3 Medical Statistics Group, University of 

Southampton, Southampton, United Kingdom 

401 THE USE OF QUANTITATIVE ULTRASOUND TO DIAGNOSE OSTEOPOROSIS IN PATIENTS 

WITH RHEUMATOID ARTHRITIS. 

JR Cryer 1 , SJ Otter 2 , CJ Bowen 3 . 1 

Podiatry, Eastbourne Downs PCT, Eastbourne, East Sussex, United 

Kingdom; 2 Health Professions, University of Brighton, Eastbourne, East Sussex, United Kingdom; 

3 

Heath Professions & Rehabilitation Science, University of Southampton, Southampton, Hampshire, 


402 FOOT PROBLEMS IN PAGETS DISEASE. 

AE Williams 1,2 , TW ONeill 2 , S Mercer 2 , CJ Nester 3 . 1 

Directorate of Podiatry, University of Salford, 

Salford, Manchester, United Kingdom; 2 Department of Rheumatology, Salford Royal Hospitals NHS 

Trust, Salford, Manchester, United Kingdom; 3 Centre for Rehabilitation and Human Performance 

Research, University of Salford, Salford, Manchester, United Kingdom 

403 UPPER LIMB FUNCTIONAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS. 

J Adams 1 , A Hammond 2 , J Burridge 1 , C Cooper 3 . 1 

School of Health Professions and Rehabilitation 

Sciences, University of Southampton, Southampton, Hants. SO17 1BJ, United Kingdom; 

2 

Rheumatology, Derby Royal Infirmary, Derby, Derbyshire, United Kingdom; 3 Medical Research 

Council, University of Southampton NHS Trust, Southampton, Hants, United Kingdom 

404 DOES FLATFOOT DEVELOP DURING PREGNANCY? A PROSPECTIVE STUDY. 

AA Ginawi, NST Gendi, AR Haloob. 1 Rheumatology, Basildon & Thurrock University Hospitals NHS 

Trust, Basildon, Essex, United Kingdom; 2 Rheumatology, Basildon & Thurrock University Hospitals 

NHS Trust, Basildon, Essex, United Kingdom; 3 Obstetrics & Gynaecology, Basildon & Thurrock 

University Hospitals NHS Trust, Basildon, Essex, United Kingdom 

405 THE IMPACT OF HAND OSTEOARTHRITIS ON THE INDIVIDUAL. 

S Hill, BN Ong, PY Choi, KS Dziedzic. Primary Care Sciences Research Centre, Keele University, 

Keele, Staffordshire, United Kingdom 

77

406 PHYSIOTHERAPISTS’ PERCEIVED PREDICTORS OF OUTCOME IN NECK PAIN. 

J Hill 1 , M Lewis 1 , KS Dziedzic 1 , J Sim 1 , EM Hay 1,2 . 1 

Primary Care Sciences Research Centre, Keele University, 

Keele, Newcastle, Staffs, United Kingdom; 2 Staffordshire Rheumatology Centre, Haywood Hospital, 

Stoke-on-Trent, Staffs, United Kingdom 

407 A STUDY TO INVESTIGATE FACTORS THAT MAY BE ASSOCIATED WITH PATIENTS’ DECISIONS 

ABOUT STARTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. 

SJ Skingle. Department of Rheumatology, Addenbrookes NHS Hospital Trust, Cambridge, 


408 OSTEO-ARTHRITIS, IDENTITY AND COPING; AN INTERPRETATIVE PHENOMENOLOGICAL 

APPROACH. 

A Mandeville 1 , K Mulligan 1 , J Smith 2 , M Shipley 3 , S Newman 1 . 1 

Unit of Health Psychology, Centre for 

Behavioural and Social Sciences in Medicine, University College London, London, United Kingdom; 

2 

School of Psychology, Birkbeck College, University of London, London, United Kingdom; 3 Centre for 

Rheumatology, University College London Hospitals, London, United Kingdom 

409 THE PREVALENCE OF DEPRESSION IN RA AND ITS RELATIONSHIP TO DISABILITY, 

PAIN AND FATIGUE. 

PS Heslop 1 , CS Chandler 2 , DJ Walker 1 . 1 

Musculoskeletal Unit, Freeman Hospital, Newcastle-upon-Tyne, 

United Kingdom; 2 School of Health, Community & Education Studies, University of Northumbria, 


410 THE DEVELOPMENT OF A HAND ASSESSMENT FOR CLINICAL RESEARCH: A CONSENSUS STUDY 

USING A MODIFIED DELPHI APPROACH. 

HL Myers 1 , KS Dziedzic 1 , E Thomas 1 , EM Hay 1,2 , PR Croft 1 . 1 

Primary Care Sciences Research Centre, Keele 

University, Keele, Staffs, United Kingdom; 2 Staffordshire Rheumatology Centre, Haywood Hospital, 

Stoke-on-Trent, Staffs, United Kingdom 

411 A SURVEY OF PRACTICE IN NURSE LED RHEUMATOID ARTHRITIS CLINICS. 

S Ryan 1 , J Hill 2 . 1 

Staffordshire Rheumatology Centre, The Haywood Hospital, Burslem, Stoke on Trent, 

ST6 7AG, United Kingdom; 2 ACUMeN, Academic Unit of Musculoskeletal Disease, Chapel Allerton 

Hospital, Leeds, LS7 4SA, United Kingdom 

412 DOES MENSTRUAL CYCLE PHASE INFLUENCE DAS 28 SCORES? 

RP Brett. Rheumatology, Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom 

413 WHAT CONSTITUTES USUAL PHYSIOTHERAPY TREATMENT FOR PAINFUL SHOULDER, 

AND WHAT FACTORS INFLUENCE THIS? 

AC Ryall. MRC Environmental Epidemiology Unit, University of Southampton, Southampton, Hampshire, 


414 THE EXTENT AND NATURE OF OUTPATIENT REFERRALS TO OCCUPATIONAL THERAPY 

AND PHYSIOTHERAPY IN EARLY RHEUMATOID ARTHRITIS. 

JS Lewis 1 , F Tonepohl 1 , LC Cory 1 , C Carmichael 1 , J McCaulder-Ojeda 1 , TR Jenkinson 1,2 . 1 Rheumatology, 

The Royal National Hospital For Rheumatic Diseases, Bath, Somerset, United Kingdom; 2 Sports and 

Exercise Sciences, University of Bath, Bath, Somerset, United Kingdom 

415 IMPACT OF USING PATIENT PARTNERS TO TEACH JOINT EXAMINATION TO NURSE 

PRACTITIONER STUDENTS. 

JM Mooney. School of Nursing, University of East Anglia, Norwich, United Kingdom 

416 AUDIT OF THE EFFECT ON PAIN SCORES OF INTRA-ARTICULAR HYALGAN INJECTION IN 

PATIENTS WITH OSTEOARTHRITIS OF THE KNEE IN A NURSE-LED CLINIC. 

DM Johnson. Department of Rheumatology, St Georges Hospital, Tooting, London SW17 0QT, 


78

417 A DEVELOPING ROLE WITHIN RHEUMATOLOGY NURSING. 

C Thwaites 1 , S Ryan 2 , A Hassell 2 . 1 

Department of Nursing and Midwifery, Keele University, Keele, 

Staffs, United Kingdom; 2 Department of Rheumatology, University Hospital of North Staffordshire 

NHS Trust, Stoke-on-Trent, Staffs, United Kingdom 

418 A REVIEW OF A CONSULTANT PHYSIOTHERAPIST’S FIRST YEAR IN POST. 

K Stevenson. 1 Physiotherapy Department, University Hospital of North Staffordshire, Stoke on 

Trent, Staffordshire, United Kingdom; 2 Department of Physiotherapy Studies, Keele University, 

Stoke on Trent, Staffordshire, United Kingdom 

419 THE IMPORTANCE OF CERVICAL SCREENING PRIOR TO ANTI TNF THERAPY. 

B Rhys-Dillon, C Rhys-Dillon. Dept of Rheumatology, University Hospital of Wales, Cardiff, Wales, 


420 CAN AN ADVANCED NURSE PRACTITIONER APPROPRIATELY MANAGE PATIENTS WITH 

EARLY RHEUMATOID ARTHRITIS USING AN INTEGRATED CARE PATHWAY? 

AE Campbell 1 , C Estrach 2 , MP Lynch 1 , VE Abernethy 1 . 1 

Rheumatology Department, St Helens and 

Knowsley NHS Trust, St Helens, Merseyside, United Kingdom; 2 Rheumatology Department, 

Countess of Chester Hospital, Chester, United Kingdom 

421 ANTI-TNF-α THERAPY PRESCRIBING IN BERKSHIRE - ARE WE COMPLIANT WITH NICE 

GUIDELINES? 

M Magliano 1 , G Ramroop 1 , R Holtom 2 , A Steuer 1 , J McNally 2 . 1 

Rheumatology, Wexham Park 

Hospital, Slough, Berkshire, United Kingdom; 2 Rheumatology, Wexham Park Hospital, Slough, 

Berkshire, United Kingdom 

422 AUDIT OF A MULTI-DISCIPLINARY JOINT INJECTION RHEUMATOLOGY SERVICE. 

J Novak, AE Griffiths, AE Campbell, VE Abernethy, JK Dawson. Rheumatology, St Helens & 

Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom 

423 THE DEVELOPMENT OF A USER LED CLINICAL SERVICE FOR NEWLY DIAGNOSED 

RHEUMATOID ARTHRITIS PATIENTS - AN ACTION RESERCH STUDY. 

MA Cox. Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, United Kingdom 

424 METHOTREXATE MONITORING IS IMPORTANT BUT PATIENT EMPOWERMENT 

IS SUB-OPTIMAL. 

MS Lillicrap, C Ellis. Department of Rheumatology, Norfolk and Norwich University Hospital, 

Norwich, United Kingdom 

425 EXPEDITED REVIEW APPOINTMENTS IN A RHEUMATOLOGY OUTPATIENT (OP) 

DEPARTMENT. 

R Shaban, A Wood, KR Mackay, FC McCrae, AL Thomas, RG Hull, JM Ledingham. Rheumatology 

Department, Queen Alexandra Hospital, Portsmouth, Hants, United Kingdom 

426 TO OPERATE OR NOT TO OPERATE. CAN AN INTERVENTION BY THE HAND 

OCCUPATIONAL THERAPIST (OT) PREVENT THE NEED FOR HAND SURGERY? 

SE Bradley 1 , P Cornell 2 . 1 

Occupational Therapy, Hand Unit, Poole Hospital NHS Trust, 

Poole, Dorset, United Kingdom; 2 Rheumatology, Poole Hospital NHS Trust, Poole, Dorset, 


427 AN INVESTIGATION OF THE PRESCRIBING TRENDS OF NON-STEROIDAL 

ANTI-INFLAMMATORY DRUGS IN AN ELDERLY POPULATION : IN A HOSPITAL AND 

PRIMARY CARE SETTING. 

ES Koshy 1 , G Coakley 2 . 1 

General Practice / Primary Care, The Fairfield Centre, London, United 

Kingdom; 2 Rheumatology, Queen Elizabeth Hospital, London, United Kingdom 

79

428 EVALUATION OF AN IN-PATIENT JOINT PROTECTION EDUCATION PROGRAMME. 

Y Mooney, C Carroll, S Haughey, O McAlinden, D Rowe. Occupational Therapy Dept, Rheumatology 

Rehabilitation, Our Lady’s Hospice, Dublin 6W, Ireland 

429 EFFECTIVENESS OF A LOAN-AND-PURCHASE SERVICE. 

AE Griffiths, AM Clayton, VE Abernethy, MP Lynch, I Spencer, JK Dawson. Rheumatology, 

St Helens & Knowsley Hospitals NHS Trust, St Helens, Merseyside, United Kingdom 

430 RHEUMATOLOGY HELPLINE. 

SA Gibson, EW Spark, BB Wood. Rheumatology, Wirral Hospital NHS Trust, Wirral, Merseyside, 


431 NURSE PRESCRIBING IN RHEUMATOLOGY PRACTICE. 

EW Spark, BB Wood, SL Hennell, E George. Rheumatology, Wirral Hospital NHS Trust, Wirral, 


432 USER SATISFACTION WITH HOSPITAL LED RHEUMATOLOGY MONITORING SERVICE. 

R Wiswell, TA O’Rourke, C Brownsell, VE Abernethy, MP Lynch, JK Dawson. Rheumatology Unit, 

St Helens & Knowsley NHS Trust, St Helens, Merseyside, United Kingdom 

433 AGE DIVIDE IN THE UPTAKE OF PNEUMOVAX AND INFLUENZA (‘FLU) VACCINATION AMONGST 

RHEUMATOLOGY PATIENTS TAKING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs). 

S Shenton, A Wood, F McCrae, K MacKay, A Thomas, R Hull, R Shaban, J Ledingham. Rheumatology 

Department, Queen Alexandra Hospital, Portsmouth, Hants, United Kingdom 

434 MANAGEMENT OF CHRONIC FATIGUE SYNDROME IN MULTIDISCIPLINARY GROUP SETTING. 

RB Belgamwar 1 , MS Jorsh 1 , A Marpole 1 , H Snowden 1 , E Mayall 1 , J Packham 2 , P Dawes 2 . 1 Department of 

Liaison Psychiatry, North Staffordshire Combined Health Care NHS Trust, Stoke-on-Trent, Staffordshire, 

United Kingdom; 2 Staffordshire Rheumatology Centre, The Haywood Hospital, University Hospital of 

North Staffordshire NHS Trust, Stoke on Trent, Staffordshire, United Kingdom 

435 AN AUDIT OF THE PROVISION AND EFFICACY OF DISEASE MODIFYING ANTI-RHEUMATIC 

DRUG INFORMATION LEAFLETS FOR PATIENTS WITH INFLAMMATORY ARTHRITIS. 

CA Adams, LP Robertson. Rheumatology Unit, Bristol Royal Infirmary, Bristol, Avon, United Kingdom 

436 THE DEVELOPMENT AND EVALUATION OF A NURSE-LED BIOLOGICS REVIEW CLINIC. 

GM Grundy 1 , L Brinkley 1 , J Lamb 1 , M Lawrence 1 , E Solomon 1 , RN Thompson 1 , VE Abernethy 2 , RJ Moots 1 . 

1 

Academic Rheumatology Dept, University Hospital Aintree, Liverpool, l9 7AL, United Kingdom; 

2 

Rheumatology, St Helens NHS Trust, St Helens, Merseyside, United Kingdom 

437 MULTI-DISCIPLINARY ANKYLOSING SPONDYLITIS SERVICE. 

AE Griffiths, J Novak, AE Campbell, JK Dawson, VE Abernethy. Rheumatology, St Helens & Knowsley 

Hospitals NHS Trust, St Helens, Merseyside, United Kingdom 

80

Abstract Reviewers 

The BSR Heberden Committee was expanded substantially for the purposes of abstract 

assessment to ensure that every abstract was peer reviewed, blind, by at least 4 reviewers. 

The Heberden Committee is extremely grateful for the assistance of everyone that gave up 

their time to review abstracts, and acknowledges them accordingly: 

Dr David Abraham 

Dr Rod Amos 

Dr Rupa Bessant, Heberden Committee 

Dr Fraser Birrell 

Dr Simon Bowman, Heberden Committee 

Dr Paul Bowness, Heberden Committee 

Dr John Brockbank 

Dr Marwan Bukhari, Heberden Committee 

Dr Hilary Capell 

Dr Jiri Chard 

Prof Yuti Chernajovsky, Heberden Committee 

Dr Ernest Choy 

Dr Ian Clark 

Dr Gavin Clunie 

Dr David Collins, Heberden Committee 

Dr Andrew Cope 

Dr Paul Creamer 

Dr Peter Croft 

Dr David D’Cruz 

Dr Chris Deighton 

Dr John Delamere 

Prof Michael Doherty 

Dr Victor Duance 

Dr Krysia Dziedzic, Heberden Committee 

Prof Brian Foxwell 

Prof Simon Frostick 

Prof Hill Gaston, Heberden Committee 

Dr Nicola Goodson 

Dr Caroline Gordon 

Dr Ian Griffiths 

Dr Alan Hakim 

Dr Frances Hall 

Dr John Halsey 

Dr Alison Hammond 

Dr Andy Hassell 

Prof Elaine Hay 

Dr Ariane Herrick 

Dr Rod Hughes, Heberden Committee 

Dr Mike Hurley 

Dr Charles Hutton 

Dr Ali Jawad 

Dr David Jayne 

Dr Adrian Jones, Heberden Committee 

Dr Andrew Keat 

Dr George Kitas, Heberden Committee 

Dr Maria Koutanji 

Dr Alison Leak, Heberden Committee 

Dr Mark Lillicrap 

Dr Raashid Luqmani 

Prof Peter Maddison, Heberden Committee 

Dr Rajan Madhok 

Dr Rizgar Mageed 

Dr Justin Mason 

Mrs Candy McCabe 

Dr Michael McDermott 

Dr Julie McHale 

Prof Iain McInnes 

Prof Robert Moots, Heberden Committee 

Dr Donncha O’Gradaigh 

Dr Elizabeth Price 

Dr John Raphael 

Dr Shirley Rigby 

Dr Graham Riley 

Dr Clive Ryder 

Dr Deva Situnayake 

Dr Manouche Tavakoli 

Dr Jon Tobias, Heberden Committee 

Mr Gareth Treharne 

Dr Richard Watts, Heberden Committee 

Dr Lucy Wedderburn 

Dr Andy Whallet 

Dr Amanda Williams 

Prof Bryan Williams 

Dr Adam Young 

Dr Steven Young 

81

Exhibition Floor Plan 

82

List of 2004 Exhibitors 

Stand Company 

1 LCA SA 

2 Eli Lilly 

3 Otsuka Pharmaceuticals (UK) Ltd 

4,5 Genzyme 

6 Janssen-Cilag 

7 Actelion 

8,9,10,11 Schering Plough 

12 Wyeth 

13,14,15,16 MSD (Vioxx & Fosamax) 

17 Q Med 

18 Dimethaid International 

20 BSR 

21 ARMA 

22 British Sjogrens Syndrome Association 

23 Arthritis Care 

24 Aventis/Alliance for Better Bone 

25 Abbott 

26 Surgicraft 

27 Lanmark 

28 Syner-Med 

Stand Company 

29 BHPR 

30 RCN 

31 Pfizer 

32 Novartis 

33 MSD (Arcoxia) 

34 4S Dawn Clinical Software 

35 Dynamic Imaging 

36 TRB Chemedica 

37 Rainy Day Software 

38 NRAS 

39 ERAN 

40 Scleroderma Society 

41 Raynauds & Scleroderma Association 

42 Kyphon Europe 

43 Vertec Scientific 

44 OUP 

45 Wisepress 

46 arc 

47 NASS 

83

Exhibitor Product Listings 

4S Dawn Clinical Software 

Some key problems with monitoring DMARD therapy are: 

• Time consumed in monitoring of laboratory test results, which must be carried out in an exacting manner 

• Not forgetting to follow up on actions decided for the patient 

• Auditing therapy management 

Dawn DMARD software overcomes this by: 

• Rigorously monitoring test results automatically 

• Produces electronic alerts 

• Providing an auditing/report writing facility 

Abbott 

HUMIRA ®▼ (adalimumab – Abbott Laboratories Ltd) is a fully human monoclonal antibody, indicated for the treatment of 

moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs including 

methotrexate has been inadequate. HUMIRA ®▼ can be given in combination with MTX or as monotherapy in case of 

intolerance to MTX or when continued treatment with MTX is inappropriate. 

Actelion 

Tracleer the first dual Endothelin receptor antagonist, a significant advance in the treatment of Pulmonary Arterial 

Hypertension (PAH) related to connective tissue disease. 

• Tracleer is the only licensed treatment for Scleroderma patients with PAH 

• Tracleer significantly improves exercise capacity 

• Tracleer significantly decreases the rate of clinical worsening 

• Tracleer has a convenient b.d. dosage. 

For further information call 0845-0750555. Reference: Tracleer SmPC June 2003 

arc 

The Arthritis Research Campaign (a r c) is the fourth-largest medical research charity in the UK with an annual income in 2002-3 

of £23.5 million. a r c funds research into all forms of arthritis and related conditions, and also provides information to the public 

(including more than 80 patient booklets) and health professionals. a r c also funds a variety of fellowships and bursaries. 

ARMA 

The Arthritis and Musculoskeletal Alliance (ARMA) is the UK umbrella organisation bringing together 27 members including 

support groups, research organisations and medical/ non-medical professionals’ societies. Visit our stand to pick up 

information on our Member organisations and find out about our consultation on Standards of Care for people with MSCs. 

Rheumatologists have been closely involved in this project and we want to hear your views on the standards. 

Arthritis Care 

Arthritis Care is the UK’s largest voluntary organisation for people with all types of arthritis. Our aim is to empower 

people to take control of their arthritis, their organisation and their lives. We offer a range of services including helplines, 

publications, self-management and hotels. We also campaign to ensure the voice of people with arthritis is heard at both a 

national and local level. 

Aventis/Alliance for Better Bone 

Actonel ® (risedronate sodium), a bisphosphonate produced by The Alliance For Better Bone Health (Procter and Gamble 

/ Aventis). The Alliance is committed to the timely identification and treatment of postmenopausal 

osteoporosis. 

Arava ® (leflunomide) produced by Aventis 

A disease-modifying antirheumatic drug (DMARD) that represents a significant advance in the treatment of adult patients with 

active rheumatoid arthritis. 

84

BHPR 

The BHPR was formed in 1985 to bring together health professionals whose major interests lay in the management 

of people with rheumatic diseases. The aim of the BHPR is to encourage a multi-disciplinary approach to the 

management of people with rheumatic diseases. To provide a forum through which health professionals can 

exchange knowledge, skills and experience. To generate greater awareness of the contribution of health professionals 

British Sjögren's Syndrome Association 

The British Sjögren's Syndrome Association is a registered charity and self help organisation dedicated to providing 

mutual support and information to individuals affected by Sjögren's Syndrome - the second most common 

auto-immune disease after Rheumatoid arthritis. We aim to educate patients, GPs, dentists and other medical 

professionals about the condition, raise awareness surrounding its existence and symptoms and support research 

into its cause and treatment. 

BSR 

The British Society for Rheumatology (BSR) is a professional medical society with 1,400 members. We are committed 

to advancing knowledge and practice in the field of rheumatology. Visit the BSR stand to find out more about the 

society's work in promoting arthritis and musculoskeletal conditions as a health priority and pick up other useful 

nformation including copies of BSR's new draft clinical guidelines. 

Dimethaid International 

Dimethaid produces and Acer Medical markets Pennsaid ® , a new topical solution of diclofenac formulated with 

DMSO, a well recognised enhancer of dermal penetration. Pennsaid ® is approved for the treatment of osteoarthritis in 

superficial joints including the knee. For more information on Pennsaid ® or the randomised, controlled clinical studies 

in osteoarthritis of the knee in which Pennsaid ® has been compared with vehicle/placebo and oral diclofenac, please 

visit the Pennsaid ® stand. 

Dynamic Imaging 

High frequency musculoskeletal ultrasound has become an established imaging technique for diagnosis and follow up 

of patients with rheumatic diseases. In addition to assessing soft tissue pathology, fluid and cartilage, bone surfaces 

can be visualised and guided aspiration, biopsy, and injections can be carried out. Dynamic assessments of joint and 

tendon movements can also aid the detection of structural abnormalities. 

Eli Lilly 

Lilly – Over 125 years of innovation 

Eli Lilly was founded by Colonel Eli Lilly in 1876 in Indianapolis, USA. Since then, Lilly has been at the forefront of 

many of the most significant breakthroughs in modern medicine from the production of the world’s first insulin treatment 

in 1922 to the recent launch of the first ever treatment to build bone in the treatment of severe osteoporosis. 

ERAN 

The Early Rheumatoid Arthritis Network (ERAN) has been recognised as part of the sponsored National Clinical Audit 

Programme (Commission for Health Improvement – CHI). 

Make sure you are involved in this rapidly expanding Network. 

Come and visit stand 39 for more information or contact Wendy Garwood on 

+44 (0)1753 480400 or wgarwood@phlexglobal.com 

Genzyme Biosurgery 

Synvisc ® is the viscosupplement clinically proven to relieve the pain and immobility of knee OA for up to 12 months. 

Now also clinically proven and approved for use in patients with symptomatic hip OA, Synvisc is effective in all stages 

of joint pathology, and is particularly indicated for patients where symptoms are not controlled by conservative 

measures, where NSAID's are contraindicated, or where surgery should be delayed or avoided. 

85

Janssen-Cilag 

Janssen-Cilag Limited is a top-ten pharmaceutical company serving the United Kingdom. It has an outstanding record of 

innovation and is a part of Johnson & Johnson, a family of around 190 healthcare companies active worldwide. Each has 

its own mission and identity. Janssen-Cilag Ltd is the maker of DUROGESIC‘ (transdermal fentanyl) and TRAMACET 〉 

(37.5mg tramadol Hcl and 325mg paracetamol). 

Kyphon Europe 

Kyphon focuses its energy in revolutionising spine therapy. 

Balloon Kyphoplasty is a minimally invasive procedure to treat vertebral body compression fractures. 

The technique is designed to reduce and stabilise the fracture in a controlled way, to correct spinal deformity and to provide 

immediate pain relief and improved quality of life. 

LCA SA 

ARTHRUM H is a viscoelastic device specially designed for viscosupplementation of synovial fluid in osteoarthritic joints. 

ARTHRUM H viscoelastic device is indicated for maintenance of endoarticular space, relief of pain and restoration of joint 

mobility by replacing and providing viscoelastic supplementation of the diseased synovial fluid present in osteoarthritic joints. 

MSD 

Arcoxia ® 

Merck Sharp & Dohme Limited (MSD) has a 60-year heritage in musculoskeletal research. Since 1936, when the company 

introduced an early therapy for rheumatoid arthritis, MSD has made significant contributions to the development of new 

medicines for arthritis and other musculoskeletal disorders, resulting in more than a dozen products including etoricoxib 

(ARCOXIA ® ). MSD is the UK subsidiary of Merck & Co., Inc. of Whitehouse Station, New Jersey, USA – a leading researchbased 

pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical 

products to improve human health. 

MSD 

Vioxx/Fosamax 

Merck Sharp & Dohme Limited (MSD) have a 60-year heritage in musculoskeletal research. Since 1936, when the company 

introduced an early therapy for rheumatoid arthritis, MSD has made significant contributions to the development of new 

medicines for arthritis and other musculoskeletal disorders, resulting in more than a dozen products including rofecoxib 

(VIOXX) and alendronate sodium (FOSAMAX). Both rofecoxib and alendronate sodium were discovered and developed by 

MSD. MSD is the UK subsidiary of Merck and Co Inc of Whitehouse Station, New Jersey, USA a leading research based 

pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical products 

to improve human health. 

NASS 

The National Ankylosing Spondylitis Society (NASS) was founded in 1976. It produces patient education material and has a 

national network of over 100 branches providing supervised remedial physiotherapy one evening per week for approximately 

2000 sufferers in one week. 

It has provided the rheumatology profession and individual patients with over 110, 000 guide books. 

NRAS 

NRAS is a patient-led national Charity focussing specifically on Rheumatoid Arthritis. 

Aims: 

• Provision of a dedicated help-line and website advisory and information service 

• Raising public, government and professional awareness of RA 

• Campaigning for increased funding for the treatment and delivery of care in RA 

• Promoting self-help in the management of the disease, informed choice and facilitating the 

networking of patients 

86

Otsuka Pharmaceuticals (UK) Ltd 

Commonwealth House, Hammersmith, London W6 8DW. Phone: 020-8600-6770 

www.otsuka-europe.com and www.Adacolumn.com 

Otsuka is a diversified health care company dedicated to the research and development of innovative medical, 

pharmaceutical, and nutritional consumer products. The Adacolumn apheresis system is an innovative therapeutic 

option available and in use in the UK since early 2003. The Adacolumn is an extracorpeal leucocyte apheresis device 

and is CE marked and approved in the EU for use in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, Behcet’s 

disease and systemic lupus erythematosus (SLE). 

OUP 

Oxford University Press is an international publishing house dedicated to the advancement and spread of learning 

in all academic fields including science, technology, and medicine. Publications cover the range of the academic 

spectrum from scholarly journals that successfully combine traditional values of quality and service together with 

innovative use of latest technologies; through to elementary college textbooks and books for the general reader; 

practical handbooks and reference works for professionals 

Pfizer 

Visit the Pfizer stand to order your copy of the BSR SPEAKER PRESENTATION SLIDES, and for more information 

about the exciting program of speakers at “HOT TOPICS 3” the Pfizer symposium. 

Also visit to find out more information on CELEBREX‚ (celecoxib) and BEXTRA (valdecoxib), 

the Pfizer Coxib portfolio. 

It is estimated that on any given day, 40 million people around the world are treated with a Pfizer medicine. 

CEL 109113/02/04 

Q Med 

Durolane ® : The Single Injection Treatment For Osteoarthritis 

Durolane is based upon a patented manufacturing process which uses NASHA (Non Animal Stablised Hyaluronic 

Acid) technology. This dramatically increases the intra-articular residence time dispensing with the need for repeated 

injections. Durolane is derived from a non-animal source, and therefore contains no residual animal impurities. 

Rainy Day Software 

RDS develops and distributes medical software. RheMOS is a drug monitoring solution that has correspondence, 

reporting, graphing, Patient Administration System and PDA modules. RheDAS enables the collection of anti-TNF data 

and can be used as a standalone module or integrated with RheMOS. It enables email submission to the BSRBR of 

relevant forms, as well as local audit of data. RheDAS is free to UK rheumatologists. 

Raynauds & Scleroderma Association 

The Raynaud’s & Scleroderma Association are launching a new range of health professional booklets. 

The association aims to promote a greater awareness and understanding of these conditions and to raise funds for 

research and welfare projects. Quarterly newsletters give up to date information on research, treatments available, 

tips and aids for daily living. 

To be added to our mailing list please visit stand no. 41. 

87

RCN 

The Royal College of Nursing (RCN) Rheumatology Forum Committee stand will have a number of useful guidance 

documents for practitioners as well as news on conferences and other educational initiatives for nurses. The RCN RF have 

recently published guidance for practitioners in the administration of subcutaneous methotrexate which will be available on 

the stand. Come and collect a copy or access it through the RCN website www.rcn.or.uk and go to guidelines. 

If you would like: • Information on joining the RCN 

• Wish to have advice on rheumatology nursing or how to develop rheumatology nursing posts 

• Would like to hear about bursaries and awards for nurses 

• Obtain guidelines prepared by the forum. 

• Or would like advice on nursing issues related to rheumatology 

Please come and visit our stand which will be manned by members of the committee who would be pleased to meet you 

The Scleroderma Society 

The Scleroderma Society is a voluntary charity founded in 1982. Our aim is to help sufferers and their families to obtain 

appropriate support/information and fund medical research. Scleroderma is a rare connective tissue disease and the Society 

helps patients/members to feel less isolated through group meetings, quarterly newsletters, telephone and email helpline 

and message board on www.sclerodermasociety.co.uk. Patient information leaflets available at our stand 

Surgicraft 

Surgicraft are delighted to be exhibiting Orthovisc, a pure hyaluronic acid injection indicated for the treatment of 

osteoarthritis in all synovial joints. 

Orthovisc is reported to have a significantly lower rate of adverse events, due to its proprietary manufacturing process and 

formulation. As an efficient and safe 3-injection treatment, Orthovisc is fast becoming the HA of choice. 

Syner-Med 

Syner-Med (PP) Ltd supply Venofer ® (i.v. iron sucrose) to the UK and Ireland health care providers. 

Anaemia is a debilitating condition which can compound the symptoms of diseases such as rheumatoid arthritis. Venofer ® is 

suitable for the treatment of iron deficiency anaemia sometimes characterised in rheumatoid patients. Venofer ® does not 

contain Dextran, therefore worsening of the joint condition and anaphylaxis are not encountered. Venofer ® is also suitable 

for patients undergoing hip and knee surgery to support blood loss where blood transfusion avoidance is considered. 

TRB Chemedica 

TRB Chemedica specialises in the manufacture of a variety of highly purified, non-animal sourced, Hyaluronic Acid based 

products. Ostenil ® is for the relief of OA pain in large joints, for example the knee and hip & Ostenil mini ® is for the relief of 

OA pain in the small joints, for example, the upper and lower limbs and the facet joints of the lumbar spine. 

Vertec Scientific 

Vertec Scientific Ltd, the UK’s leading supplier of Dexa scanners introduces the Hologic DiscoveryTM including Hologic’s 

innovative Instant Vertebral Assessment (IVA), the new Standard of Vertebral Osteoporosis Assessment. Vertec are also 

launching the New Hologic ExplorerTM just released in the UK. 

Wisepress 

Wisepress Online Bookshop is pleased to present a display of titles selected especially for the British Society of 

Rheumatology Annual Conference 2004 from the world’s leading publishing houses. All titles can be bought / ordered at 

the congress or via our website: www.wisepress.co.uk . Whatever your book requirements, Wisepress will be happy to help 

Wyeth 

Enbrel is a twice – weekly injection licensed for the treatment of active rheumatoid arthritis (RA) including early RA, 

ankylosing spondylitis (AS), active and progressive psoratic arthritis (PsA) and active juvenile chronic arthritis (JCA). Enbrel 

has a unique mode of action as the only approved tumor necrosis factor (TNF) receptor, and has been used in over 

215,000 people worldwide, including over 4,000 British adults and children since its UK launch in 2000. 

88

Acknowledgements 

The British Society for Rheumatology would like to thank the following companies for 

their support in the areas listed below: 

MSD for their support of the BSR Young Investigator Awards. 

Novartis for sponsoring the provision of the programme on screens around the EICC. 

Pfizer for sponsoring the delegate bags, printed programmes and speakers CD-ROMs. 

Wyeth for sponsoring the registration staff and badges, and for organising the fun run. 

Abbott, Genzyme Biosurgergy, MSD, Novartis, Pfizer and Schering Plough 

for supporting the provision of satellite symposia for delegates. 

BSR, 41 Eagle Street, London WC1R 4TL 

Telephone: +44 (0) 207 242 3313 Fax: +44 (0) 207 242 3277 

Email: conferences@rheumatology.org.uk 

Website: www.rheumatology.org.uk 

A Company limited by guarantee with charitable status 

VAT No. 404 5637 66 Company Reg. No. 3470316 Charity Reg. No. 1067124 

89

View conference programme - The British Society for Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?